Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008063888 - COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR

Considered void:  01.08.2008
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

COMPOUNDS MODULATING C-FMS AND/OR C-KlT ACTIVITY
AND USES THEREFOR

RELATED PATENT APPLICATIONS
[0001] This application claims priority to U.S. Provisional App. No. 60/860,749, entitled "Compounds Modulating c-Fms and c-Kit Activity and Uses Therefor", filed November 22, 2006, and is related to U.S. Patent App. No. 11/435,381 , entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed May 16, 2006, which claims the benefit of U.S.
Provisional App. No. 60/682,063, entitled "Compounds Modulating c-Kit Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/682,051, entitled "Compounds Modulating c-Fms Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/682,042, entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/692,750, entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed June 22, 2005, and U.S. Provisional App. No.
60/692,960, entitled "Compounds and Methods for Kinase Modulation, and Indications Therefor", filed June 22, 2005, all of which are incorporated herein by reference in their entireties and for all purposes.

FIELD OF THE INVENTION

[0002] This invention relates to ligands for c-fms and c-kit, and to methods for use thereof. The information provided is intended solely to assist the understanding of the reader. None of the infoπnation provided nor references cited is admitted to be prior art to the present invention. Each of the references cited is incorporated herein in its entirety and for any purpose.

BACKGROUND OF THE INVENTION

[0903] C-fms and c-kit arc both type III transmembrane receptor protein tyrosine kinases (RPTKs) that regulate key signal transduction cascades that control cellular growth and proliferation. Both receptors have similar structural features comprising five extracellular immunoglobulin (IG) domains, a single transmembrane domain, and a split cytoplasmic kinase domain separated by a kinase insert segment.

c-Fms
|0004] C-fms is a member of the family of genes originally isolated from the Susan McDonough strain ot teline sarcoma viruses, The cellular proto-oncogene FMS (c-fms, cellular feline McDonough sarcoma) codes for the receptor for the macrophage colony-stimuktmg tactor (M- CSF) C-fms is crucial for the growth and differentiation of the monocyte-macrophage lineage, and upon binding of Vf-CSF to the extracellular domain of c-fms, the receptor dimeπzes and trans- autophosphorylates cytoplasmic tyrosine residues

[0005] M-CSF, first described by Robinson and co-workers (Blood 1969, 33 396-9), is a cytokine that controls the production, differentiation, and function of macrophages M-CSF stimulates differentiation of progenitor cells to mature monocytes, and prolongs the survival of monocytes Furthermore, M-CSF enhances cytotoxicity, superoxide production, phagocytosis, chemota\is, and secondary cytokine production of additional factors in monocytes and macrophages Examples of such additional factors include granulocyte colony stimulating lactor (G-CSF) interleukin-6 (IL-6), and mterleukm-8 (IL-8) M-CSF stimulates hematopoiesis, promotes differentiation and proliferation of osteoclast progenitor cells, and has profound effects on lipid metabolism Furthermore, M-CSF is important in pregnancy Physiologically, large amounts of M-CSF are produced in the placenta, and M-CSF is believed to play an essential role in trophoblast differentiation (Motoyoshi, lnt J Hematol 1998, 67 109-22) l hc elevated semm levels of M-CSF m early pregnancy may participate in the immunologic mechanisms responsible for the maintenance of the pregnancy (Flanagan & Lader, Curr Opm Hematol 1998, 5 181-5)

[0006] Related to c-fms and c-kit are two p_latelet -derived growth factor receptors, alpha (i e , pdgfra) and beta (pdgfrb) (PDGF) 1 he gene coding for pdgfra is located on chromosome 4ql 1 -q!2 in the same region of chromosome 4 as the oncogene coding for c-kit The genes coding for pdgfra and c-fms appear to have evolved from a common ancestral gene by gene duplication, inasmuch as these two genes are tandemly linked on chromosome 5 They are oriented head to tail with the 5-pnme exon of the c-fms gene located only 500 bp from the last 3-pπme exon of the gene coding for pdgfra Most gastrointestinal stromal tumors (GIST) have activating mutations in c-kit and most patients with GISTs respond well to Gleevec, which inhibits c-kit Hemπch et al (Science 2003, 299 "OS-IO) have shown that approximately 35% of GISTs lacking c-krt mutations, have intragenic activation mutations m tht gene encoding pdgfra, and that tumors expressing c-kit or pdgfrd are indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression Thus, c kit and pdgfra mutations appear to be alternative and mutually exclusive oncogenic mechanisms m GISTs [0007} Similarly, the observation that production of M-CSF, the major macrophage growth factor, is increased in tissues during inflammation points out a role for c-frns in diseases, such as for example inflammatory diseases. More particularly, because elevated levels of M-CSF are found in the disease state, modulation of the activity of c-fms can ameliorate disease associated with increased levels of M-CSF.

c-Kit
[0008] The Stem Cell Factor (SCF) receptor c-kit plays an important role in the development of melanocytes and mast, germ and hematopoietic cells. Stem Cell Factor (SCF) is a protein encoded by the Sl locus, and has also been called "kit ligand" (KL) and mast cell growth factor (MGF), based on the biological properties used to identify it (reviewed in Tsujimura, Pathol Int 1996, 46:933-938; Loveland, et al., J. Endocrinol 1997, 153:337-344; Vliagoftis, et al,, Clin Immunol 1997, 100:435-440; Broudy, Blood 1997, 90: 1345-1364; Pignon, Hermatol Cell Ther 1997, 39: 1 14-1 16; and Lyman, et al., Blood 1998, 91 : 1 101 -1 134.). Herein the abbreviation SCF refers to the physiological ligand for c-kit.

[0009] SCF is synthesized as a transmembrane protein with a molecular weight of 220 or 248 Dalton, depending on alternative splicing of the mRNA to encode exon 6. The larger protein can be proteolytically cleaved to form, a soluble, glycosylated protein which noncovalently dimerizcs. Both the soluble and membrane-bound forms of SCF can bind to and activate c-kit. For example, in the skin, SCF is predominantly expressed by fibroblasts, keratinocytes, and endothelial cells, which modulate the activity of melanocytes and mast cells expressing c-kit. In bone, marrow stromal cells express SCF and regulate hematopoiesis of c-kit expressing stem cells. In the gastrointestinal tract, intestinal epithelial cells express SCF and affect the interstitial cells of Cajal and intraepithelial lymphocytes. In the testis, Sertoli cells and granulosa cells express SCF which regulates spermatogenesis by interaction with c-kit on germ cells.

SUMMARY OF THE INVENTION

[0010] The present invention relates to compounds active on c-fms, c-kit, or both c-fms and c-kit. In accordance with one aspect of the present invention, it has been discovered that in the treatment of diseases amenable to treatment by an effective amount of a modulator of either c-fms alone or c-kit alone, the efficacy of treatment can be enhanced if said compounds are dual inhibitors of both c-fms and c-kit. In another aspect of the present invention, compounds active on c-fms, c-kit, or both c-fms and c-kit are also active on one or more of TrkA, TrkB and HGK. In particular, the invention provides compounds of Formula II, and all sub-generic formulae thereof (e.g. Formula Ha, lib, Hc, Hg and Up), Formula III, or additional compounds as described in the synthetic examples, as well as methods of using such compounds as described below. Thus, the invention provides methods of using compounds that can be used therapeutically and/or prophylactically involving modulation of c-fms, c-kit, or both c-fms and c-kit, or involving one or more of TrkA, TrkB and HGK in addition to c-fms, c-kit, or both c-fms and c-kit.

100111 The compounds of Formula II have the following structure:



Formula II
all salts, prodrugs, tautomers, and isomers thereof,
wherein;

D has a structure selected from the group consisting of


in which ? indicates the attachment point of D to A2 of Formula II;
A2 is -CH2- or -C(O)-;
B is selected from the group consisting of hydrogen, -CN, -OR41, -SR41, -NHR41, -NR4:R41,
-NR39C(O)R4' , -NR39S(O)2R41 , -C(O)NR39R41, -C(O)R41 , -S(O)^NR39R41, -S(O)2R41, halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryi. wherein lower alkyl is optionally substituted with one or more substituents selected from the group
consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino. dϊ-alkylamino, cycloalkyl,
heterocycloalkyl, aryl, and heteroaryi, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as B, or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH2, -CK, -NO2,
-S(O)2NH2, -C(O)NH2, -OR42, -SR42, -NHR42, -NR42R42, -NR39C(O)R42, -NR39S(O)2R42, -S(O)2R*2, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; M4 is -NR39CH2-, -NR39CH(R40)-, -NR19CH2CH2-, or -NR39C(O)-;
M5, Mιo, and Mis are selected from the group consisting of a bond, -NR39-, -S-, -O- , -NR19CII2-, -NR39CH2CH2-, -NR39CH(R40)-, -SCH2-, -OCH2-, -C(O)NR35-, -S(O)2NR39-, -CH2NR19-, -CH(Rω)NR39-, -NR59C(O)-, and -NR19S(O)2-;
M8 is selected from the group consisting of a bond, -CH2-, -CH2C(O)-, -S(O)2-, -S(O)2CH2-, -S(O)2CH(CH3)-, -S(O)2CH2CH2-, -S(O)2NR39-, -S(O)2NR39CH2-, -S(O)2NR35CH(CH1)-, -S(O)2NR19CH2CH2-, -C(O)-, -C(O)CH2-, -C(O)CH(CH3)-, -C(O)CH2CH2-, -C(O)NR19-, -C(O)NR39CH2-, -C(O)NR39CH(CH3)-, and -C(O)NR35CH2CH2-;
Q1. QU. Q4i. Q61. and Q141 are aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of -OR41, -SR41, -S(O)R4', -S(O)2R4!, -NHR41, -NR41R41, -NR39C(O)R41, -NR39S(O)1R41, halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as a substituent of Q1, Q", Q41, Q61, or Q141, or as a substituent of lower alkyl arc optionally substituted with one or more substituents selected from the group consisting of -OH. -NH2. -CN, -NO2, -S(O)2NH2, -C(O)NH2, -OR42, -SR42, -NHR42, -NR42R42, -NR39C(O)R42,
-NR30S(O)2R42, -S(O)2R42, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
Q12 is fluoro, chloro or -CF3;
Q13 and Q14 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl;
Q"2, Q24, Q52, and Q34 are independently selected from the group consisting of hydrogen, halogen, lower alJcyl, fluoro substituted lower alkyl, -XR44R44. -OR44, and -SR"4, provided, however, that at least one of Q22 and Q2-* and at least one of Q57 and QM is hydrogen, fluoro, chloro, lower alkyl or fluoro substituted lower alkyl;
Q74 and Q152 are hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl,
-NR44R44, -OR44, or -SR44; Q72 is hydrogen, lower alkyl or fluoro substituted lower alkyl

R39 at each occurrence is independently selected from the group consisting of hydrogen and lower alkyl;

R40 is selected from the group consisting of lower alkyl, and fluoro substituted lower alkyl,

R41 at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R41 or as substituents of lower alkyl are are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH2, -CN, -NO2, -S(O)2NH2, -C(O)NH2, -OR42, -SR42, -NHR42, -NR42R42, -NR39C(O)R42, -NR3^S(O)2R42, -S(O)2R42, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
R42 at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono- alkylammo, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituenls selected from the group consisting of halogen, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy; and
each R44 is independently hydrogen, lower alkyl or fluoro substituted lower alkyl;
provided, however, that the compound is not



[0012] In one embodiment, a compound of Foπnula II has a structure according to the following sub-generic structure, Formula Ha,
a



Formula Ha,
all salts, prodrugs, tautomers, and isomers thereof,
wherein:
Qla is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, and -OR41;
Q5 is hydrogen, -CN, -OR4', fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more
substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, and -OR41; and
A2, M4, Q12, Q13, Q14 and R4! are as defined for Formula II;
provided, however, that the compound is not


[0013] In one embodiment of compounds of Formula Ha, A2 is -CH2- and M4 is -NHCH2-. In one embodiment A2 is -C(O)- and M4 is -NHCH2-. In one embodiment A2 is -C(O)- and M4 is

-NHC(O)". In one embodiment A2 is -CH2- and M4 is -NHC(O)-.

[0014] In one embodiment of compounds of Formula Ha, A2 is -CH2-, M4 is -NHCH2-, Q5 is -OR41, -CN, Ci-3 alkyl, fluoro substituted CM alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl arc optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, and -OR4 '; and Qu and Qw are hydrogen.

[0015] In one embodiment of compounds of Formula Ha, A2 is -C(O)-, M4 is -NHCH2-, Q5 is -OR4!, -CN, C1^ alkyl, fluoro substituted Ci_3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, and -OR41; and Qπ and Q14 are hydrogen.

[0016] In one embodiment of compounds of Formula Ha, A2 is -C(O)-, M4 is -NHC(O)-, C/ is -OR41, -CN, C]_3 alkyl, fluoro substituted C)_3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR4', -NR41R41, and -OR41; and Q13 and Q14 are hydrogen.

[0017] In one embodiment of compounds of Formula Ha, A2 is -CH2-, M4 is -NHC(O)-, Q5 is -OR41, -CN, C] 3 alkyl, fluoro substituted C^ alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, and -OR41; and Q13 and Q14 are hydrogen.

[0018] In one embodiment, further to any of the embodiments of Formula Ha above, R41 is R4".

[0019] In one embodiment, further to any of the embodiments of Formula Ha above, Qi a is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy and trifluoromethoxy; A2 is -CH2-; M4 is -NHCH2-; and Q5 is -CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluorornethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. In one embodiment, further to any of the embodiments of Formula Ha above, Qla is phenyl monc substituted with chloro, preferably at the 4-pobition, A2 is -CH2-; M4 is -NHCH7-: and Q3 is -CN, fluoro, chloro, methyl,
trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. In one embodiment, further to any of the embodiments of Formula Ua, Qla is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy, preferably at the 6-position; A2 is -CH2-; M4 is -NHCH2-; Q5 is -CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy.

[0020] In one embodiment of compounds of Formula Ha, A2 is -CH2-; M4 is -NHCH2-: Qla is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy and trifluoromethoxy; Q5 is hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, -CN, or l -methyl-lH-pyrazole-4-yl; Q12 is fluoro or chloro; and QB and Q14 are hydrogen. In one embodiment, A2 is -CH2-; M4 is -NHCH2-; QIa is phenyl mono substituted with chloro, preferably at the 4-position; Q5 is hydrogen, chloro, methyl, methoxy, or -CN; Q12 is fluoro or chloro; and Q13 and Q14 are hydrogen. In one embodiment, A: is -CH2-; M4 is -NHCH2-; Qla is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy, preferably at the 6-position; Q5 is hydrogen, chloro, methyl, methoxy, -CN, or l-mcthyl-lH-pyrazole-4-yl; Q12 is fluoro or chloro; and QB and Q14 are hydrogen.

[0021] In one embodiment of compounds of Formula Ha, the compound is selected from the group consisting of:
(4-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-amine (P-0132),
(4-Chloro-benzyl)-[6-chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0161),
[6-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-ρyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0174),
[6-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0176),
{6-Chlorc-5-[5^1-methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridin-3-ylmelhyl]-pyτidin-2-yI h

(6-trifluoromethyl-pyridin-3-ylmethyl)-amme (P-0179),
[S-fS-Chloro-lH-pyTrolo'Ll.S-bJpyTidin-S-yliriethy'O-δ-fluϋro-pyridin-z-ylj-Cβ-trifluoromethyl^ pyridin-3-ylmethyl)-amine (P-0186),
[6-Fluoro-5-(5-methoxy-lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl- pyridin-3-ylmethyl)-aminc (P-0187),
[6-Fluoro-5-(lH^yrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluorom6thyl-pyridin-3- ylmethyl)-amine (P-0188),
3-{2-Chloro-6-[(6-trifluoromethyl-pyridiπ-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH- pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0232),
[6-Chloro-5-(5-methy]-l H-pyrrolof2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl- pyridin-3 -ylmethyl)-amine (P-0233),
f6-Chloro-5-(5-methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-(6-trifluoroincthyl- pyridin-3 -ylmethyl)-amine (P-0234),
[6-Fluoro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylraethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-yIπn3lhyl)- amine (P-0378),
[5 -(5 -ChI oro- 1 II-pyrτolo[2,3 -b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl] -(6-methoxy -pyridin-3 -ylmethyl)-amine (P-0379), and
all salts, prodrugs, tautomers, and isomers thereof.

[0022] In one embodiment, a compound of Formula II has a structure according to the following sub-generic structure, Formula lib,



Formula lib,
all salts, prodrugs, tautomers, and isomers thereof,
wherein:
A3 is -CH2- or -C(O)-;
Q15 is hydrogen, -CN, -OR4', fluoro, chloro, lower alkyl, fluoro substituted lower alkyl,
cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, hctcrocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR4 ',
-NR41R41. and -OR41: and
M5, Q1 : , Q22, Q24f and R41, are as defined for Formula H.

[00231 In one embodiment of compounds of Formula lib, M5 is -NR39CH2-, -NR35CH(R4")- or -NR^C(O)-; A3 is -CH2- or -C(O)-, preferably -CH2-; Q11 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR42, -NR42R42, and -OR4*; Q'5 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy. fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR42. -NR42R42, and -OR42; and Q22 and Q24 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably hydrogen, fluoro, chloro, or -CF1, more preferably both Q22 and Q24 are hydrogen; wherein R42 is as defined for Formula II,

[0024] In one embodiment of compounds of Formula lib, M5 is -NHCH2-; A3 is -CH2-; Q1 ' is phenyl or heteroaryl, wherein phenyl or heteroaryl are optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; Q15 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl arc optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and Q22 and Q24 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably hydrogen, fluoro, chloro, or -CF3, more preferably both Qn and Q24 are hydrogen.

[0025] In one embodiment of compounds of Formula lib, M5 is -NHCH2-; A3 is -CH2-; Q1 1 is phenyl substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, fluoro substituted methyl, methoxy, and fluoro substituted methoxy; Q15 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, preferably hydrogen or chloro; and Q22 and Q24 are hydrogen.

[0026] In one embodiment of compounds of Formula lib, the compound is selected from the group consisting of:
(4-Chloro-benzyl)-[5-(5-chloro-lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0260),
[5-(5-Chloro-lHφ>τrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2.6-difiuoro-bcnzyl>amine

(P-026I),
[5-(5-ChJoro-lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyrirnidin-2-yl]-C2-trifluoromethyl-benzyl)-amine (P-0262),
(2-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridIn-3-ylmethyl)-pyrimidm-2-ylJ-amine

(P-0263), [5-(5-Chloro-lH-pyrrolot2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-benzyl)-amine

(P-0264),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,4-difluoro-benzyl)-amine

(P-0265),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-ben/yl)- amine (P-0266),
[S-CS-Chloro-l H-pyrrolop^-bJpyridin-S-ylmethyO-pyrimidin-l-ylJ^.S-difluoro-benzy^-amiπe

(P-0267),
[5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidiπ-2-yl]-(3-trifluoromethyl-benzyl)-amine (P-0268),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-5-trifluoromethyl-bcnzyl)-amine (P-0289),
(2-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0291),
(2,5-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0292).

(2-Chloro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2!3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0293),
(3-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0294),
(3,5-Difluoro-benzyl)-t5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-aminc (P -0295),

(2-Fluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0300),

(2-Chloro-benzyl)-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0301),

[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl)-aminc

(P-0302),
[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethoxy-benzyl)-amine

(P-0303),
(5 -Chloro-2-£luoro-benzyl)-[5 -( 1 H-pyrτolo[2,3-b]pyridin-3 -ylmethyl)-pyri midin-2-yl] -amine

(P-0304),
(2,4-Dichloro-benzyl)-[5-(lH-pyn-olo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0305).

(2,4-Difluoro-benzyl)-[5-(lH-μyrro]o[2,3-b]pyridin-3-y!methyl)-pyrimidin-2~yl]-amine (P-0306),

(4-Chloro-ben2yl)-[5HlH-p>τrolo[2,3-b]ρyridin-3->lmethyI)-pyrimidin-2-yl]-aminc (P-0307),

[5-(lH-Pyrroiυ[2,3-b|pyridin-3-yimethyi)-pyπmidin-2-yϊ]-(4-trifluoromethyl-benzy!)-aπiine

(P-0308),
(2-Fluoro-3-trifluorornethyi-benzyl)-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yi]-amine (P-0309),
(2,5-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl>pyrimidm-2-yl]-arnine (P-0310).

(S-Chloro-l-fluoro-benzyO-fS-ClH-pyrrolop^-bJpyridin-S-ylmethylj-pyrimidin^-ylJ-amine

(P-0311),
(2-Difluoromethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-ammc

(P-0312),
(2,3-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyrimidin-2-yl]-amine (P-0313),

(4-Chloro-2-f!uoro-benzyl)-[5-(lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]]-aminc

(P-0314),
(5-Fluoro-2-trifluoromethyl-benzyl)-[5-(lH-pyrτolo[2)3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]- amine (P-0315),
(2-Chloro-4-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0316),
(5-Chloro-2-mεthyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0317),
(5-Fluoro-2-methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0318),
(2-Fluoro-4-trifluoromcthyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0319),
(4-Fluoro-2-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0320),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethy])-pyrimidin-2-yl]-(2-difluoromcthoxy-benzy])-amine (P-0390),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluoro-2-trifluoromethy]-benzyl)-amine (P-0391),
(3-Chloro-2-fluoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-ρyrimidin-2-yl]-amine (P-0392),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro~3-trifluoromcthyl-bcnzyl)-amine (P-0393),
[5-(5-Chlorθ'lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-f]uoro-4-trifluoromethyl-benzyl)-amine (P-0394),
[5-(5-Chloro-l H-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,3-difluoro-benzyi)-amine

(P-0395),
(2-Chloro-4-fluoro-benzyl)-[5-(5-chloro-lH-pyrroio[2,3-b]pyridin-3-ylmethyl)-pyr.midin-2-yI] -amine (P-0396),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-tnfluoromcthoxy-benzyl)-amine (P-0402),
(2-Chloro-5-fiuoro-benzyl)-[5-(lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-ρyrimidin-2-yl]-amine (P-0407),
(2-Chloro-5-fluoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-ρyriπiidm-2-yl]- amine (P-0408), and
all salts, prodrugs, tautomers, and isomers thereof.

[0027] In one embodiment, a compound of Formula II has a structure according to the following sub-generic structure, "Formula lie,



Formula lie,
all salts, prodrugs, tautomers, and isomers thereof,
wherein:
A6 is -CH2- or -C(O)-;
M8a is -CH2-, -CH2C(O)-, -C(O)NR39CH2-, -C(O)NR39CH(R40)-, or -C(O)NR39CH2CH2-;

Q45 is hydrogen, -CN, -OR41, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41,
-NR41R41, and -OR41; and
Q41, Q52, Q54, R39, R40, and R41 are as defined for Formula II;

provided, however, that the compound is not
"


|ΘΘ28) In one embodiment of compounds of Formula lie. M*a is -C(O)NR39CH2-,
-C(O)MR39CH(CH3)-, or -C(O)NR39(CH2)2-; A6 Is -CH2- or -C(O)-, preferably -CH2-; Q41 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl. fluoro substituted lower alkyl, -NIIR4"*, -NR4~R4", and -OR42; Q45 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroar>'l, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR42, -NR42R42, and -OR42; and Q52 and Q54 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably Q32 and Q54 are independently hydrogen, fluoro, chloro, methyl, or -CF3; wherein R42 is as defined in Formula II.

[0029] In one embodiment of compounds of Formula He, M8a is -C(O)NHCH2-,
-C(O)NHCH(CHj)- or -C(O)NH(CH2)2-; A6 is -CII2- or -C(O)-, preferably -CH2-; Q41 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, fluoro substituted methyl, methoxy, and fluoro substituted methoxy; Q45 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen or chloro; and Q52 and Q54 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably Q52 and Q54 are methyl.

[0030] In one embodiment of compounds of Formula lie, the compound is selected from the group consisting of.
3-(l-Benzyl-3,5-dimethyl-lH-pyrazol-4-ylmethyl)-lH-pyrrolo[2,3-b]pyridine (P-0133),
2-[3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazol-l-yl]-l -phenyl-cthanone

(P-0134),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 4-methoxy-benzylamide (P-0135),
3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-chloro-benzylamide (P-0136),
3, 5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-fluoro-benzylamide (P-0137),
3-[3,5-Dimethyl-l-(5-trifluoromethyl-furan-2-ylmethyl)-lH-pyrazol-4-ylmethyl]-lH-pyrrolo[2,3-b]pyridine (P-0138),
3-[3.5-Dimethyl-l-(5-inethyl-isox-aol-3-ylmcthyl>ni-pyrazol-4-ylmethyl]-lH-pyrrolo[2.3-bjpyridine (P-0139),
3,5 -Dimethyl -4-( 1 H-pyrrolo[2,3-b]ρyridin-3-ylmeth>l)-pyrazole-l -carboxylic acid 4-chloro-benzylamide (P-0140),
3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-ρyrazole-l -carboxylic acid [2-(4-methoxy-phenyl)-ethyl]-amide (P-0141), 3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 3-methoxy- benzylamidc (P-0142),
3-{3,5-Dimethyl-l -[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-y]methyl]-lH-pyrazol-4- ylmethyl}-lH-pyrrolo[2,3-b]pyridine (P-0143),
3-[3,5-Dimcthyl-l -(4-methyl-2-phenyl-thiazol-5-ylmethyl)-l H-pyrazol-4-ylmethyl]-l H-pyrrolo[2,3-b]pyridine (P-0144),
3,5-Dimethyl-4-(lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-methoxy-benzylamide (P-0145),
3 ,5-Ditnethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid [2-(2,4-dichloro-phenyl)-ethyl]-amide (P-0146),
3,5-Dimcthyl-4-(lII-ρyrrolof2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide (P-0147),
3,5-Dimethyl-4-(l H-ρyrro]o[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid [2-(2-fluoro-phenyl)-cthyl]-amide (P-0148),
3, 5-Dimethyl-4-(lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid ((S)-I -phenyl-ethyl)-amide (P-0149),
3,5-Dimethyl-4-(lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 3-fluoro-benzylamide (P-0150),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazolc-l -carboxylic acid 4-fluoro-benzylamide (P-0151),
3)5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 4-methyl-benzylamide (P-0152),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-methyl-benzylamide (P-0153),
4-(5-Cbloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazolc-l-carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide (P-0157),
4-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3>5-dimethyl-pyrazole-l -carboxylic acid 4-fluoro-benzylamide (P-0158),
4-(5 -Chloro- 1 H-pyrrolo[2,3 -b]pyridin-3 -ylmethyl)-3 t5-dimethyl-pyrazole- 1 -carboxylic acid 4-chloro-bcnzylamide (P-0159),
4-(5-Chloro-lH-pyrrQlo[2,3-b]ρyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-l -carboxylic acid [(S)-l-(4-fluoro-phenylVethyl]-amidc (P-0160) , and
all salts, prodrugs, tautomers, and isomers thereof.

(00311 In one embodiment, a compound of Formula II has a structure according to the following sub-generic structure, Formula Hg,

Formula Hg,
all salts, prodrugs, tautomers, and isomers thereof,
wherein:
A8 is -CH2-, or -C(O)-;
Q65 is hydrogen, -CN5 -OR41, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl,
cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41,
-NR41R41, and -OR41; and
M10, Qbl, Q72, Q74, and R41 are as defined for Formula II.

[0032] In one embodiment of compounds of Formula Hg, M10 is -NR19CH2- or -NR39-(CH2)r; A8 is -CH2- or -C(O)-, preferably -CH2-; Q61 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR42, -NR42R42, and -OR42; Q65 is hydrogen, -CN1 fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR42, -NR42R42, and -OR42; and Q74 is hydrogen, fluoro, chloro, lower alkyl or fluoro substituted lower alkyl, wherein R42 is as defined for Formula II.

[0033] In one embodiment of compounds of Formula Hg, M10 is -NHCH2-; A8 is -CH2-; Q6! is phenyl optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, trifluoromethyi, methoxy, difluoromethoxy or trifluoromethoxy; Q6' is hydrogen, fluoro, -CN, or l-methyl-pyrazGl-4-yl; Q '" is lower alkyl or fluoro substituted lower alkyl; and Q is hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl. In one embodiment. Mn, is -NHCH2-; A8 is -CH2-; Q6'' is 4-fluoro-phenyl; Q65 is hydrogen, chloro, -CN, or 1 -methyl-pyrazol-4-yl; Q72 is methyl or ethyl; and Q'4 is hydrogen or chloro.

[0034] In one embodiment, the compound of Formula Hg is selected from the group consisting of :
[l -Ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-(4-fluoro-benzyl)-aminc (P-0165),
(4-Fluoro-benzyl)-[l-methyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-amine

(P-0169),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylπiethyl)-l-methyl-lH-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (P-0170),
(4-Fluoro-benzyl)-{l-mcthyl-5-[5-(l-methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridiπ-3-ylmethyl]-lH-pyrazol-3-yl}-amine (P-0180),
(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazoL-3-yl]-methanone (P-0184),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-l-ethyl-lH-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (P-Ol 85),
3-[5-(4-Fluoro-bcnzylamino)-2-methyl-2H-pyrazol-3-ylmethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0191),
(3-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l -methyl-lH-pyrazol-3-yl]-amine (P-0410),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l-methyl-lH-pyrazol-3-yl]-(2,5-difluoro-bcnzyl)-amine (P-0411) , and
all salts, prodrugs, tautomers, and isomers thereof,

[0035] In one embodiment, a compound of Formula II has a structure according to the following sub-generic structure, Formula Up,



Formula Up,
all salts, prodrugs, tautomers. and isomers thereof,
wherein:


Q14S is hydrogen. -CN, -OR41, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl.
cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, hcterocycloalkyl, arvi or hεtercaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fiuoro substituted lower alkyl, -NHR41,
-NR41R41, and -OR41;
Q " is hydrogen, fiuoro, chloro, lower alkyl, fiuoro substituted lower alkyl, lower alkoxy, or fiuoro substituted lower alkoxy; and
Mi8, Q141, and R41, are as defined for Formula II;

provided, however, that the compound is not
or


[0036] In one embodiment of compounds of Formula Up, Mi8 is -NR39CH2- or -NR39 -(CH2),-; Ai6 is -CH2- or -C(O)-, preferably -CH2-; Q'41 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fiuoro substituted lower alkyl, -NHR42, -NR42R42, and -OR42; Q145 is hydrogen, -CN, fiuoro, chloro, lower alkyl, fiuoro substituted lower alkyl, lower alkoxy, fiuoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fiuoro substituted lower alkyl, -NHR42, -NR42R42, and -OR42; and Q1S2 is hydrogen, fiuoro, chloro, lower alkyl, or fiuoro substituted lower alkyl; wherein R42 is as defined for Formula II.

[0037] m one embodiment of compounds of Formula Up, M18 is -NH-CH2- or -NH-(CH2)^-, preferably -NH-CH2-; A16 is -CH2- or -C(O)-, preferably -CH2-; Q141 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with 1 or 2 substituents selected from the group consisting of fiuoro, chloro, lower alkyl, fiuoro substituted lower alkyl, loweT alkoxy, fiuoro substituted lower alkoxy, and heterocycloalkyl; Q145 is hydrogen, -CTs, fiuoro, chloro, lower alkyl, fiuoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen, -CN, or chloro; and Q'" is hydrogen, fiuoro, chloro, lower alkyl, or fluoro substituted lcwer alkyl, preferably hydrogen or chloro, more preferably chloro.

(U038J In one embodiment, the compound of Formula Ih is selected from the group consisting of [4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-timine (P-0156),
[4-Ethyl-5-(lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-thiazol-2-yl]-(4-fluoio-benzyl)-amme (P-0162),

(4-Fluoro-benzyl)-[4-methyl-5-(l H-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-thiazol-2-yl]-amme
(P-0163),
[4-Chloro-5-(l H-pyrrolo[2,3-b]pyndin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine

(P-0164),
[4-Chloro-5-(l H-pyrrolo[2,3-b]pyndm-3-ylmethyl)-thiazol-2-yl]-pyπdin-2-ylmethyl-amme

(P-0167),
[4-Chloro-5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyndin-4-ylmethyl-amine

(P-0168),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2-ylmethyl)-amine (P-0171),
[4-Chloro-5-(lH-pyrrolo[2,3-bJpyridin-3-ylmcthyl)-thiazol-2-yl]-(l,5-dimetliyl-lH-pyra7ol-3-ylmethyl)-amine (P-0172),
[4-Chloro-5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl-pyπdin-3-ylmethyl)-amine (P-0173),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2!5-dimethyl-2H-pyrazol-3-ylmethyl)-amine(P-0175),
[2-(4-Fluoro-benzylamino)-thiazol-5-yl]-(lH-pyrrolo[2,3-b]pyridin-3-yl)-methanone (P-0177).

{2-[(4-Chloro-benzyl)-methyl-ammo]-thiazol-5-yl}-(lH-ρyiτolo[2,3-b]pyridin-3-yl)-methanone (P-0178),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-thiazol-2-ylJ-thiazol-2-ylmethyl-amine (P-0189),
[4-Chloro-5-(5-chloro-lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thia7ol-2-yl]-(6-methoxy-pyπdm-3-ylmethyl)-amine (P-0190),
Benzyl-[4-chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-thiazol-2-yl]-amine (P-0192), [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-thiazol-2-yl]-(3-methoxy-benzyl)-amine (P-0193),
(4-Chloro-ben7y])-[4-chloro-5-(5-chloro-lH-pyiτolo[2,3-b]pyridm-3-ylmethyl)-thiazol-2-yl]-amine (P-0194),
[4-Chloro-5-(5-chloro-lH-ρyrrolo[2,3-b]pyπdin-3-ylmethyi)-thiazol-2-yi]-(4-fluoro-benzyb-amine (P-S 195),
[4-Chloro-5-(5-chloro-lH-pyrroIo[2)3-b]pyndin-3-ylmethyl)-thiazol-2->l]-(2,4-dimethyl-thiazol-5-ylmethyl)-amme (P-0196),
[4-Chloro-5-(5-chloro-lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H-imidazol-4-ylmethyl)-amine (P-Ol 97), [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lhiazol-2-yl]-(2-ethyl-2H-pyrazol-3- ylmethyl)-amine (P-0198),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-thiazol-2-yl]-(6-methoxy-pyridin-2- ylmethyl)-amine (P-0199),
[4-Chloro-5 -(5 -chloro- 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-thiazol-2-yl] -(3 -fluoro-pyridin-4- ylmcthyl)-amine (P-0200),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmetliyl)-thiazol-2-yl]-(2-methyl-thiazol-4- ylmethyl)-amine (P-0201),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-inethyl-thiazoI-5- ylmethyl)-amine (P-0202),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-thiazol-2-yl]-(5-chloro-pyridm-2- ylmethyl)-amine (P-0203),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thia7:ol-2-yl]-(2,4-dimethyl-thiazol-5-ylmethyl)-amine (P-0204),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H-imidazol- 4-ylmethyl)-amine (P-0205),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyτidin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2-ylmethyl)-amine (P-0206),
^-Chloro-S-ClH-pyrrolo^J-bJpyridin-S-ylmethy^-thiazol^-ylJ-CS-methoxy-pyridin-S-ylmethyl)-amine (P-0207),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4,5-dimethyl-thiophen-2-ylmethyl)-amine (P-0208),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,5-dimethyl-thiophen-3-ylmethyl)-amine (P-0209),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (P-0231),
[4-Chloro-5-(5-chloro-lII-pyrrolo[2,3-b]pyτidin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyI-amine (P-0236),
[4-Chloro-5-(5-chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl-amine (P-0237),
[4-Chloro-5-(5-chloro-lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-chloro-pyridin-4- >imcthyl)-amine (P-0238),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(l -ethyl-lH-pyrazol-4-ylmethy!)-amme (P-0239),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2-ylmethyl)-amine (P-0240), ^-Chloro-S^S-chloro-lH-pyiTolotl.S-bjpyridm^-ylmethyO-thiazol^-ylj^S-methoxy-pyridin-S- ylmethyl)-amine (P-0241),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl- pyridin-3-ylmethyl)-amine (P-0242),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-6-fluoro- beπzyl)-amine (P-0243),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]ρyridiπ-3-ylmethyl)-thiazol-2-yl]-phenethyl-amine

(P-0244),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-difluoro-ben2yl)-amine (P-0245),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-fluoro-benzyl)-amine (P-0246),
[4-ChIOrO-S-(S-ChIOrO- lH-pyrrolo[2)3-b]pyridin-3-ylmetliyl)-thiazol-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-0247),
(2-Chloro-benzyl)-[4-chloro-5 -(5 -chloro- 1 H-pyrrolo[2,3 -b]pyridin-3-ylmethyl)-thiazol-2-yl] -amine (P-0248),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2 -methyl-benzyl)-amine (P-0249),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-4-fluoro-benzyl)-amine (P-0250),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-fluoro-pyridin-2-ylmethyl)-amine (P-0251),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-moφholm-4-yl-pyridin-2-ylmethyl)-amine (P-0252),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3,5-dichloro-pyridin-4-ylmethyl)-amine (P-0253),
[4-Chloro-5-(5-chloro-lII-pyrrolo[2>3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0254),
[4-Chloro-5-(5-chloro-lH-pyrrolot2.3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2-ylmethyl)-amine (P-0255),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyi)-aminc
(P-0290) , and
ali salts, prodrugs, tautomers, and isomers thereof.

(0039] The compounds of Formula III have the following structure:

3



Formula III,
all salts, prodrugs, tautomers, and isomers thereof,
wherein:
L4 is -CH2-, -CH2CH2-. -CH(R40)-, -C(O)- or -C(O)NH-;
R81 is selected from the group consisting of hydrogen, -OR41, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR41, -NR41R41, -OR41 and -S(O)2R41;
R82 is selected from the group consisting of hydrogen, C^3 alkyl, fluoro substituted C2Λ alkyl, OH, Ct_3 alkoxy, and fluoro substituted Cι.3 alkoxy;

R83 is heterocycloalkyl, heteroaryl, or
, in which ^ indicates the
attachment point of R83 to L4 of Formula III, wherein heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHR41, -NR41R41, -OR41 and -S(O)2R41;
R92, R93, Rβ4, R95, and R96 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHS(O)IR4',
-NHC(O)R4', -NHR41, -NR41R41, -OR41 and -S(O)2R4"'; and
R and R41 are as defined for Formula II;

provided, however, that the compound is not
H

10040] In one embodiment of compounds of Formula III, L4 is -CH2-, -CH2CH2-, -CH(CH3)- or -C(O)-; R81 is hydrogen, fluoro, chloro, -CN, lower alkyl, fluoro substituted lower alkyl, lower

alkoxy, or fluoro substituted lower alkoxy; R82 is hydrogen; R83 is
R , wherein R92,

R93, R94, R95, and R'6 are independently hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, provided, however, that when R94 is fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, at least one of R92, R93, RS5, and R96 is fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy.

[0041] In one embodiment of compounds of Formula III, L4 is -CH2-, -CH2CH2-, -CH(CH3)- or -C(O)-; R81 is hydrogen, fluoro, chloro, -CN, methyl, or methoxy, preferably hydrogen, chloro,

-CN, or methyl; R82 is hydrogen; R° is
R , wherein R92, R93, R94, R95, and R% arc independently hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy, preferably hydrogen, chloro, methyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy, provided, however, that when R94 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy, at least one of R**', R93, R95, and R9* is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy,
difluoromethoxy or trifluoromethoxy.

[0042] In one embodiment of compounds of Formula III, L4 is -CH2-; RS1 is fluoro, chloro, -CN.

methyl, or methoxy, preferably chloro, -CN, or methyl; R82 is hydrogen; R83 is
R
wherein R94 is hydrogen and R92, R93, R95, and R* are independently hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy.

[0043] hi one embodiment of compounds of Formula III, L4 is -CH2-, -CH2CH2-, -C(O)-, or -CH(CH3)-, preferably -CH2- or -C(O)-; R81 is hydrogen or flouro; RS2 is hydrogen; RS1 is


, wherein R is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, methyl, or trifluoromethyl, and wherein R93, R94, R95, and R96 are independently hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy, preferably hydrogen or fluoro. In one embodiment, L4 is -CH2-, -C(O)-, or -CH(CH3)-; R81 is hydrogen; R82 is hydrogen; R92 is fluoro. chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; and R93, R94, R95, and R96 are hydrogen. In one embodiment, L4 is -CH2-, -C(O)-, or -CH(CH3)-; R81 is hydrogen; R82 is hydrogen; R92 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; R94, R95, and R96 are hydrogen; and R93 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, trifluoromethyl or methoxy, more preferably fluoro. In one embodiment, L4 is -CH2-, -C(O)-, or -CH(CH3)-; R81 is hydrogen; R82 is hydrogen; R92 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; R93, R95, and R96 are hydrogen; and R94 is fluoro. chloro. methyl, ethyl. trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro. ehloro, methyl or trifluoromethyl, more preferably fluoro. In one embodiment, L4 is -CH2CHI- or -C(O)-, Ru is hydrogen: Rn' is hydrogen; R92, R95, and K9t are hydrogen; R93 is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably hydrogen, fluoro, chloro. methyl, trifluGromethyl, methoxy, or trifluoromethoxy more preferably fluoro, chloro, trifluoromethyl or methoxy; and R94 is hydrogen, fluoro, or chloro; provided, however, that when L4 is -C(O)- and R94 is fluoro or chloro, R93 is not hydrogen. In one embodiment, L4 is -CH2CH2-, R81 is hydrogen; R82 is hydrogen: R92, R94, R95, and R96 are hydrogen; and R93 is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably hydrogen or fluoro In one embodiment, L4 is -C(O)-, RS1 is hydrogen, R82 is hydrogen; R92, R95, and R96 are hydrogen; R93 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, trifluoromethyl or methoxy; and R94 is hydrogen, fluoro, or chloro.

[0044] In one embodiment of compounds of Formula III, RS3 is pyrrolidine, morpholme, pyridine, pyπmidme, pyrazme, pyrazole, isoxazole, imidazol, or benzimidazole, wherein R^ is optionally substituted with one or more substituents independently selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylammo, -NHR41, -NR41R4 , -OR41 and -S(O)2R41, preferably wherein RS3 is optionally substituted with 1 or 2 substituents independently selected from fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, or cycloalkylamino, more preferably fluoro, chloro. methyl, trifluoromethyl, methoxy or morpholine.

[0045] In one embodiment of compounds of Formula III, L4 is -CH2-, -CH2CH2-, -CH(CH1)- or -C(O)-, preferably -CH2-, -CH2CH2-, or -C(O)-; R81 is hydrogen, fluoro. chloro, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen, chloro, methyl or -CN; R82 is hydrogen; and R83 is pyrrolidine, morpholine, pyridine, pyπmidine, pyrazine. pyrazole, isoxazole, imidazole, or benzimidazole, wherein R81 is optionally substituted with 1 or 2 substituents independently selected from fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, or cycloalkylamino, preferably fluoro, chloro, methyl, trifluoromethyl, methoxy or morpholine.

[0046] In one embodiment of compounds of Formula III, the compound is selected from the group consisting of:
Pyridin-3-ylmethyl-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]-amme (P-0094), (5-Methyl-isoxazol-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethy])-pyridin-2-yl]-amme (P-0095),
(2-Pyrrohdin-l -yl-cthyl)-[5-(lH-pyrrolot2,3-b]pyridin-3-ylmethyl)-pyi idiπ-2-yl]-amme (P-0096), [l -(4-Methanesulfonyl-phenyl)-ethyl]-r5-(lH-ρyrrolo[2,3-b]ρyridm-3-ylmethyl)-pyπdiπ-2-yij-amine (P-0097),
(2-Morphohn-4-yl-ethyl)-[5-( lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-amine (P-0099), 3,4-DichIoro-N-[5-(lH-p\rrolo[2)3-b]pyridin-3-\lmethyl)-pyridm-2-yl]-benzamide (P-OlOO), 2-Chloro-4-fluoro-N-[5-(l H-pyrrolo[2.3-b]pyπdin-3-vlmethyl)-pyridin-2-yl]-benzamide (P-OlOl), 2,5-Dimethyl-2H-pyrazole-3-carboxyhc acid [5-(lH-ρyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2- yl]-amide (P-0102),
Thiophene-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide

(P-0103),
2-Methoxy-N-[5-(l H-p>τrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamidc (P-Ol 04),

N-[5-(lH-Pyrrolo[2>3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isoriicotinamide (P-0105),
Pyrazine-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide

(P-Ol 06),
Pyridine-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide

(P-0107),
6-Methyl-N-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-nicotinamide (P-0108),

4-Fluoro-3-mcthyl-N-[5-( l II-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide

(P-0109),
5-Methyl-pyrazine-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3~ylmethyl)-pyridin-2-yl]-amide (P-OI lO),
3-Chloro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-OlI l),

4-Fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethyl-benzamide

(P-0112),
N-[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromcthoxy-benzamide

(P-0113),
N-[5 -( 1 H-Pyrrolo[2,3 -b]pyridin-3 -ylmethyl)-pyridin-2-yl] -3-tri fluoromethyl-benzamide (P-0114),

3-Chloro-4-fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0115),

3,4-Difluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0116),

2-Chloro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0117),

5-Fluoro-2-methyl-N-[5-(lH-p>τrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide

(P-Ol 18),
2-Fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-Ol 19),

3 -Methoxy-N-[5 -( 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyridin-2-yl]-benzamide (P-0120),

3-Fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0121),

3-Methy]-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0122),

2-Chloro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yi]-isonicotinaraide (P-0123).

((R)-I -Phenyl-cthyl)-[5-(lH-pyrro]o[2>3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0125).

(3-Moφholin-4-yl-berι^l)-[5-(lH-pyπ'olo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-aminc

(P-0126),
[!-(2-Fluoro-phcnyl)-cthyl]-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyr)-pyridin-2-yl]-amiπe

(P-0127).
[2-(3-Fluoro-phenyl)-ethyl]-[5-(lH-pyrrolo[2)3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0128),
(3-Chloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethy])-pyπdin-2-yl]-amine (P-0129),

( 1 -Methyl- 1 H-imidazol-4-ylmethyl)-[5-( 1 H-pyiτolo [2,3 -b]pyπdin-3 -ylmethyl)-pyridin-2 yl] amine (P-0130),
(l,5-Dimethyl-lH-pyrazol-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-pyridin-2-yl1- amine (P-0131),
[S-CS-Chloro-lH-pyrrolop^-bJpyπdin^-ylmethylJ-pyπdin^-y^-Cό-trifluoromethyl-pyπdiπ-S- ylmethyl)-amme (P-0181),
[5-(lH-Pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2-yl]-(6-tπfluoromethyl-pyπdin-3-ylmeth>l)- amine (P -0182),
(3-Chloro-pyπdm-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylπiethyl)-pyridm-2-yl]-amine

(P-0183),
(2-Chloro-6-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2-yl]-amiπe

(P-0210),
Phenethyl-[5-(lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyπdιn-2-yl]-amine (P-0211),
(2,4-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0212)

(2-Fluoro-benzyl)-[5-(lH-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amme (P-0213),

(3-Bromo-pyπdin-4-ylmcthyl)-[5-(lH-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-pyridm-2-yl]-amme

(P-0214),
(2-Methoxy-pyπdm-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-pyridin-2-yl]-amme

(P-0215),
(2-Chloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0216),

(2-Methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0217),

(1 -Methyl- lH-benzoimidazol-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyndin-2-yl]-amme (P-0218),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(l H-pyirolo[2,3-b]pyndin-3-ylmethyl)-pyndm-2-yl]-amme

(P-0219),
(lH-Benzoimidazol-2-ylmethyl)-[5-(lH-pyrro]o[2,3-b]pyridm-3-ylmethyl)-pyπdin 2-yl] -amine

(P-0220),
(2-Chloro-4-flαoro-benzyl) [5 (lH-pyrrolo[2,3-b]pyπdin-3-ylmcthyl)-pyπdin-2-yl]-amine
(P-022I),
(5-Methcxy-pyπdm-3->lmcth>j.)-[5-(lH-pyrrolo[2 3-b]pyπdin-3-ylmethyl)-pyndin-2-ylj-anint

(P-0222)
(3-riuoro-ρyiidm-4-ylmethyl)-[5-(lH-ρyτrolo[2,3-b]pyπdm-3-)lmethyl)-pyπdm-2-yl] amine

(P-0223),
(6-Methoxy-pyndin-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmeth>l)-pyπdm-2-yi]-aminc (P-0224),
(4-FIuoro-2-tnfluoromethyl-ben2y])-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2->l] amine (P-0225),
[5-(lH-Pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridm-2-yl]-(2-trifIuoromethyl-benzyl)-ammc
(P-0226),
(3)5-Dichloro-pyndm-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmcthyl)-pyπdin-2-yl]-dmine (P-0227),
(6-Mθφholin-4-yl-pyridin-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridm-2-vl] amine (P-0228),
(3-Fluoro-pyridin-2-ylmethyl)-[5-(l H-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-pyπdin-2-\l]-dminc

(P-0229),
(5-Fluoro-pyπdin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-amme

(P-0230),
(3-Chloro-pyridm-4-ylmethyl)-[5-(5-chloro-lH-pyrroIo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0235),
3-{6-[(3-Chloro-pyridm-4-ylmethyl)-amino]-pyridm-3-ylmethyl}-lH-pyrrolo[2,3-b]pyndine-5-carbonitπle (P-0256),
3-[6-(4-Chloro-benzylammo)-pyndin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile

(P-0257),
Propane- 1 -sulfonic, aud (2,4-difluoro-3-{[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2- >lamino]-methyl}-phcnyl)-amide (P-0258)
Propane- 1 -sulfonic acid (3-{[5-(5-chloro-lH-pyrrolo[2,3-b]ρyiidin-3-ylmethyl)-pyridm-2-ylamino]-methyl}-2,4-difluoro-phenyl)-amide (P-0259),
3-[6-(4-Trifluoromethyl-benzylamino)-pyπdin-3-ylmethyl]-lH-pyrτolo[2,3-b]pyridine-5-ϋarbonitπle (P-0269),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-(2-fluoro-benzyl)-amme
(P-0270),
3-[6-(2-Fluoro-benzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]ρyridme-5-carbomtπle

(P-0271),
(2-Fluoro-benz>I) [5 -(5 mcth>l-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p>πdm-2-ylJ-amine

(P-0272)
3 {6 [(6 lrifluoromctliyl-ρyπdm-1->lrnethylj-amino]-pyπdin-3-ylmethyl} I H pyrro!o[2 3-b]pyndme-5-carbonitπlc (P-0273),
3-[6-(2-TiifluoromethyI-benzylammo)-pyridin-3-ylmethyl]-lH-pyn"olo[2,3-bJpyridinc-5-carbonitnle (P-0274)
[5-(5-Chloro-lH-pyrrolo[2 3-b]pyriαin-3-ylmethyl)-pyridin-2->l]-(2-tπfluorumethyl-benzyl)- amine (P-0275),
[5<5-Methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl)- amine (P-0276),
3-[6-(2,6-Difluoro-benzylamino)-pyridin-3-yImethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0277),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-difluoro-beii2yl)-amine

(P-0278),
(2-Chloro-beπzyl)-[5-(5-methyl-lH-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0279),
(2-Chloτo-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P-0280),
3-[6-(2-Chloro-bcnzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile

(P-0281),
(ό-Methoxy-pyridin-S-ylmethy^-fS-CS-methyl-lH-pyrroloP^-bJpyridin-S-ylmethylJ-pyridin-Z-yl]-amine (P-0282),
[5-(5-Chloro-lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridiπ-2-yl]-(6-methoxy-pyridin-3-ylmethyO-amine (P-0283),
3- {6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl} -lH-pyrrolo[2,3-b]pyridinc-5-carbonitrile (P-0284),
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-lH-pyrrolo[2,3-b]pyridiii-3-ylraethyl)-pyridin-2-yl]-amine (P-0285),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-0286),
3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH-pyrτolo[2,3-b]p3'Tidine-5-carbonitrile (P-0287),
(2-Ethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0288),

(2,5-Difluoro-benzyl)-[5-(.lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyτidin-2-yl]-amine (P-0296),

(2,5-Difluoro-benzyl)-[5-(5-methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0297),
f5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-(2,5-difluoro-ben2yl)-amine

(P-0298),
3-[δ-(2,5-Difluoro-bcnzylamiπo)-pyridin-3-ylmethyl]-lH-pyπiolo[2J3-b]pyridinc-5-carbonitπle

(P-0299),
3-[6-(2-Trifluoromethoxy-benzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]ρyridine-5-carbonitrile (F-0321),
[5-(lH-Pyrrolo[2)3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethoxy-benzyl)-amine (P-0322),
3-[6-(2-Ethoxy-benzylaminϋ)-pyτidin-3-ylmethyl]-lH-pyπOlo[2,3-b]pyridine-5-carbonitrile

(P-0323),
[S-CS-Chloro-l H-pyrrolopj-bJpyridin-S-ylmethy^-pyridin^-ylJ-CS-fluoro-pyridin-S-ylmethyl)- amine (P-0324),
[S-CS-Fluoro-lH-pyrroloP^-bJpyridin-S-ylmethy^-pyridin^-ylJ-CZ-trifluoromethyl-benzyl)- amine (P-0325),
[5-(5-Methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifIuoromethyl-benzyl)- amine (P-0326),
(2-Chloro-benzyl)-[5-(5-fluoro-lH-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P-0327),
(2-Chloro-benzyl)-[5-(5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-ρyridin-2-yl]-amirie

(P-0328),
(2,5-Difluoro-benzyl)-[5-(5-fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0329),
(2,5-Difluoro-benzyl)-[5-(5-methoxy-lH-pyrrolof2,3-b]pyiidin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0330),
[5-(5-Fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-0331),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-lH-pyrro]o[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0332),
(2,6-Difluoro-benzyl)-[5-(5-fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0333),
(2,6-Dif!uoro-benzy])-[5-(5-methoxy-lH-pyτrolo[2,3-b]pyridiπ-3-ylmethyl)-pyτidin-2-yl]-aminc

(P-0334),
(2-Methoxy-benzyl)-[5-(l H-pyrrolo[2,3-b]ρyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0336),

3-t6-(2-Methoxy-benzylamino)-pyridin-3-ylmcthyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile

(P-0337),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-difluoromethoxy-benzyl)-amine (P-0338),
3-[6-(2-Difluoromethoxy-benzylamino)-pyτidin-3-ylmethyl]-lH-pyrrolo[2,3-bJpyridinc-5-carbonitrile (P-0339),
(2,6-DifluorO-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyridin-2-yl]-amine (P-0340),

(2,6-Difluoro-benzyl)-[5-(5-methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-ylj-amiπe

(P-0341),
(2,4-Dichlϋro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0342), (3-Fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0343),

(2-Fluoro-4-trifluorometliyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]- amine (P-0344),
(4-Chloro-2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]ρyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0345),
(3-Fluoro-5-trifluoromethyl-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridin-2-yl]- amine (P-0346),
(2-Morpholin-4-yl-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]- amine (P-0347),
(4-Chloro-3 -trifluoromethyl-benzyl)-[5 -( 1 H-pyrrolo [2,3 -b]ρyridin-3 -ylmethyl)-pyridin-2-yl] -amine (P-0348),
(2-Chloro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0349),
(2-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrro]o[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0350),
(2,3-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0351),

(2-Fluoro-3-methoxy-benzy])-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0352),
DimethyI-(5-{[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2-yl)-amine (P-0353),
(3-Chloro-2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0354),
(5-Fluoro-pyridin-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0355),
(S^-Difluoro-benzy^-fS-ClH-pyrrolo^^-bJpyridin-S-ylmethyO-pyridin^-ylJ-amine CP-OSSό),

(2-Propoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0357),

(2-Morpholin-4-yl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyτidin-3-ylmethyl)-pyτidm-2-yl]-amine

(P-0358),
(2-Chloro-3-methoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0359),
(2-Fluoro-6-trifluoromethyl-ben2yl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p>τidin-2-yI]-amine (P-0360),
[2-(2-Morpholiπ-4-yl-ethoxy)-ben2yl]-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0361).
(2,3-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]ρyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0362).

(2-Chloro-3-triπuorϋmethyl-benzyl)-[5-(lH-pyrrolo[2)3-b]pyridm-3-ylmethyi)-pyridin-2-yIJ- amine (P-0363),
(2-Chloro-5-fIuoro-benzyl)-[5-(lH-pyrrolo[2,3-bJpyπdm-3-ylmethyl)-pyridin-2-yl]-amme (P-0364),
(Z-Fluoro-S-trifluoromethyl-benzyO-fS-ClII-pyrrolofl^-bJpyridin-S-ylmethyO^pyridm-Z-yl]- amine (P-0365),
(S-FIuoro^-mcthoxy-benzyO-^-ClH-pyrrolofZ^-bJpyπdin-S-ylmethyO-pyridin^-ylJ-amiπe

(P-0366),
(2-Difluoromethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine

(P-0367),
(2-Fluoro-4-methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-yl]-amine

(P-0368),
[2-(3-Dimethylamino-propoxy)-benzyl]-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0369),
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]-amine (P-0370),
(2-FIuoro-5-methoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]-amme

(P-0371),
(4-Fluoro-2-mcthyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-ylJ-amme

(P-0372),
(3-Chloro-5-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyndm-3-ylmethyl)-pyridin-2-yl]-amine

(P-0373),
(6-Cyclopentyloxy-pyπdin-3-ylmethyl)-[5-(lH-pyπOlo[2,3-b]pyπdm-3-ylmethyl)-pyridin-2-yl]-amine (P-0374),
(5-Fluoro-2-trifluoromethyl-benzyI)-[5-(lH-pyiτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0375),
[5-(lH-Pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluoro-ethoxy)-pyridm-3-ylmethyl] -amine (P-0376),
Propane-1 -sulfonic acid (2-fluoro-3-{[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-0377),
(2,5-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridiπ-3-ylmethyl)-pyridm-2-yl]-amine (P-0380)

Pyπimdm-5-ylmethyl-t5-(lH-pyrrolof2,3-b]pyπdin-3->lmcthyl)-ρyridin-2-yl]-amine (P-038I),

(5-Chloro-2-fluoro-benzyl)-[5-(1 H-ρyrrυlo[2,3-b]pyπdin-3-ylmethy])-pyπdin-2->lJ-aminc

(P-0382),
(2-Ethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0383),

2,2-Dimethyl-N-(3-{[5-(lII-pyiτolo[2,3-b]pyridin-3-ylmethy])-pyridin-2-ylammo]-methy]}-p yπ din-2 -yl)-propionamide (P-0384) , Methyl-(3-{[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methy[}-pyridm-2-yl)- amine (P-0385),
Methyl-CS-itS-ClH-pyrrulotl.S-bJpyridin-S-ylincthy^-pyridin-l-ylaminol-methylJ-pyrimidin-Z- yl)-amine (P-0386),
(Z-Chloro^-methanesulfonyl-benzyO-fS-tlH-pyπ-oloP^-bJpyridin-S-ylmcthyO-pyridiii^-yi]- amine (P-0387),
Possibly to be added (P-0388),
(5-Fluoro-2-methyI-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0397),
Dimethyl^S-ltS-ClH-pyrrolop.S-bjpyridin-S-ylmethy^-pyridin^-ylammoJ-methylJ-pyridin-l- yl)-amine (P-0399),
(5-Chloro-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethy])-pyridin-2-yl]-aminc

(P-0400),
(2-Methoxy-pyrimidin-5-ylmethyl)-[5-(lH-pyrrolϋ[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0401),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl] -amine (P-0409),
l-(3-Fluoro-phenyl)-3-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridin-2-yl]-urea (P-0412) , and all salts, prodrugs, tautomers, and isomers thereof.

[0047) In one embodiment, a compound of the invention is:
(4-Chloro-benzyl)-[6-( 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyridazin-3 -yl] -amine (P-0092),

(4-Mθφholin-4-ylmethyl-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0093),
(2-Methoxy-ethyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0098),

[4-Chloro- 1 -ethyl-5 -( 1 H-pyrrolo [2,3-b]pyridin-3-ylmethyl)- 1 H-pyrazol-3 -yl]-[ 1 -(4-fluoro-phenyl)-meth-(E)-ylidene]-amine (P-0166),
( (2,2-Diiluoro-benzo[l ,3]dioxol-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2~ yl]-amine (P-0398); or
all salts, prodrugs, tautomers, and isomers thereof.

[0048] In certain embodiments of the above compounds, compounds are excluded where N (except where N is a heteroaryl ring atom). O, or S is bound to a carbon that is also bound to N (except where N is a heteroaryl ring atom), O, or S, except where the carbon forms a double bond with one of the heteroatoms, such as in an amide, carboxylic acid, and the like; or where K (except where N is a heteroaryl ring atom), O, C(S), C(O), or S(O)n (n is 0-2) is bound to an alkene carbon of an alkenyl group or bound to an alkyne carbon of an alkynyl group; accordingly, in certain embodiments compounds which include linkages such as the following are excluded from the present invention: -NR-CH1-NR-, -0-CH2-NR-, -S-CH2-NR-, -NR-CH2-O-, -0-CH2-O-, -S-CH2-CK-NR-CH2-S-, -0-CH2-S-, -S-CH2-S-, -NR-CH=CH-, -CH=CH-NR-, -NR-C ≡C-. -CMT-NR-, -0-CH=CH-, -CH=CH-O-, -0-C ≡€-, -C ≡€-0-, -S(O)0-2-CH=CH-, -CH=CH-S(O)0 r. -S(OVJ-C *-, -C *-S(0)(W-. ^C(O)-CH=CH-, -CH=CH-C(O)-, -C ≡€-C(O)-, or -C(O)-C *-, -C(S)-CH=CH-, -CH=CH-C(S)-, -C ≡€-C(S)-, or -C(S)-C --C-.

[0049] In reference to compounds herein, specification of a compound or group of compounds includes pharmaceutically acceptable salts of such compound(s), prodrug(s), and all stereoisomers, unless clearly indicated to the contrary. In reference to compounds of Formula II, it is understood that such reference includes compounds of Formulae Ha, lib, He, Hg and Up, and all sub-embodiments thereof.

[0050] In another aspect, the invention provides methods for treating a c-kit-mediated disease or condition in an animal subject (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal c-kit activity (e.g. kinase activity). Invention methods involve administering to the subject suffering from or at risk of a c-kit-mediated disease or condition an effective amount of a compound of Formula II or Formula III, and all sub-embodiments thereof. In one embodiment, the c-kit mediated disease is selected from the group consisting of malignancies, including mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia.

f 005 Ij In a related aspect, compounds of Formula II or Formula III, and all sub-embodiments thereof, car. be used in the preparation of a medicament for the treatment of a c-kit-mediated disease or condition selected from the group consisting of malignancies, including mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic leukemia.

chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia,

[0052] In a further aspect, the invention provides methods for treating a c-fms -mediated disease or condition in an animal subject (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal c-fms activity (e.g. kinase activity). Invention methods involve administering to the subject suffering from or at risk of a c- fms-mediated disease or condition an effective amount of compound of Formula II or Formula III, and all sub-embodiments thereof. In one embodiment, the c-fms mediated disease is selected from the group consisting of immune disorders, including rheumatoid arthritis, systemic lupus erythematosis (SLE), and transplant rejection; inflammatory diseases including inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, and atherosclerosis; metabolic disorders, including Type I diabetes, Type Il diabetes, insulin resistance, hyperglycemia, and lipolysis; disorders of bone structure, mineralization and bone formation and resorption, including osteoporosis, increased risk of fracture, Paget 's disease, hypercalcemia, and metastasis of cancer to bone; kidney diseases, including nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes-associated renal complications (e.g. diabetic nephropathy), and hypertrophy; disorders of the central nervous system, including multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease; inflammatory and chronic pain, including bone pain; and cancers, including multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia (CML), prostate cancer, breast cancer, ovarian cancer, and metastasis of tumors to other tissues.

[0053] In a related aspect, compounds of Formula II or Formula 111, and all sub-embodiments thereof, can be used in the preparation of a medicament for the treatment of a c-fms-mediated disease or condition selected from the group consisting of immune disorders, including rheumatoid arthritis, systemic lupus erythematosis (SLE), and transplant rejection; inflammatory diseases including inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, and atherosclerosis; metabolic disorders, including Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, and lipolysis; disorders of bone structure, mineralization and bone formation and resorption, including osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, and metastasis of cancer to bone; kidney diseases. including nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes-associated renal complications (e.g. diabetic nephropathy), and hypertrophy;

disorders of the central nervous system, including multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease, inflammatory and chronic pam, including bone pam, and cancers, including multiple myeloma, acute myeloid leukemia, chrome myeloid leukemia (CML), prostate cancer, breast cancer ovanan cancer, and metastasis ot tumors to other tissues

[0054] In a further aspect, the invention provides methods for treating a c-fms-mediated and c kit-mediated disease or condition in an animal subject (e g a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e g , a disease or condition characterized by abnormal c-tms activity and c-kit activity (e g kinase activity) Invention methods involve administering to the subject suffering from or at risk of a c-fms-mediated and c-kit mediated disease or condition an effective amount of compound of Formula II or Formula III, and all sub-embodiments thereof Ln one embodiment, the c-fms and c-kit mediated disease is selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasm associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chrome myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors metastasis of cancer to bone or other tissues hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosa, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, , glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pam, and bone pain.

[0055] In a related aspect, compounds of Formula II or Formula III, and all sub-embodiments thereof, can be used in the preparation of a medicament for the treatment of a c-fms-mediated and c-kit mediated disease or condition selected from the group consisting of mast cell tumors small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin coloi octal carcinoma carcinoma m situ Schwann cell neoplasm associated with
neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovanan cancer prostate cancer canine mast cell tumors, metastasis of cancer to bone or other tissues, hypertrophv, asthim , rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget' s disease, hypercalcemia, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory' pain, chronic pain, and bone pain.

[0056] In particular embodiments, the compound has an IC53 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit than on Ret, PDGF, or both Ret and PDGF. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit than on c-fms. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-fms than on c-kit. In certain embodiments, the compound has in combination each pairing of activity (e.g. IC50) and/ or selectivity as specified m this paragraph.

[00S7J In particular embodiments, the compound has an IC50 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay for c-kit, c-fms, or both c-kit and c-fms kinase activity. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit, c-fms, or both c-kit and c-fms than on Ret, PDGF, or both Ret and PDGF.

[0058] An additional aspect of this invention relates to compositions that include a
therapeutically effective amount of a compound of Formula II or Formula III and all sub-embodiments thereof and at least one pharmaceutically acceptable carrier, excipient, and/or diluent, including combinations of any two or more compounds of Formula II or Formula III. The composition can further include one or more different pharmacologically active compounds, which can include one or more compounds of Formula II or Formula III

[0059] In a related aspect, the invention provides kits that include a composition as descπbed herein. In particular embodiments, the composition is packaged, e.g., in a vial, bottle, flask, which may be further packaged, e.g., within a box, envelope, or bag; the composition is approved by the U S. Food and Drag Administration or similar regulatory agency for administration to a mammal, e g , a human, the composition is approved for administration to a mammal, e g , a human, for a c-kit- and/or c-fms-mediated disease or condition, the kit of the invention includes written instructions on use and/or other indication that the composition is suitable or approved for administration to a mammal, e g , a human, for a c-kit- and/ or c-fms-mediated disease or condition, the composition is packaged in unit dose or single dose form, e g , single dose pill;., capsules, or the like

[0060] In another aspect, the present invention also provides a method for modulating c-kit or c-fms activity by contacting c-kit or c-fms with an effective amount of a compound of formula Il or Formula III and all sub -embodiments thereof active on c-kit and/or c-fms (such as compounds developed using methods descπbed herein) The compound is preferably provided at a level sufficient to modulate the activity of the c-kit or c-fms by at least 10%, more preferably at lea&i 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater than 90% In many embodiments, the compound will be at a concentration of about 1 μM, 100 μM, or 1 mM, or in a range of 1-100 nM 100-500 nM 500-100O nM, 1 -100 μM, 100-500 μM, or 500-1000 μM In particular embodiments the contacting is carried out in vitro

[0061] Additional aspects and embodiments will be apparent from the following Detailed Description and from the claims

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0062] As used herein the following definitions apply

[0063] "Halo" and "halogen" refer to all halogens, that is, chloro (Cl), fluoro (F) bromo (Br), or iodo (I)

[0064] "Hydroxyl" and "hydroxy" refer to the group -OH

[0065] "Thiol" refers to the group -SH

[0066] 'Lower alkyl" alone or m combination means an alkane-deπved radical containing from 1 to 6 carbon atoms (unless specifically defined) that includes a straight chain aikyi or branched alkyl The straight chain or branched alkvl group is attached at any available point to produce a stable compound In many embodiments a lower alkyl is a straight or branched alkyl group containing from i -6 1-4, or 1-2 carbon atoms, such as methyl, ethyl, propyl, isopropyl bυtyi t butyl and the like "Optionally substituted lower alkyl" denotes lower alkyl that is mdepcndcnth substituted, with one or more, preferably 1, 2 3, 4 or 5, also 1 , 2 or 3 substituents attached at am available atom to produce a stable compound For example "fluoio substituted lower alkyl" denotes a lower alkyl group substituted with one or more fluoro atoms, such as perfluoioalkyl where preferably the lower alkyl is substituted with 1 , 2 3, 4 or 5 fluoro atoms, also 1 , 2, or 3 fluoro atoms \^ hile it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as - OR, NHR, -C(O)KHR, and the like, substitution of the alkyl R group is such that substitution ot the alkyl carbon bound to any -O-, -S-, or -N- of the moiety (except where -N- is a heteroaryl ring atom) excludes substituents that would result in any -O-, -S-, or -N- of the substituent (except where -N- is a heteroaryl πng atom) being bound to the alkyl carbon bound to any -O-, -S , or -N-of the moiety

[0067] "Cycloalkyl" refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, πng members per πng, such as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and the like A "substituted cycloalkyl" is a cycloalkyl that is independently substituted, with one or more, preferably 1 , 2, 3, 4 or 5, also 1 2, or 3 substituents, attached at any available atom to produce a stable compound

[0068] "Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the πng are replaced by heteroatoms of O, S or N, and are optionally fused with benzo or heteroaryl of 5-6 ring members Heterocycloalkyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary πng nitrogen Heterocycloalkyl is also intended to include compounds in which one of the πng carbons is oxo substituted, i e the πng carbon is a carbonyl group, such as lactones and lactams The point of attachment of the heterocycloalkyl πng is at a carbon or nitrogen atom such that a stable ring is retained Examples of heterocycloalkyl groups include, but are not limited to, morpholmo, tetrahydrofuranyl, dmydropyπdinyl, pipeπdinyl, pyrrolidmyl, pyrrohdonyl, piperazmyl, dihydrobenzofuryl, and dihydroindolyl A 'substituted heterocycloalkyl" is a heterocycloalkyl that is independently substituted, with one or more, preferably 1 , 2, 3, 4 or 5, also 1 , 2, or 3 substituents, attached at any available atom to produce a stable compound

[0069] "Aryi" ?lone or in combination refers to a monocyclic or bicyclic ring system containing aromatic such as phenyl or naphthyl which may be optionally fused with a cyc'oalkyl of tsreferably 5-7 more preferably 5 6, ring members A ' substituted aryP is a« dryi that is independently substituted with one or more, preferably 1 , 2 3 4 or 5, also 1 2 or 3 substituents, attached at any available atom to produce a stable compound [0070] "Ηeteroaryl" alone or in combination refers to a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1 -4, more preferably 1 -3, even more preferably 1-2, heteroatoms independently selected from the group consisting of O. S, and N. IIeteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, and indolyl. ''Nitrogen containing heteroaryi" refers to heteroaryl wherein any heteroatoms are N. A "substituted heteroaryl" is a heteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1 , 2, or 3 substituents, attached at any available atom to produce a stable compound.

[0071] "Lower alkoxy" denotes the group -ORZ, where Rz is lower alkyl. "Substituted lower alkoxy" denotes lower alkoxy in which Rz is lower alkyl substituted with one or more substituents as indicated herein attached at any available atom to produce a stable compound. Preferably, substitution of lower alkoxy is with 1, 2, 3, 4, or 5 substituents, also 1, 2, or 3 substituents. For example "fluoro substituted lower alkoxy" denotes lower alkoxy in which the lower alkyl is substituted with one or more fluoro atoms, where preferably the lower alkoxy is substituted with 1 , 2, 3, 4 or 5 fluoro atoms, also 1 , 2, or 3 fluoro atoms. While it is understood that substitutions on alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that -O-, -S-, or -N- (except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy -O-. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an -O-, -S-, or -N- of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkync carbon of the other moiety.

[0072] "Lower alkylthio" denotes the group -SRaa, where Raa is lower alkyl. "Substituted lower alkylthio" denotes lower alkylthio in which Raa is lower alkyl substituted with one or more substituents as indicated herein attached at any available atom to produce a stable compound. Preferably, substitution of lower alkylthio is with 1, 2, 3, 4, or 5 substituents, also 1, 2, or 3 substituents. For example "fluoro substituted lower alkylthic" denotes lower alkyithio in which the lower alkyl is substituted with one or more fluoro atoms, where preferably the lower alkylthio is substituted with 1 , 2, 3, 4 or 5 fluoro atoms, also 1 , 2, or 3 fluoro atoms. While it is understood that substitutions on alkylthio are attached at any available atom to produce a stable compound, substitution of alkylthio is such that -O-, -S-, or -N- (except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkylthio -S-, Further, where alkylthio is described as a substituent of another moiety, the alkylthio sulfur is not bound to a carbon atom that is bound to an -O-, -S-, or -N- of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety.

10073] "Mono-alkylamino" denotes the group -NHR1* where Rhb is lower alkyl, "Di- alkylamino" denotes the group -NRbbRcc, where Rbb and Rcc are independently lower alkyl.
''Cycloalkylamino" denotes the group -NRddRee, where Rdd and Ree combine with the nitrogen to form a 5-7 membered heterocycloalkyl, where the heterocycloalkyl may contain an additional heteroatom within the ring, such as -O-, -N-, or -S-, and may also be further substituted with lower alkyl. Examples of 5-7 membered heterocycloalkyl include, but are not limited to, piperidine, piperazine, 4-methylpiperazine, morpholine, and thiomorpholine. While it is understood that when mono-alkylamino, di-alkylamino, or cycloalkylamino are substituents on other moieties that are attached at any available atom to produce a stable compound, the nitrogen of mono-alkylamino, di-alkylamino, or cycloalkylamino as substituents is not bound to a carbon atom that is bound to an -O-, -S-, or -N- of the other moiety.

[0074] As used herein, the term c-kit-mediated disease or condition refers to a disease or condition in which the biological function of c-kit affects the development and/or course of the disease or condition, and/or in which modulation of c-kit alters the development, course, and/or symptoms. For example, mutations in the c-kit gene such as the W42, Wv, and W41 mutations reported by Herbst et al al (J. Biol. Chem., 1992, 267: 13210-13216) confer severe, intermediate, and mild phenotypic characteristics, respectively. These mutations attenuate the intrinsic tyrosine kinase activity of the receptor to different degrees and are models for the effect of modulation of c-kit activity. A c-kit mediated disease or condition includes a disease or condition for which c-kit inhibition provides a therapeutic benefit, e.g. wherein treatment with c-kit inhibitors, including compounds described herein, provides a therapeutic benefit to the subject suffering from or at risk of the disease or condition.

f0075j As used herein, the term c-fms -mediated disease or condition refers to a disease or condition in which the biological function of c-fms affects the development and/or course of the disease or condition, and/or in which modulation of c-fms alters the development, course, anά'or symptoms. For example, the Csflf/Csflf mutant mouse of Dai et al (Blood, 2002s 99: 1 1 1 -120) which lacks c-fms is an animal model for diseases or conditions wherein c-fms activity has been abolished. A c-fms mediated disease or condition includes a disease or condition for which c-fms inhibition provides a therapeutic benefit, e.g. wherein treatment with c-fms inhibitors, including compounds described herein, provides a therapeutic benefit to the subject suffering from or at risk of the disease or condition

[0076] As used herein, the term "composition" refers to a formulation suitable for administration to an intended animal subject for therapeutic purposes that contains at least one pharmaceutically active compound and at least one pharmaceutically acceptable carrier or excipient

|0077] The term "'pharmaceutically acceptable" indicates that the indicated material does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration For example, it is commonly required that such a material be essentially sterile, e g , for injectibles

[0078] In the present context, the terms "therapeutically effective" and "effective amount" indicate that the materials or amount of material is effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or medical condition, and/ or to prolong the survival oi the subject being treated

[0079] As used herein, the term "modulating" or ''modulate" refers to an effect of altering a biological activity, especially a biological activity associated with a particular biomolecule such as c-kit or c-fms For example, an agonist or antagonist of a particular biomolecule modulates the activity of that biomolecule, e g , an enzyme

[0080] The term "c-kit activity" refers to a biological activity of c-kit, particularly including kinase activity The term "c-fms activity" refers to a biological activity of c-fms, particularly including kinase activity

I. General

[0081] In one aspect, the present invention concerns compounds of Formula II, Ha, lib, He, Hg, Up or III and all sub-embodiments thereof, that are inhibitors of c-kit, c-tms, or both c-kit and c-fms, and the use of the compounds, in treating diseases that are mediated by c-kit c-fms, ot both c-kit and c-fms

Exemplary Diseases Associated with c-Kit.
f 0082] The compounds described herein are useful for treating disordeis related to c-kit t g diseases related to unregulated kinase signal transduction, including cell proliferative disorders fibrotic disorders and metabolic disorders, among others As described in more detail below and in Lipson et al., U.S. 20040002534 (U.S. applicatioα 10/600, 868, filed June 23, 2003) which is incorporated herein by reference in its entirety, cell proliferative disorders which can be treated by the present invention include cancers, and mast cell proliferative disorders.

|0083] The presence of c-kit has also been associated with a number of different types of cancers. In addition, the association between abnormalities in c-kit and disease are not restricted to cancer. As such, c-kit has been associated with malignancies, including mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia.

Exemplary diseases associated with c-fms

[0084] The presence of c-fms has been associated with a number of different types of diseases. As such, c-fms has been associated with immune disorders, including rheumatoid arthritis, systemic lupus erythematosis (SLE), and transplant rejection; inflammatory diseases including inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, and atherosclerosis; metabolic disorders, including Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, and lipolysis; disorders of bone
structure.mineralization and bone formation and resorption, including osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, and metastasis of cancer to bone; kidney diseases, including nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes-associated renal complications (e.g. diapetic nephropathy), and hypertrophy; disorders of the central nervous system, including multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease, inflammatory and chronic pain, including bone pain; and cancers, including multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia (CML), prostate cancer, breast cancer, ovarian cancer, and metastasis of tumors to other tissues.

Exemplary diseases associated with TrkA and TrkB

|008SJ TrkA: Target kinase TrkA (i.e., neurotrophic tyrosine kinase, receptor, typeJJ is a 87,5 IcDa tyrosine kinase encoded by chromosome Iq21-q22 (symbol: NTRKl). TrkA inhibitors may be useful in treating pain (e g chronic pam, neuropathic pam), cancer (e g prostate cancer lung cancer, pancreatic cancer), arthritis, diabetic retinopathy, macular degeneration and psoriasis

[00861 TrkB: Target kinase TrkB (i e , neurotrophic tyrosine kinase, receptor, type 2) is a 92 kDa tyrosine kinase encoded by chromosome 9q22 1 (symbol NTRK2) TrkB inhibitors may be useful in treating cancer (e g prostate cancer, lung cancer, Wilms tumors, neuroblastoma, pancreatic cancer)

Exemplary diseases associated with HGK

[0087] HGK: Target kinase HGK (i e , mitogen-activated protein kinase kinase kinase kinase 4) is a 130 kDa seπne'threonine kinase encoded by chromosome 2ql 1 2-ql 2 (symbol MAP4K4) HGK inhibitors may be useful in treating metabolic indications, including re-sensitizing fat and muscle cells to insulin, ameliorating the pathology in adipocytes, ameliorating the pathology m muscle cells, and type II diabetes, a broad range of oncology indications, including blocking the migration, invasion and metastasis in many different tumor types, and T-cell mediated autoimmune diseases

IV. Kinase Activity Assays

[0088] A number of different assays for kinase activity can be utilized for assaying for active modulators and/or determining specificity of a modulator for a particular kinase or group or kinases In addition to the assay mentioned in the Examples below, one of ordinary skill in the art will know of other assays that can be utilized and can modify an assay for a particular application For example, numerous papers concerning kinases described assays that can be used

[0089] Additional alternative assays can employ binding determinations For example, this sort of assay can be formatted either in a fluorescence resonance energy transfer (FRET) format, or using an AlphaScreen (amplified /ummescent proximity homogeneous assay) format by varying the donor and acceptor reagents that arc attached to streptavidm or the phospho-specific antibody

V. Organic Synthetic Techniques

|OΘ9O] A w idc array of organic synthetic techniques exist in the art to meet the challenge of constructing potential modulators Many of ttiese organic synthetic methods are described m αetau .n standard reference sources utilized by those skilled in the art One example of sun a ieferenee is. March, 1994, Advanced Organic Chemistry, Reactions. Mechanisms and Structure New York McGraw Hill Thus, the techniques useful to synthesi7e a potential modulator of kinase function are readily available to those skilled in the art of organic chemical synthesis

VI. Alternative Compound Forms or Derivatives

[0091] Alternative forms or derivatives, such as (a) Isomers, Prodrugs, and Active Metabolites (b) Tdutomers, Stereoisomers, Regioisomers, and Solvated Forms (c) Prodrugs and Metabolites (d) Pharmaceutically acceptable salts and (e) Polymorphic forms, are described, for example m US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference in its entirety

VII. Administration

[0092] The methods and compounds will typically be used in therapy for human subjects However, they may also be used to treat similar or identical indications in other animal subjects In this context, the terms "subject," "animal subject," and the like refer to human and non-human vertebrates, e g mammals, such as non-human primates, sports and commercial animals, e g equmes, bovmes, porcmes, ovmes, rodents, and pets, e g , canmes and felines A descπption of possible methods and routes of administration may be found, for example, in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated b> reference in its entirety

EXAMPLES
[0093] A number of examples illustrative of the present invention are described below In most cases, alternative techniques could also be used The examples are intended to be illustrative and are not limiting or restrictive to the scope of the invention Unless specifically noted to the contrary, in cases where a compound number is not preceeded by a "P-" (e g , "P-0001") in the Examples section, compound naming and/or enumeration is not related to naming and/or enumeration employed in other sections of this application Similarly, structure and substituent naming and enumeration within the Examples are independent of structure and substituent naming and enumeration in above sections of this application unless clearly indicated oth&rwi_.e

JΘ094] In toe following Examples, it is understood that the solvents and reagents used or suggested are not limiting, and can be substituted appropriately with solvents and reagents KΠOA Π to those of skill in the art Reaction products ma> be isolated by means known in the art such ai extraction with a suitable solvent, precipitation from a suitable solvent, chromatography using a suitable solvent system, including silica gel column chromatography, HPLC, preparative TI C and the like Exemplary methods for synthesis of compounds of the present invention may be round in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference. The lH-pyrrolo[2,3-b]pyridine core of compounds described in the examples may also be referred to as ?-azaindole in the examples.

Example 1: Synthesis of [5-(5-Bronio-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4- chloro-benzyl)-amine (P-0038)

[0095] [5-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-chloro-benzyl)- amine P-0038 was synthesized in 5 steps from commercially available 2-Amino-5-bromopyridine 15 as shown in Scheme 19.

Scheme 19


Step 1- Synthesis of(5-Bromo-pyridin-2-yl)-(4-chloro-henzyl)-amine (41)

[0096] To 2-Amino-5-bromopyridine (15, 6.10 g, 0.0352 mol) in toluene (90.0 rnL) were added 4-chlorobenzaldehyde (40, 5.00 g, 0.0356 mol), trifluoroacetic acid (8.0 rnL, 0.10 mol) and triethylsilane (16.5 mL, 0.103 mol). The reaction was heated to reflux for 48 hours. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated. The crude residue was crystallized with ethyl acetate to give compound (41, 6,8 g, 65.4%).

Step 2 - Synthesis of6-(4-Chloro-benzylamino)-pyridine-3-carbaldehyde (42)

10097J To (5-Bromo-pyridin-2-yl)-(4-chloro-benzyl)-amine (41, 10.00 g, 0.03360 mol) i inr tetrahydrofuran (400,0 rnL) under an atmosphere of nitrogen at -78 0C was added n-butylhthium (17.5 mL, 2.00 M in cyclohexane). After 90 minutes, tert-butyllithium (42.00 mL, Ϊ .70 M in hexane) was added to the reaction. After 80 minutes, N,N-dimethvlformamide (6.9 mL, 0.089 mol) was added to the reaction. The reaction mixture was stirred at -78 "C for 2 hours, then allowed to warm to room temperature for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated to give the crude compound, which was crystallized from terr-butoxyl methyl ether to provide compound (42, 7.66 g, 92.2%).

Step 3 - Synthesis of(4-Chloro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (43)

[0098] To 6-(4-Chloro-benzylamino)-pyridine-3-carbaldehyde (42, 2.00 g, 8.1 1 mmol) in diehloromethane (20.0 mL) were added triethylamine (1.70 mL, 12.2 mmol), di-tert-butyldicarbonate (2.00 g, 9.16 mmol) and 4-dimethylaminopyridine (52.3 mg, 0.43 mmol). The reaction was stirred at room temperature for 48 hours. The reaction was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give compound (43, 2.50 g, 89.3%).

Step 4 — Synthesis of {5-[(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl}-(4-chloro-benzyl)-carbamic acid tert-butyl ester (45)

10099] To 5-bromo-7-azaindole (44, 198.0 mg, 1.01 mmol) in methanol (30.0 mL, 0.741 mol) were added (4-Chloro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (43, 355.0 mg, 1.02 mmol) and potassium hydroxide (80.0 mg, 1.42 mmol). The reaction was stirred at room temperature 48 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 8% methanol in diehloromethane to give compound (45, 200.0 mg, 36.8%).

Step 5 - Synthesis of[5-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-chJorθ' benzylj-amine (P-0038)

[0100] To {5-[(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl}-(4-chloro-benzyl)-carbamic acid tert-butyl ester (45, 180.0 mg, 0.33 mmol) in acetonitrile (30.0 mL) were added trifluoroacetic acid (2.0 mL, 0.026 mol) and triethylsilane (4.0 mL, 0.025 mol). The reaction was heated to reflux for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 10% methanol ir diehloromethane to give compound (P-0038, 120 mg, 85.2%). MS(ESI)[M-HHT ~ 427.2, 429.2.

[01011 Additional compounds were prepared following the protocol of Scheme 19, optionally replacing 4-chlorobenzaldehyde 40 with an appropriate aldehyde in Step 1 and optionally r >eplacmg 5-bromo-7-azamdole 44 with an appropπate azamdole in Step 4 The following compounds were made following this procedure
[5-(5-Chloro-lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylJ-(6-tπfluoromethyl-pyπdin-':i- ylmcthyl)-amine (P-0181),
[5-(lH-Pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-(6-tπfluoromethyl-pyridin-3-ylmeth> l)-amine (P-0182),
3 - [6-(4-Chloro-benzylamino)-pyπdin-3-ylmethyl] - 1 H-pyrrolo [2, 3-b]pyπdine-5 -carbonitnle

(P-02S7),
3-[6-(4-Trifluoromethyl-benzylammo)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyπdine-5-carbonitnle (P-0269),
[5-(5-Chloro-lH-pyrrolo[2,3-bJpyndin-3-ylmethyl)-pyridm-2-yl]-(2-fluoro-benzyl)-dmme

(P-0270),
3-[6-(2-riuoro-benzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyπdme-5-carbonitπle

(P-0271),
(2-Fluoro-benzyl)-[5-(5-methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine

(P-0272),
3-{6-[(6-Tπrluoromethyl-pyridin-3-ylmethyl)-ammo]-pyridm-3-ylmethyl}-lH-pyiτolo[2,3-b]pyndme-5-carbonitnle (P-0273),
3-[6-(2-Tπfluoromethyl-benzylainino)-pyndin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyπdine-5-carbonitnle (P-0274),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyndm-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0275),
[5-(5-Methyl-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0276),
3-[6-(2,6-Difluoro-bcnzylamino)-p>τidin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyπdme-5-carbonitrile

(P-0277),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyridin-2-yl]-(2,6-difluoro-benzyl)-amine

(P-0278),
(2-Chloro-benzyi)-[5-(5-methyl-l H-p>τrolo[2 3-b]pyrκiin-3-ylmethyl) pyπdin-2-vlJ-amme

(P-0279)
(2-Chloro benzyl) [5 (5-chloro-lH-pyrrolo[2 3-bjpyπdin-3-ylmethyl)-pyndin-2-ylj-amme

(P-0280),
3-[6-(2-Chloro-benz>lamino)-pyτidin-3-ylmethyl]-l H-pyrrolo[2,3-b]pyπdine-5-carbonitπle

(P-0281X Cό-Methoxy-pyridin-S-ylmethyO^S-CS-methyl-lH-pyrrolofl^-blpyridin-S-ylmethy^-pyπdiii-Z- yl]-amiπe (P-0282),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3- ylmethyl)-amine (P-0283),
3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH-pyrrolo[2.3-b]pyridine-5- carbonitrile (P-0284),
(Z-Methoxy-pyridin-S-ylmethy^-fS-CS-methyl-lH-pyrrolofZ^-bJpyridin-S-ylmethy^-pyridin-I-yl] -amine (P-0285),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-0286),
3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH-pyrrolo[2,3-b]pyridinc-5-carbonitrile (P-0287),
(2-Ethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0288),

(2,5-Difluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylJ-aminc (P-0296),

(2,5-Difluoro-benzyl)-[5-(5-methyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0297),
[5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,5-difluoro-benzyl)-aminc

(P-0298),
3-[6-(2,5-Difluoro-benzylamino)-pyridin-3-ylmethyl]-lII-pyrrolo[2,3-b]pyridine-5-carbonitrile

(P-0299),
3-[6-(2-Trifluoromethoxy-benzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0321),
[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifIuoromethoxy-benzyl)-amine
(P-0322),
3-[6-(2-Ethoxy-benzylamino)-pyridin-3-yLmethyl]-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile

(P-0323),
[5-(5-Fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0325),
[5-(5-Methoxy-lH-pyrτolo[2,3-b]p>τidin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0326),
(2-Chloro-benzyl)45-(5-fluoro-lHφyrrolo[2,3-b]pyridin-3-ylmethyl)-pyriciin-2-yl]-amme
(P-0327).
(Z-Chloro-beiizyO-fS-CS-methoxy-lH-pyrrolop.j-bJpyrldin-S-ylmethylJ-pyridin^-ylj-amine (P-0328).
(2,5-Difluoro-benzyl)-[5-(5-fluoro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine fP-0329), (2,5-Difluoro-benzyl)-[5-(5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme
(P-0330),
[5-(5-Fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyπdin-3->lmcthyD- amine (P-0331),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-lH-pyrrolo[2,3-bJpyπdin-3-ylmethyl)-pyridin-2- yl] -amine (P-0332),
(2,6-Difluoro-benzyl)-[5-(5-fluoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyndin-2-yl]-ainine
(P-0333),
(2,6-Difluoro-benzyl)-[5-(5-methoxy-lH-pyiτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P-0334),
(2-Methϋxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme (P-0336),
3 -[6-(2-Methoxy-benzylamino)-pyri din-3 -ylmethyl] - 1 H-pyrrolo[2 ,3 -b]pyridine-5 -carbonitπle
(P-0337),
(2,6-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-ylJ-ammc (P-0340), and
(2,6-Difluoro-benzyl)-[5-(5-methyl-lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P-0341)
The following table indicates the aldehyde used in Slep 1 in Column 3 and the azaindole used in
Step 4 in Column 2 to provide the compound of Column 4. Column 1 provides the compound
number and Column 5 the measured mass spectrometry result
'






[0102] Additional compounds were prepared following the protocol of Scheme 19, Steps 4 and 5, replacing (4-Chloro-benzyl)-(5-formyl-pyπdin-2-yl)-carbamic acid tert-butyl ester 43 with an appropriate protected aldehyde and 5-bromo-7-azaindole 44 with an appropriate azaindole in Step 4. Aldehydes were prepared as described in Example 60. The following compounds were made following this procedure:
3-{2-Chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH- pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0232),
[ό-Chloro-S-CS-methyl-lH-pyrroloP.S-bJpyridin-S-ylrnethyO-pyridin^-yll-fβ-trifluoromethyl- pyπdm-3 -ylmethyl)-amine (P-0233),
[6-Chloro-5 -(5 -methyl- 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyridin-2-yl] -(6-tritluoromcthyl- pyridin-3 -ylmethyl)-amine (P-0234),
(3-Chloro-pyπdin-4-ylmethyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]- amine (P-0235),
3-{6-[(3-Chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-ylmethyl}-lH-pyrrolo[2,3-b]pyridine-5- carbonitrile (P-0256),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-(2-difluoromethoxy-benzyl) amine (P-0338),
3-[6-l2-Difluoromethoxy-benzylamino)-pyndin-3-ylmethyl]-iH-pyrrolo[2,3-b]p>ndine-5- caibomtrile (P-0339),
I he following table indicates the aldehyde used m Column 2 and the azaindole αsed in Column 3 to provide the compound of Column 4. Column 1 provides the compound number and Column 5 the measured mass spectrometry result.


Example 2: Synthesis of l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde 47

[0103] Compound 47 was synthesized in 2 steps from 7-azaindole 1 as described in Scheme 20.

Scheme 20


Step 1 - Preparation of IH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (46)
[0104] To lH-Pyrrolo[2,3-b]pyπdiπe (1, 16.0 g, 135 mmol) in water (110 mL), were added hexamethylenetetramine (26.0 g, 1 S5 mmol), and acetic acid (55.0 mL, 967 mmol). The reaction was refluxed for 12 hours Water (329 mL) was added and the reaction was cooled to room temperature. The reaction was filtrated and washed with water to give compound (46, 15.0 g. 76%) MS(ESI)[MX-IT]+ = 147.

Step 2 — Preparation of ' 1 -triisopropylsilanyl- 1 H-pyrrolo [2,3-hj 'pyridine-3-carbaldehyde (47) [0105] Io lH-Pyrrolo[2,3-b]pyπdme-3-carbaldehyde (46, 4.05 g, 27.71 mmol) m
tetrahydrofuran (30.0 mL) were added sodium hydride (60% in mineral oil, 1.5 g. 38 mmol) and trπsopropylsilyl chloride (8.0 mL, 38 mmol) under an atmosphere of nitrogen. The reaction was stirred for 2 hours at room temperature. The reaction was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 10 % ethyl acetate in hexane to give compound (47, 3.0 g, 36%). MS(ESI)[M+HT = 303.

[0106] l-(tert-Butyl-dimethyl-silanyl)-3-iodo-lH-pyrrolo[2,3-b]pyridine 66



was prepared following the protocol of Scheme 20 Step 2, substituting lH-Pyrrolo[2,3-b]pyπdme-3-carbaldehyde 46 with 3-iodo-lH-pyrrolo[2,3-b]pyridine and triisopropylsilyl chloride with tert-Butyl-dimethyl-silyl chloride.

[0107] l-Benzenesulfonyl-lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde 55



was prepared following the protocol of Scheme 20, substituting tπisopropylsilyl chloride *v:th benzenεsulfonyl chloride in Step 2 Example 3: S>nthesis of 5 substituted 7-azaindole intermediates
[0108] 5 -(2 Morphohn-4-yl-ethoxy)-lH-pyrrolo[2,3-b]pyπdme 79 was synthesized in 1 Step from commercially available 5-bromo-azaιndole as shown in Scheme 31

Scheme 31


Step 1 — 5-(2-Morpholιn 4-yl-ethoxy)-lH-pyrrolo[2,3-b] pyridine (79)

[0109] To 4-morpholineethanol (30 mL, 0 2 mol) m N, N-dimethylformamide (30 mL) was slowly added sodium hydride (7 g, 60% dispersion in mineral oil, 0 2 mol) After the solution turned clear, a solution of 5-bromo-7-azamdole (44, 1 0 g, 0 0051 mol) in N,N-dimethylformamide (5 mL) and copper(I) bromide (1 4 g, 0 0098 mol) were added The reaction mixture was stirred at 120 0C under nitrogen for 2 hours The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and water The organic layer was collected, washed with a solution of ammonium chloride and ammonium hydroxide (4 1), brine, and dried over magnesium sulfate After removal of solvent, the residue was puπfied by silica gel column chromatography elutmg with ethyl acetate in hexane to provide the compound as an off-white solid (79, 0 62 g, 50%) MS (ESI) [M+H+]+ = 248 25

[0110] Additional 5-substituted 7-azaindoles were prepared following the protocol of Scheme 31, replacing 4-morpholineethanol with either 2-diethylammo-ethanol, 3-diethylamino-propan-l -ol, 2-piperidin-l-yl-ethanol, or 2-pyrrolidin-l-yl-ethanol to provide diethyl-[2-(lH-pyrrolo[2,3~ b]pyπdm-5~yloxy)-ethyl]-amine, Diethyl-[3-(lH-pyrrolo[2,3-b]pyπdin-5-yloxy)-propyl] amine 5-(2-pipeπdin-l-yl-ethoxy)-lH-pyrrolo[2,3-b]pyndmc, and 5-(2-pyrrolidin-l-yl-ethoxy)-lH-ρyrrolo[2 3-b]pyπdme. respectively

Example 4: Synthesis of 3,5-Dimethyl-4-(IH-p>n olo[23-blP>ridtin-3-ylmethyI)-p> i aΛθfe- acid benzylamide P-0084

[0111] 3,5-Dimcth>l-4-(lH-pyrτolo[2,3-b]pyndin-3-ylmethyl)-pyrazolc-l-carboxylic acid benzylamide P-0084 was synthesized in 6 steps from dimethyl-(lH-pyrrolo[2,3-b]pyπdin-3- ylmethyl)-amine 2 as shown in Scheme 158.

Scheme - 158


Step 1: Preparation of3-Dimethylaminomethyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (511)
[0112] To dimethyl-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-amine (2, 2.50 g, 14.3 mmol.) in tetrahydrofuran (200.0 mL) was added sodium hydride (0.685 g, 60% in mineral oil, 17.1 mmol). After 10 minutes, di-te^-butyldicarbonate (3.74 g, 17.1 mmol) was added to the reaction. The reaction was stirred al room temperature overnight. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give as a white solid (511, 3.80 g, 96.7%).

Step 2: Preparation of 3-Chloromethyl-pyrroIo[2,3-bJpyridine-l -carboxylic acid tert-hutyl ester (512)
[0113] To 3-dimethylaminomethyl-pyrrolo[2,3-bJpyridine-l-carboxylic acid tert-butyl ester (511, 2.60 g, 9.44 mmol) in toluene (50.00 mL) was added isopropyl chloroformate (11.3 mL, 1.0 M in toluene) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica ge! column chromatography eluting with 20% ethyl acetate in hexane to give a white solid (512, 2.O g, 79.4%).

Step 3 ■- Preparation of 3-(2-Acetyl'3-oxo-butyl J-pyrrυlυf 2, 3-bJpyridine-l -carboxylic acid lert-butyl ester (513):
[0114] To acetylacetone (0.563 g, 5.62 mmol) in dimethyl sulfoxide (29.0 mL) was added sodium hydride (0.225 g, 60% in mineral oil, 5.62 mmol). After 20 minutes, 3-chloromethyl- pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (512, 1.00 g, 3.75 mmol) was added to the reaction. The reaction was stirred at room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column
chromatography eluting with 40% ethyl acetate in hexane to give a colorless oil (513, 0.59 g, 48.0%). MS (EST) [M+HT = 331.4.

Step 4 - Preparation of3~(3,5-Dimethyl-lH-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (514)
[0115] To 3-(2-acetyl-3-oxo-butyl)-pyrrolo[2,3-b]pyπdine-l -carboxylic acid tert-butyl ester (513, 1.20 g, 3.63 mmol) in methanol (15.0 mL), cooled to -20 °C under an atmosphere of nitrogen, was added hydrazine (0.128 g, 4.00 mmol) in dichloromethane (6.0 mL). The reaction was stirred for 2 hours. The reaction was concentrated to remove the solvents, and the residue was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 60% ethyl acetate in hexane to give a white solid (514, 1.0 g, 84.4%). MS (ESI) [M+tTJ = 327.4.

Step 5 - Preparation of 3-(l -BenzyIcarbamoyl-3,5-dimethyl-l H-pyrazol-4-ylmethyl)-pyrrolo[2 ,3-b]pyridine-l -carboxylic acid tert-butyl ester (515)
[0116] To 3-(3,5-dimethyl-lH-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine-l -carboxylic acid tert-butyl ester (514, 60.0 mg, 0.18 mmol) in dichloromethane (6.0 mL) were added 1 ,8-diazabicyclo[5.4.0]undec-7-cnc (0.033 mL, 0.220 mmol) and benzyl isocyanate (29.4 mg, 0.220 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 2 hours. The reaction was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give crude compound (515, approx. 50 mg) that was used in the next step directly. MS (ESI) [M+H+]+ = 460.5.

Step 6 - 3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l~carboxylic acid kenzylamide (P-0084)
[01171 To 3-( 1 -benzylcarbamoyl-3,5-dimelhyl-l H-pvrazol-4-ylmethyl)-pyrroio|2,3-b]pyridine-1 -carboxylic acid tert-butyl ester (515, 50.0 mg, 0.1 ϊ mmol) in dichloromethane (6.0 mL) was added trifluoroacetic acid (0.20 mL, 2.6 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 20 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give a white solid (P-0084, 1 1 0 mg, 28 1 %). MS (ESI) [M+H+]+ = 360.5.

[0118] 3-(3,5-Dimethyl-lH-p>ra/ol-4-ylmethyl)-pyrrolo[2!3-b]pyridme P-0124



was prepared from 3-(3,5-Dimethyl-lH-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyπdme-l-carboxyhc acid tert-butyl ester (514, 15.0 mg, 0.046 mmol) by dissolving in dichloromethane (10.0 mL) to which tπfluoroacetic acid (0.10 mL, 1.3 mmol) was added. The reaction was stirred at room temperature for 1 hour, then poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate wa^ concentrated and washed with ethyl acetate in hexane to give an off-white solid (P-0124, 7.5 mg, 72.0%). MS (ESI) [M+H+]+ = 227.3.

[0119J Additional compounds were prepared following the protocol of Scheme 158, replacing dimethyl-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-amine 2 with (5-chloro-lH-pyrrolo[2,3-b]pyπdm-3-ylmethyl)-dimethyl-amine (prepared as described in Example 10, Scheme 164, isolated after step 1) in Step 1 and replacing ben/yl isocyanate with an appropriate electrophilc in Step 5. The following compounds were made following this procedure'
4-(5 -Chloro-1 H-pyrrolo[2 ,3 -b]pyridin-3 -ylmethyl)-3 ,5-dimethyl-pyrazole- 1 -carboxv lie acid [2-(4-fluoro-phenyl)-ethyl]-amide (P-0157),
4-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-l-carboxylic acid 4-fluoro-benzylamide (P-0158),
4-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-l -carboxyhc acid 4-chloro-benzylamide (P-0159), and
4-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-l -carboxylic acid [(S)-I -(4-fluoro-phenyl)-ethyl]-amide (P-0160)

{0120J The electrophile used in place of benzyl isocyanate in Step 5 is indicated in Column 2 of the following table, with the compound structure given in Column 3 Column 1 ρro\ides the compound number and Column 4 the experimental mass spectrometry result

Example 5: Synthesis of l4-chloro-5-(lH-pyrrolo[2,3Λ)]pyridin-3-ylmethyl)-thiazol-2-yl]- pyridin-4-ylmethyl-amine P-Ol 68

[0121] μ-Chloro-SKlH-pyrroloP^-bJpyridin-S-ylmethyO-thiazol^-ylJ-pyridin^-ylmethyl- amine P-0168 was synthesized in 5 steps as shown in Scheme 159.

Scheme 159


Step 1 - Preparation of4-chloro-2-[(pyridin-4-ylmethyl)-amino]-thiazole-5-carbaldehyde (517): [0122] To a solution of 4-(aminomethyl)pyridine (516, 1.16 mL, 1 1 ,5 mmol) and N,N- diisopropylethylamine (3.S mL, 22 mmol) in tetrahydrofuran (50 mL) was added 2,4-dichloro- thiazole-5-carbaldehyde (93, 2.0 g, 11.0 mmol) in tetrahydrofuran (5 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. The crude compound 4-chloro-2-[(pyridin-4-ylmethyl)-amino]-thiazole-5-carbaldehyde (517) was used for the next step without purification.

Step 2 - Preparation of (4-chloro-5-formyl-thiazol~2-yl)-pyridin-4-ylmethyUcarbamic acid lert-butyl ester (518):
[0123] A mixture of 4-chloro-2-[(pyridin-4-ylmethyl)-amino]-thiazole-5-carbaldehyde (517, 3.28 g, 11.0 mmol), di-tert-butyldicarbonate (4.0 g, 18 mol) and triethylamine (10 mL, 74 mmol) in dichloromethane (120 mL) was stirred at room temperature for 6 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to provide the desired compound as a yellow solid (518, 564 mg, 15%). MS (ESI) [M+H+]+= 354.1.

Step 3 - Preparation of {4-chloro-5-[hydroxy-(l-triisopropylsilanyl-lH-pyrrolo[2,3-h]pyridin-3-yl)-methyl]-thiazol-2-yl}-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (519):
[0124] To a solution of 3-iodo-l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, 0.44 g, 1 .1 mmol) in tetrahydrofuran (20 mL) at -20 °C, isopropylmagnesium chloride (2 M in
tetrahydrofuran, 0.6 mL, 1.2 mmol) was added dropwise. The reaction mixture was allowed to warm to 0 0C in 10 minutes. The reaction mixture was then cooled to -40 0C. A solution of (4-chloro-5-formyl-thiazol-2-yl)-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (518, 0.26 g, 0.73 mmol) in tetrahydrofuran (4 mL) was added to the reaction mixture. The reaction mixture was allowed to warm to -10 °C over 30 minutes. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate :n hexanes to provide the desired compound as a yellow solid (519, 397 mg, 86%). MS (ESI)
[M-Hr] = 628.3.

Step 4 — Preparation of[4-chloro-5-(lH-pyrrolo[2,3-b]ρyridin-3-ylmethyl) -thιazol-2-yl] -pyndin- 4-ylmethyl-carbamic acid tert-butyl ester (52Q)'
[0125] A mixture of {4-chloro-5-[hydroxy-(l -triisopropylsilanyl-lH-ρvrrolo[2,3-b]pyridin-3-yPj-methyl]-thiazol-2-yl}-pyτidin-4-ylmethyl-carbamic acid tert-butyl ester (519, 0.397 g, 0.57 mmol), triethylsilane (1.0 mL, 6.3 mmol), and trifluoroacetic acid (0.5 mL, 6 mmol) in acctonitrilc (10 mL) was stirred at 40 0C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography cluting with methanol in dichloromethane to provide the desired compound as a yellow solid (520, 126 mg, 49%). MS (ESI) [M+HT= 456.2.

Step 5 - Preparation of[4-chloro-5~(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyrιdin 4-ylmethyl-amine (P-0168):
[0126] To a solution of [4-chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (520, 126 mg, 0.000276 mol) in dichloromethane (2 mL) was added hydrogen chloride (4 M in 1 ,4-dioxane, 2 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into cold sodium bicarbonate solution, extracted with ethyl acetate, washed with brine and dried over magnesium sulfate. After removal of solvents, the residue was washed with ethyl acetate to provide the desired compound as a light yellow solid (P-0168, 68.4 mg, 70%). MS (ESI) [M+H+]f = 356.2.

[0127] Additional compounds were prepared following the protocol of Scheme 159, replacing 4-(aminomethyl)pyridine 516 with an appropriate amine. The following compounds were made following this procedure;
[4-Chloro-5-(lH-p>τrolo[2,3-fe]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine

(P-Θ164),
[4-Chloro-5-(lH-pyrrolo[2,3-6]pyridin-3-ylmethyl)-thiazol-2-ylJ-pyridin-2-ylmethyl-amine

(P-0167),
[4-Chloro-5-(lH-p>τrolo[2,3-έι]ρyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2- ylmethyl)-amine (P-0171),
[4-Chloro-5-(lH-pyrrolo[2,3-6]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl-pyiidin-3- ylmethyl)-amine (P-0173),
[4-Chloro-5-(lH-p>τrolo[2,3-Z?]pvridin-3-ylmethyl)-thiazol-2-yl]-(l,5-dimethyl-lH-pyra?ol-3- ylmethyO-amine (P-0172),
[4-Chloro-5-(lH-pyrrolo[2,3-έ]pyridin-3-ylmethyl)-thia7Jol-2-yl]-(2,5-dimcthyl-2H-pyra/ol-3 ylmethyO-amine (P-Ol 75), and
^-Chloro-S^lH-pyrroiop.S-δJpyridin-S-ylmethy^-thiazol^-ylJ^-fluoro-henzyiyamine (P- 0156).
The following table indicates the amine (Column 2) used in Scheme 159 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the observed mass.


Example 6: Synthesis of [4-eth>l-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(4- fluoro-benzyl)-amine P-0162 and (4-fluoro-benzyl)-[4-methyl-5-(lH-pyrrolo[2,3-b]pyridin-3- ylmethyl)-thiazol-2-yl]-amine P-0162

[0128] [4-Ethyl-5-(l H-pyrrolo[2.3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-ammc P-0162 was synthesized in 1 step from [4-chloro-5-(lH-pyrrolo[2, 3-bJ pyndm-3-ylmethyl)- thvazol-2-yl]-(4-fluoro-benzyl)-amine P-0156 as shown m Scheme 160.

Scheme 160


Step 1 - Preparation of[4-ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine (P-0162):
[0129] Into a round bottom flask, under an atmosphere of nitrogen, [l ,l'-bis(diphenyl phosphino) ferrocene] dichloro palladium (II), complex with dichloromethane (1 : 1 ), was placed with toluene (15 mL, 140 mmol). [4-Chloro-5-(lH-pyrrolo[2,3-b] pyridm-3-ylmethyl)-thiazoI-2-yl]-(4-fluoro-benzyl)-amine (P-0156,145 mg, 0,4 mmol) was added in 5 ml of toluene at room temperature. The mixture was stirred for 10 minutes. To the stirring reaction, a solution of 3.13 M ethyl magnesium bromide in ether (1.86 mL) was added dropwise at room temperature. The opaque solution was heated to 60 0C. Tetrahydrofuran (10 mL) was added to the warm solution. The mixture was heated to reflux for an additional two hours. After cooling to 0 0C, the reaction was quenched with a solution of citric acid at pH 4-5 in ice-water and stirred to room temperature. The mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. Purification with flash chromatography, eluting with a gradient of ethyl acetate :hexanes (20:100), gave a yellow solid that was further washed with ethyl acetate to give F-0162 (15 mg,10%) as an off-white solid. MS (ESI) [IVH-H+]"= 367.2.

[0130] (4-Fluoro-benzyl)-[4-methyl-5-(lH-p yrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine P-0163



was prepared using the protocol of Scheme 160, substituting the 3.13 M ethyl magnesium bromide in ether solution with 1.4 M of methylmagnesium bromide in tetrahydrofuran. MS (ESI) [M+J-L] = 353,2.

Example 7: Synthesis of (4-Chloro-benzyl)-[6-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridazϊn-3-yl]-amine P-0092

flll31 j (4-Chloro-benzyl)-[6-(lH-ρyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridazin-3-ylJ-amine P-0092 was synthesized in 3 steps as shown in Scheme 161.

Scheme 161


Step 1 - Synthesis of(6-bromo-pyridazin-3-yl)-(4-chloro-benzyl)-amine (522);
[0132] To 6-bromo-pyridazin-3-ylamine (521, 0.85 g, 0.0049 mol) in acetonitrile (30.0 mL) were added 4-chlorobenzaldehyde (40, 0.82 g, 0.0058 mol), triethylsilane (4.0 mL, 0.025 mol) and trifluoroacetic acid (2.0 mL, 0.026 mol). The reaction was heated to reflux for 4 hours, then poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and washed with ethyl acetate to give a white solid (522, 1.0 g). MS (ESI) [M+H+]+= 298.3, 300.2.

Step 2 - Preparation of3-[6-(4-chloro-benzylamino)-pyridazin-3-ylmethyl]-pyrroln[2,3-b] pyridine- 1-carboxylic acid tert-butyl ester (523):
[0133] To (6-bromo-pyridazin-3-yl)-(4-chloro-benzyl)-amine (522, 0.560 g, 1.88 mmol) in tetrahydrofuran (45.0 mL), under an atmosphere of nitrogen at -78 0C, was added n-butyllithium (2.50 M in hexane, 0.760 mL) slowly. After 10 minutes, l,2-bis-(chloro-dimethyl-silanyl)-ethane (0.201 g, 0.94 mmol) in tetrahydrofuran (5.0 mL) was added to the reaction. The reaction mixture was allowed to stir at room temperature for 3 hours. The reaction was cooled to -78 0C, followed by addition of 1.70 M of tert-butyllithium in hexane (1.20 mL) slowly. The reaction was stirred for 20 minutes, followed by addition of a solution of CuCN.2LiCl (0.6 M in tetrahydrofuran, 3,00 mL) and 3-chloromcthyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (512, 0,47 g, 1.8 mol) in tetrahydrofuran (10,0 mL). After 30 minutes, the reaction was allowed to warm to room temperature for 10 minutes. The reaction was poured into water and extracted with ethyl acetate f he organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was treated with trifluoroacetic acid (1.0 mL) dissolved in dichloromethane (10.0 mL) for 10 minutes. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified with silica gel column chromatography eluting with 60% ethyl acetate i in hexane to give the desired compound (523, 0.10 g, 23.8%). MS (ESI) [IvKHT = 450.1.

Step 3 - Preparation υf(4-chloro-henzyl)-[6-(lH-pynolo[2,3-b]pyridin-3-y!methyl)-pyridazιn-3-yl] -amine (P-0092):
[0134] To 3-[6-(4-chloro-benzylamino)-pyτidazin-3-ylmethyl]-pyrrolo[2,3-b]pyridine-l -carboxylic acid tert-butyl ester (523, 50.0 mg, 0.11 1 mmol) in dichloromethane (10.0 mL) was added triiTuoroacetic acid (0.30 mL, 0.0039 mol). The reaction was stirred at room temperature overnight. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give an off-white solid (P-0092, 7.3 mg, 19.0%). MS (ESI) [M+HT = 350.1.

Example 8: Synthesis of [l-ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-ylj-(4-fluoro-benzyl)-amine P-0165

[0135] [l-Ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-(4-fluoro-benzyl)-amine P-0165 was synthesized in 7 steps as shown in Scheme 162.

Scheme 162


Step I - Preparation of5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (525):
[0136] To 5-nitro-2H-pyrazole-3-carboxylic acid (524, 10.0 g, 0.0637 mol) in methanol (100.0 inL) was added concentrated sulfuric acid (1.00 mL, 0.0180 mol). The reaction was stirred at room temperature overnight. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give a white solid (525, 1.5 g, 13.8%).

Step 2 - Preparation of2-ethyl-5-nitro-2H-pyrazote-3-carboxylic acid methyl ester (526):
[0137] To 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (525, 2.50 g, 0.0146 mol) in N,N-dimethylformamide (62.5 mL) were added iodoethane (1.2 mL, 0.016 mol) and potassium carbonate (4.17 g, 0.0301 mol) under an atmosphere of nitrogen. The reaction was stirred at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (526, 1.3 g, 44.7%).

Step 3 - Preparation of5-amino-2-ethyl-2H-pyrazole-3-carboxylic acid methyl ester (527):
[0138] To 2-ethyl-5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (526, 1.30 g, 6.53 mmol) in methanol (60.0 mL) was added 20% Pd(OH)2/C (0.1 g). The reaction was stirred under an atmosphere of hydrogen overnight. The reaction was filtered and concentrated to give a light yellow solid (527, 1.0 g, 90.6%).

Step 4 — Preparation of2-ethyl-5-(4-βuυrυ-benzylaminυ)-2H-pyrazυle-3-carbυxylic acid methyl ester (529):
[0139] To 5-amino-2-ethyl-2H-pyrazole-3-carboxylic acid methyl ester (527, 1.00 g, 5.91 mmol) in acetonitrile (27.5 mL) were added 4-fluorobenzaldehyde (528, 0.660 mL, 6.26 mmol), triethylsilane (4.77 mL, 0.0298 mol) and trifluoroacetic acid (2.38 mL, 0.0310 mol). The reaction was stirred at 80 °C for 4 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% tc 100% ethyl acetate in hexane to give a white solid (529, 1.00 g, 61 %).

Step 5 - Preparation of2-ethyl~5-(4-fluoro-benzyiamino)-2H-ρyrazolc-3-carbahlehyde (53Q)' [0140] To 2-ethyl-5-(4-fiuoro-benzylamino)-2H-pyrazole-3-carboxylic acid methyl ester (529, 1.00 g, 3.61 mol) in tetrahydrofαran (70.0 mL) under an atmosphere of nitrogen at room temperature, lithium tetrahydroaluminate (1.00 M of in tetrahydrofuran, 10.00 mL) was slowly added The reaction was stirred at room temperature overnight, followed by slowly adding sodium sulfate decahydrate (15 0 g) After 2 hours, the reaction was filtered, concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate m hexane to give a yellow oil (530, 0 16 g, 18%) MS (ESI) [MTH+J+ = 248 2

Step 6 - Preparation of l-ethyl-5-[methoxy-(lH-pyrrolo[2, 3-b]pyndιn-3-\l)-meth\l]-lH-py t azol 3-y I- (4-βuorυ-benzyl) -arm ne (531)
[0141] 1 o lH-Pyrrolo[2,3-b]pyridine (1, 54 0 mg, 0 46 mmol) m methanol (15 0 πiL) were added 2-ethyl-5-(4-fluoro-benzylammo)-2H-pyrazole-3-carbaldehyde (530, 1 10 0 mg, 0 44 mmol) and potassium hydroxide (0 6O g 0 011 mol) under an atmosphere of nitrogen The reaction was stirred at room temperature overnight, then poured mto water and extracted with ethyl acetate The organic layer was dried over anhydrous sodium sulfate and filtered 1 he filtrate was concentrated and purified by silica gel column chromatography eluting with 40% ethyl acetate in hexane to give a white solid (531, 0 12 g, 71 1%) MS (ESI) [M-H+] = 378 2

Step 7 - Preparation of[l-ethyl-5-(lH-pyrrolo[2,3-b]pyrιdιn-3-ylmethyl)-lHpyrazol-3-yl]-(4-fluυro-benzyl)-amme (P-0165)
[0142] To l -cthyl-5-[mcthoxy-(lH-pyrrolo[2,3-b]pyπdin-3-yl)-methyl]-lH-pyrazol-3-yl-(4-fluoro-benzyl)-amine (531, 0 12 g, 0 32 mmol) m acetomtrile (10 0 mL, 0 191 mol) were added tπethylsilane (0 60 mL, 0 0038 mol) and trifluoroatetic acid (0 30 mL, 0 0039 mol) The reaction was stirred at 80 0C tor 2 hours The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate The organic layer was dried over anhydrous sodium sulfate and filtered The filtrate was concentrated and washed with ethyl acetate and hexane to give crude compound 1H NMR indicated that the reaction was incomplete I he crude compound was dissolved in dichloromethane (15 0 mL), tπfluoroacetic acid (0 30 mL) and tπethylsilane (0 60 mL) The reaction was stirred at 43 0C for 72 hours The reaction was concentrated poured into aqueous potassium carbonate and extracted with ethyl acetate I he organic layer was dried over anhydrous sodium sulfate and filtered The filtrate was concentrated and washed with ethyl acetate and hexane to give an off-white solid (P-0165, 18 7 mg, 17%) MS (FSI) [M^H ] = 350 3

|01431 (4-Fluoro-benzyl)-[l-methyl-5-(lH-pyπolo[2,3-b]pyridm-3-ylmethyl;-lH-pyiazol-3-vI] amine P-Ol 69

was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in Step 2. MS (ESI) [M+HT = 336.3.

[0144] [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l-methyl-lH-p>τazol-3-yl]-(4-fluoro-benzyl)-amine P-0170



was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in step 2 and lH-pyrrolo[2,3-b]pyridine 1 with 5-chloro-lH-pyrrolo[2,3-b]pyridine in step 6. MS (ESI)

[0145] (4-Fluoro-benzyl)-{l-methyl-5-[5-(l-methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridin-3 -ylmethyl]- 1 H-pyrazol-3 -yl} -amine P-0180



was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in step 2 and lH-Pyrrolo[2,3-b]pyridine 1 with 5-(l-Methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine (prepared as described in Example 18, Scheme 172) in step 6. MS (ESI) OHM"] ' = 416.2.

[0146] 3-[5-(4-Fluoro-benzylamino)-2-methyl-2H-pyrazol-3-ylmethyl]-lH-pyrrolo[2J-b]pyridine-5-carbonitrile P-0191



was prepared using the protocol of Scheme 162, substituting lH-Pyrrolo[2.3-b]pyridme 1 with I ] ] Pyrrolo[2,3-b]pyridine-5-earbonitrile in Step 6. MS (ESI) [M+II+]+ = 361.5.

Example 9: Synthesis of [4-chIoro-l-ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH- pyrazol-3-yl]-[l-(4-fluoro-phenyI)-meth-(E)-yIidene]-aπiine P-0166

[0147] [4-chlorol -ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-[l -(4- fluoro-phenyl)-meth-(E)-ylidene]-aminc P-0166 was synthesized in 1 step as shown in Scheme 163.

Scheme 163


Step 1 - Preparation of [4-chIoro-l-ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl] -[ l-(4-fluoro-phenyl)-meth-(E)-ylidene] -amine (P-0166):
[0148] To [l-ethyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (P-0165, 10.1 mg, 0.0289 mmol, prepared as described in Example 8, Scheme 162) in acetonitrile (8.0 niL) was added N-chloro-succiπimide (4.18 mg, 0.0318 mmol). The reaction was stirred at room temperature for 2 hours. The reaction was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0166, 1.1 mg). MS (ESI) [M+H+]+ = 382.1.

Example 10: Synthesis of 5-chloro-3-chIoromethyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester

[0149] 5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-l -carboxylic acid tert-butyl ester was synthesized in 3 steps as shown in Scheme 164.

Scheme 164



Step 1 - Preparation nf (5-chloro-lH-pyrroh[2,3-b]pyridin-3-ylmethyl)~dimethyl~amine (533) |0150] To 5-Chloro-lH-pyrrolo[2,3-b]pyridine (532, 8.00 g, 0.0524 mol) in isopropyl alcoho (250.0 ml) were added dimethylamme hydrochloride (4.79 g, 0.0587 mol) and formaldehyde (1.77 g, 0.0589 mol). The reaction was stirred at room temperature overnight, followed by refluxing for 4 hours. The reaction was concentrated, poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (533, 10.0 g, 91 %), that was used directly in the next step.

Step 2 and 3 — Preparation of5-chloro-3-chloromethyl-pyrrolo[2, 3~b]pyridine~l~carboxylic acid tert-bulyl ester (535):
[0151] 5-Chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-l -carboxylic acid tert-butyl ester 535 was prepared following the protocol of Scheme 158 (Example 4) steps 1 and 2, substituting dimethyl-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-arαine 2 with (5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-dimethyl-amine 533 in step 1.

Example 11: Synthesis of (4-chloro-benzyl)-[5-(5-chIoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-amine P-0132

[0152] (4-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-amine P-0132 was synthesized in 3 steps as shown in Scheme 165.

Scheme 165


Step I Preparation of(4-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (536) '
I0153J To 2,6-difluoropyridine (58, 9.85 g, 0.0856 mol) in N-mcthylpyrrolidinone (50.0 ml.) were added p-chlorobcnzylaminc (61, 10.5 mL, 8.63 mmol) and N.N-diisopropyIethylamine (30,0 mL, 0,172 mol). The reaction was stirred at 90 0C overnight. The reaction was poured mto water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25% ethyl acetate in hexane, then washed with ethyl acetate/hexane to give a white solid (536, 1O g, 50%).

Step 2 - Preparation of(5-bromo~6-fluoro-pyridin-2-yl)-(4-chloro-benzyl)-amine (537):
[0154] To (4-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (536, 1.03 g, 4.35 mmol) in acetonitrile (30.0 mL), under an atmosphere of nitrogen, N-bromosuccinimide (0.820 g, 4.61 mol) was added slowly. After 2 hours, the reaction was poured into a solution of sodium thiosulfatc and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and crytstallized with ethyl acetate and hexane to give a white solid (537, 1.10 g, 80.1%).

Step 3 - Preparation of(4-chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl] -amine (P-0132):
[0155] To (5-bromo-6-fluoro-pyridin-2-yl)-(4-chloro-benzyl)-amine (537, 2.76 g, 8.75 mol) in tetrahydrofuran (90.0 mL), under an atmosphere of nitrogen at -78 0C, n-butyllithium (2.50 M in hexane, 3.64 mL) was added slowly. After 60 minutes, l ,2-bis-(chloro-dimethyl-silanyl)-efhane (0.942 g, 4.38 mol) in tetrahydrofuran (S.0 mL) was added to the reaction. The reaction mixture was allowed to stir at room temperature for 2 hours. The reaction was cooled to -78 0C, followed by addition of tert-butyllithium (1.70 M in hexane, 10.50 mL). The reaction was stirred for 30 minutes, followed by addition of 0.65 M of CuCN.2LiCl in tetrahydrofuran (14.0 mL). The reaction was stirred at -35 0C for 10 minutes, followed by addition of 5-chloro-3-chloromethyl-pyrrolo[2,3~b]pyridine-l-carboxylic acid tert-butyl ester (535, 1.70 g, 5.64 mol, prepared as described in Example 10, Scheme 164) in tetrahydrofuran (10.0 mL). The reaction was allowed to warm to room temperature for 1 hour and 2 N HCl (30 mL) was added to the reaction mixture, then stirred for 30 minutes. The reaction was poured into aqueous ammonia and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified with silica gel column chromatography eluting with 30% ethyl acetate in hexane to give the desired compound (P-0132, 0.75 g, 33.1 %). MS (ESI) [M+H'f = 401.1.

Example 12: Synthesis of 5-chloro-3-(2,6-difluoro-pyridin-3-ylmethyI)-lH-pyrrolo[2,3-bjpyridine P-0155

[0156] 5-Chloro-3-(2,6-difluoro-p>τidin-3~ylmethyl)-lH-pyrrolo[2,3-b]pyridine P-0155 was synthesized in 1 step as shown in Scheme 166.

Scheme 166


Step 1 — Preparation of 5-chloro-3-(2,6-difluoro-pyridin-3-ylmethyl)-lH-pyrrolo[2,3-b] pyridine (P-0155):
[0157] To 2,6-Difluoropyridine (58, 3.40 g, 0.0295 mol) in tetrahydrofuran (200.0 mL), under an atmosphere of nitrogen at -78 0C, 2.50 M of n-butyllithium in hexane (12.0 mL) was added slowly. After 60 minutes, CuCN.2LiCl (0.75 M in tetrahydrofuran, 40.0 mL) was added to the reaction mixture. After 5 minutes, 5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (535, 4.20 g, 0,0139 mol, prepared as described in Example 10, Scheme 164) in tetrahydrofuran (20 mL) was added to the reaction. The reaction was stirred at -78 0C overnight, then poured into water and ammonia (10 mL), and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography cluting with 15% ethyl acetate in hexane to give a white solid (P-0155, 300 mg, 7.7%). MS (ESI) [M-H+P = 278.1.

Example 13: Synthesis of 3-(2,6-difluoro-pyridin-3-ylmethyl)-lH-pyrrolo[2,3-b]pyridine P-0154

[0158] 3-(2,6-difluoro-pyridin-3-ylmethyl)-lH-pyrrolo[2,3-b]pyτidine P-0154 was synthesized in 1 step as shown in Scheme 167.

Scheme 167



536 P-0154

Step 1 - Preparation of3-(2,6-difluoro-pyridni-3-ylmethyl)-lII-pyrrolo[2,3-b]pyridine (P-0154): [0159] To 3-(2,6-difluoro-pyridin-3-ylmethyl)-pyrrolo[2,3-b]pyridinc-l -carboxylic acid tert-butyl ester (536, 0.35 g, 1.0 mmol, prepared as described in Example 10, Scheme 164, replacing 5-chloro-lH-pyrrolo[2,3-b]pyridine 532 with lH-pyrrolo[2,3-t>]pyridinc in step 1) in N- methylpyrrolidinone (3.00 mL) were added p-chlorobenzylamine (0,20 mL, 1.6 mmol) and N ,N- diisopropylethylamine (0.30 mL, 0.0017 mol). The reaction was stirred at 50 0C for 72 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and the crude intermediate was dissolve in dichloromethane (15.0 mL) and trifluoroacetic acid (0.5 mL). The reaction w as stirred at room temperature for 2 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column
chromatography eluting with 35% ethyl acetate in hexane to give a white solid (P-0154, 0.18 g, 72%). MS (ESI) [M+H+]+ = 246.2.

Example 14: Synthesis of 5-((lH-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-(4-chlorobenzyl)-6-chloropyridin-2-amine P-0161

[0160] 5-((lH-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-(4-chlorobenzyl)-6-chloropyridin-2 -amine P-0161 was synthesized in 6 steps as shown in Scheme 168.

Scheme 168


Step 1 - Preparation of(4-chloro-benzyl)-(6-chloro-pyridin-2-yl)-amine (538):
[0161] To 6-chloro-pyridin-2-ylamine (537, 5.60 g, 0.0436 mol) in acctonitrile (300 mL) were added 4-chlorobenzaidehyde (40, 6.7 g, 0.048 mol), trifluoroacetic acid (13 mL, 0.17 mol) and triethylsilane (21 mL, 0.13 mol). The reaction was heated to reflux for 4 hours, then concentrated, poured into water, extracted with ethyl acetate, and washed with sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The filtrate was purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (538, 6.5 g, 59%), MS (ESI) [M+H"]+ = 255.1.

Step 2 - Preparation of(5-bromo-6-chloro-pyridin~2-yl)-(4-chloro-benzyl)-amine (539):
[0162] To (4-chloro-benzyl)-(6-chloro-pyridin-2-yl)-amine (538, 4.00 g, 0.0158 mol) in acetonitrile (66.7 mL, 1 ,28 mol) under an atmosphere of nitrogen, N-bromosuccinimide (2.81 g. 0.0158 mol) in acetonitrile (20 mL) was added slowly. The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and crystallized with ethyl acetate in hexane to give a white solid (539, 2.60 g, 95.3%).

Step 3 — Preparation oj'2-chloro-6-(4-chloro-benzylamino)-pyridine-3-carbaldehyde (540):
[0163] To (5-bromo-6-chloro-pyridin-2-yl)-(4-chloro-benzyl)-amine (539, 2.60 g, 7. S3 mmol) in tetrahydrofuran (60.0 mL) under an atmosphere of nitrogen at -78 0C, isopropylmagnesium chloride (2.00 M in tetrahydrofuran, 4.20 mL) was added over 10 minutes, The reaction was stirred at -78 0C for 20 minutes, then allowed to warm to room temperature for 10 minutes. The reaction was cooled to -78 0C. tert-Butyllilhium (1.70 M in hexane, 10.2 mL) was added to the reaction over 10 minutes. After 40 minutes, N,N-dimcthylformamidc (1.80 mL, 0.0232 mol) was added to the reaction. The reaction was stirred at -78 0C for 40 minutes, then allowed to warm to room temperature for another 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in hexane to give a light yellow solid (540, 1.0 g, 45.4%). MS (ESI) [M-H+]" = 279.0.

Step 4 - Preparation of(4-chloro-benzyl)-(6-chloro-5-formyl-pyrιdin~2-yl)-carbamic acid tert-butyl ester (541):
[0164J To 2-chloro-6-(4-chloro-benzylamino)-pyridine-3-carbaldehydc (540, 0.40 g, 1.42 mmol) in dichloromethane (10.0 mL) were added 4-dimethylaminopyridine (10,0 mg, 0.082 mmol), di-tert-butyldicarbonate (0.693 g, 3.17 mmol) and triethylamine (0.50 mL, 0.0036 mol). The reaction was stirred at room temperature overnight, then concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (541, 0.45 g, 831

Step 5 - Preparation of(4-chloro-ben∑yl)-6-chloro-5-[hydroxy-(lH-pyrrolo[2.3-b]pyndιn-3 Vt)-methylJ-pyridin-2-yl'Carbamic acid tert-butyl ester (542):
[0165] To lH-Pyrrolo[2,3-b]pyridine (1, 465 mg, 3.93 mmol) in methanol (50 mL) were added sodium hydroxide (0.630 g, 0.0157 mol) and (4-chloro-benzyl)-(6-chloro-5-forrayl-pyridin-2-yI)-carbamic acid tert-butyl ester (541, 1.5 g, 0.0039 mol). The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (542, 1.Og, 51 %), MS (ESI) [M+ H+]+= 499.1.

Step 6 - Preparation of5-((IH-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-(4-chlorobenzyl)-6-chlϋropyrldin-2-amine (P-Ol 61):
[0166] To (4-chloro-benzyl)-6-chloro-5-[hydroxy-(l H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-pyridin-2-yl-carbamic acid tert-butyl ester (542, 1.00 g, 2.00 mmol) in acetonitrile (130.0 mL) were added triethylsilane (11.5 mL, 0.0720 mol) and trifluoroacetic acid (5.5 mL, 0.071 mol). The reaction was heated to reflux for 2 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give a light yellow solid (P-0161, 480 mg, 62%). MS (ESI) [M+jTf = 383.1, 385.1.

[0167] [6-Chloro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0174



was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehydc 40 with 6-trifluoromethyl-pyridine-3-carbaldehyde in step 1. MS (ESI) [M+IT]+ = 418.2.

[0168] [ό-Chloro-S^S-chloro-lH-pyrroloP^-bJpyridin^-ylmethyO-pvridin^-y^^ό-trifluoromethyl-pyridin-3 -ylmethyl)-amine P-0176



was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehyde 40 with 6-trifluoromethyI-ρyridine-3-carbaldehyde in step i and lH-Pyrrolo[2,3-b]pyridine 1 with 5-chloro-lll-pvrrolo[2,3-b]pyridine in step 5. MS (ESI) [M-H 'f = 452.0.

[0169] {6-Chloro-5-[5-(l-methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl]-pyridin-2-yl}-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0179
was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehyde 40 with 6-trifluoromethyl~pyridine-3~carbaldehyde in step 1 and lH-Pyrrolo[2,3-b]pyridinc 1 with 5-(l - Methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine (prepared as described in Example 18, Scheme 172) in step 5. MS (ESl) [M+H+]+ = 498.0.

Example 15: Synthesis of (3-chloro-benzyl)-[5-(lH-pyrrolo[2,3-blpyridin-3-ylmethyl)- pyridin-2-yl]-amine P-0129

[0170] (3-Chloro-benzyl)-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-0129 was synthesized in 1 step as shown in Scheme 169.

Scheme 169


Step 1 Preparation of(3-chloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-yImethyI)-pyridin-2-ylJ-amine (P-0129):
[0171] 3-(6-bromo-pyridin-3-ylmcthyl)-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (6a, 10 mg, 0,023 mmol) was combined with 3-chlorobenzyl amine (543, 13 mg, 0.093 mmol) in dioxane (0.3 niL). Tris(dibenzylideneacetone)-dipalladium(0) (3 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthcne (Xantphos, 3 mg) and sodium tert-butoxide (15 mg) were added. The mixture was heated at 100 0C overnight. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in DMSO and purified by reverse phase HPLC on a YMC-Pack ODS-A C-18 column (50mm x 10mm ID), eluting with water with 0.1 % trifluoroacetic acid and 5-40% acetonitrile with 0.1 % trifluoroacetic acid over 13 minutes ai a flow rate of 6 mL/ minute to provide the desired compound P-0129. MS (ESI) [Mi-H ] ' = 349.1.

[0172] Additional compounds were prepared following the protocol of Scheme 169, replacing 3-chlorobenzyl amine 543 with an appropriate amine. The following compounds were made following this procedure: (4-Morpholin-4-ylmethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]- amine (P-0093),
Pyridm-3-ylmethyl-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-yl]-amine (P-0094),

(5-Methyl-isoxazol-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2-yl]-4innc

(P-0095),
(2-Pyrrolidm-l-yl-ethyl)-[5-(lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyτidm-2-yl]-amine (P- 0096).
[l-(4-Methanesulfonyl-phenyl)-ethyl]-[5-(lH-pyπOlo[2,3-b]pyridm-3-ylmethyl)-pyπdin-2-y[]- amine (P-0097),
(2-Methoxy-ethyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]-amine (P-0098)

(2-Morpholin-4-yl-ethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme (P- 0099),
((^-l-Phenyl-ethy^-fS-ClH-pyrrolo^.S-blpyridin^-ylmethyO-pyridm^-yη-amine CP-OnS),

(3-Morpholin-4-yl-benzyl)-[5-(lH-p>τrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0126),
[l-(2-Fluoro-phenyl)-ethyl]-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0127),
[2-(3-Fluoro-phenyl)-ethyl]-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme (P- 0128),
(l-Methyl-lH-imidazol-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]- amine (P-0130), and
(l^-Dimethyl-lH-pyrazol^-ylmcthy^-tS^lH-pyrrolo^β-blpyridin-S-ylmethyO-pyndin^- yl]-amine (P-0131).

[0173] The following table indicates the amine (Column T) used in Scheme 169 to provide the compounds (Column 3). Column 1 provides the compound number and column 4 the observed mass.



Example 16: Synthesis of 3-cnloro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2- yll-benzamide P-OlIl

[0174] 3-Chloro-N-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-benzamide P-Ol Il was synthesized in 1 step as shown in Scheme 170.

Scheme 170


Step 1 - Preparation of3-chloro-N-[5-(lH~pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin-2-ylj-benzamide (P-0111):
[0175] 3-(6-Bromo-pyridin-3-ylmethyl)-l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (6a, 10 mg, 0.023 mmol) was combined with 3-chloro-bcnzamide (544, 15 mg, 0.096 mmol) in dioxane (0.4 niL). Tris(dibenzylideneacetone)-dipalladium(0) (3 mg), 4,5-bis(diphenylphosphino)-9,9~ dimethylxanthene (Xantphos, 3 mg), and sodium fcr/-butoxide (15 mg) were added. Cesium carbonate (20 mg) was added and the mixture was heated at 100 °C overnight. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in DMSO (0.2 mL) and purified by reverse phase HPLC on a YMC-Pack ODS-A C-18 column (50mm x 10mm ID), eluting with water with 0.1 % trifluoroacetic acid and 5-40% acctonitrile with 0.1% trifluoroacetic acid over 13 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0111. MS (ESI) [M+tT]+= 363.1.

|0176] Additional compounds were prepared following the protocol of Scheme 170, replacing 3-chloro-benzamide 544 with an appropriate amide. The following compounds were made following this procedure:
3,4-Dichloro-N-[5-(lH-ρvrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-OlOO),

2-Chloro-4-fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-bcnzamidc (P- 0101),
2,5-Dimethyl-2H-pyrazole-3-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)- pyridin-2-yl]-amide (P-0102),
Thiophene-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide

(P-0103), l-Methoxy-N-fS-ClH-pyiToloP^-blpyπdm-S-ylmethyO-pyπdin^-ylJ-ibonicotindmide (P- 0104),
N-[5-(lH-Pyrrolo[2,3-b]pyπdm-3-ylmeth>l)-pyπdm-2-yl]-isomcotinamide (P-0105),

Pyrazine-2-carboxylic acid [5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyndm-2-yl]-amidc (P- 0106),
Pyπdine-2-carboxylic acid f5-(lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-pyridm-2-yl]-amide (P- 0107),
6-Methy l-N-[5 -( 1 H-pyrrolo[2 ,3 -b]pyridin-3 -ylmethyl)-pyπdin-2-yl]-nicotmamide (P-0108) .

4-Fluoro-3-methyl-N-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-benzamide (P- 0109),
S-Methyl-pyrazme^-carboxyhc acid [5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2 yl] amide (P-OIlO),
4-Fluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-yl]-3-tπfluoromethyl- ben7amide (P-0112),
N-[5-(lH-Pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyndm-2-yl]-3-tnfluoromethoxy-benzamide (P- 0113),
N-[5-(lH-Pyrrolo[2,3-b]pyπdin-3-ylmcthyl)-pyridm-2-yl]-3-tπfluoromethyl-benzamide (P- 0114),
3-Chloro-4-fluoro-N-[5-(lH-pyπOlo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-bcnzamide (P- 0115),
3,4-Difluoro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylraethyl)-pyridm-2-yl]-ben2amide (P-0116)

2-Chloro-N-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-bcnzamide (P-0117),

5-Fluoro-2-methyl-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-benzamide (P- 0118),
2-F luoro-N-[5 -( 1 H-pyrrolo [2 ,3 -b]pyπdin-3 -ylmethyl)-ρyπ dm-2 -yl J -b enzami de (P-0119) ,

3-Methoxy-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-benzamide (P-0120),

3-Fluoro-N-[5-(lH-pyrrolo[2,3-b]pyτidin-3-ylmethyl)-pyridm-2-yl]-benzamide (P-0121),

3-Methyl-Nf-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0122), and

2-Chloro-N-[5-(l H-pyrrolo[2 3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-isonicotmamide (P-0123)

[0177] The follovvmg table indicated the amide (Column 2) used in Scheme 170 to provide tne compounds (Column 3) Column 1 provides the compound number and Column 4 the observ ed mass 85

Example 17: Synthesis of 3,5-dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyrazoIe-l- carboxylic acid 4-methoxy-benzylamide P-0135

[0178] S^-Dimethyl^-ClH-pyrroloP^-blpyridin-S-ylmethyO-pyrazole-l -carboxylic acid 4- methoxy-benzylamide P-0135 was synthesized in 1 step as shown in Scheme 171 ,

Scheme 171


Step 1 - Preparation of3,5-dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l- carboxylic acid 4-methoxy-benzylamide (P-0135):
[0179] 3-(3,5-dimethyl-lH-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine-l -carboxylic acid tert- butyl ester (514, 10 mg, 0.03 mmol) was dissolved in dichloromethane (0.5 mL). 1,8- Diazabicylo[5.4.0]unde-7-ene (6 mg, 0.04 mmol) was added. 1 -Isocyanatomethyl-4-methoxy- benzene (545, 6.5 mg, 0.04 mmol) was added. The reaction was allowed to proceed at room temperature for 30 minutes. Acetic acid (0.2 mL) was added to the reaciton. The solv ents were removed under reduced pressure. The residue was dissolved in dimethyl sulfoxide (0.2 mL) and purified by reverse phase HPLC on a Phenomcnex column (50mm x 10mm ID), eluting with vuitei with 0 1 % trifluoroacctic acid and 20-100% acetonitrile with 0.1% trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0135. MS (ESI)
[M^HT = 390.3.

[0180] Additional compounds were prepared following the protocol of Scheme 171 , replacing l-isocyanatomethyl-4-methoxy-benzene 545 with an appropriate isocyanate or bromide. The following compounds were made following this procedure:
3-(l -Bcn2yl-3,5-dimethyl-lH-pyrazol-4-ylmethyl)-lH-pyrrolo[2,3-b]pyridine (P-0133),

2-[3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazol-l -ylj-l -phenyl-ethanone

(P-0134),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-chloro- benzylamide (P-0136),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 2-fluoro- benzylamide (P-0137),
3-[3 ,5 -Dimethyl- 1 -(5 -trifluoromethyl-furan-2-ylmethyl)- 1 H-pyrazol-4-ylmethyl] - 1 H- pyrrolo[2,3-b]pyridine (P-0138),
3-[3,5-Dimethyl-l -(5-methyl-isoxazol-3-ylmethyl)-lH-pyrazol-4-ylmethyl]-lH-pyrrolo[2,3- bjpyridine (P-0139),
3,5-Dimethyl-4-(lH-pyττolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 4-chloro- benzylamide (P-0140),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid [2-(4- ethoxy-phenyl)-ethyl]-amide (P-0141),
3,5-Dimethyl-4-(l H-pyiτolo[2,3-b]pyridin-3-ylrnethyl)-pyrazole-l -carboxylic acid 3-methoxy- benzylamide (P-0142),
3-{3,5-Dimethyl-l-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-lH-pyrazol-4- ylmethyl}-lH-pyrrolo[2,3-b]pyridine (P-0143),
3-[3,5-Dimethyl-l-(4-methyl-2-phenyl-thiazol-5-ylmethyl)-lH-pyrazol-4-ylmethyl]-lH- pyrrolo[2,3-b]pyridine (P-0144),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 2-methoxy- benzylamide (P-0145),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid [2-(2,4- dichloro-phenyl)-ethyl] -amide (P-0146),
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid [2-(4- fluoro-ρhenyl)-cthyl]-amide (P-0147),
3.5-Dimethyl-4-(lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-p>τazole-l -carboxylic acid [2-(2- fluoro-phenyl)-ethyl]-amidc (P-0148),
3,5-Dimcthyl-4-flH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid (.(S)-I - phenyl-ethyl)-amide (P-0149),
3.5-Dimethyl-4-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 3-fluoro- bcnzylamide (P-0150), 3,5-Dimethyl-4-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 4-fluoro- benzylamide (P-0151),
3,5-Dimethyl-4-(l H-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 4-methyl- benzylamide (P-0152), and
3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-methyl- benzylamide (P-Ol 53).

[0181] The following tabic indicates the isocyanate or bromide (Column 2) used in Scheme 171 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the observed mass.




Example 18: Synthesis of 5-(l-methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine 547.

[0182] 5-(l-Methyl-lH-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine 547 was synthesized in 1 step from 5-bromo-lH-pyrrolo[2,3-b]pyridine 44 as shown in Scheme 172.

.Scheme 172


Step 1 - Preparation of 5-(l-Methyl-lH-pyrazol-4-yl)-lH-pyrrolo [2, 3-b] pyridine (547)- [0183] To 5-bromo-7-azaindole (44, 1.04 g, 5.28 mmol) in 1 00 M potassium carbonate in water (15.8 mL) and tetrahydrofuran (50.0 mL) were added l-methyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-lH-pyrazole (546, 1.65 g, 7.92 mmol),
Tetrakis(triphenylphosphine)palladium(0) (0.305 mg, 0.26 mmol) and tetra-n-butylammonium iodide (0.20 g, 0.53 mmol). The reaction mixture was stirred at 70 0C overnight. The reaction mixture was poured into water and the organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was purified with silica gel column chromatography eiutsng with 25% ethyl acetate in hexane to provide a light yellow solid (547, 670 mg, 64,0%),
MS(ESI)[M-TH"1] = 199.4.

Example 19: Synthesis of [2-(4-fluoro-benzylamino)-thiazol-5-yl]-(lH-pyrrolo[2,3-b]pyridin- 3-yl )-methanone P-0177.

[0184] [2-(4-Fluoro-benzylamino)-thiazol-5 -yl]-(lH-pyrrolo[2,3-b]pyridin-3-yl )-methanone P- 0177 was synthesized in 2 steps as shown in Scheme 173,

Scheme 173


Step 1 - Preparation of(4-fluoro-benzyl)-[5-(lH-pyrrolo[2, 3-b]pyridine-3-carbonyl)-thiazol-2-ylj-carbamic acid lert-butyl ester (549):
[0185] A mixture of {4-chloro-5-[hydroxy-(l-triisopropylsilanyl-lH-pyrTolo[2,3-b]pyridin-3-yl)-methyl]-thiazol-2-yl}-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (548, 0.397 g, 0.57 mmol, prepared according to the protocol of Scheme 159, Example 5, replacing 4-(aminomethyl)pyridine 516 with 4-fluoro-benzylamine in step 1, isolated after step 3), triethylsilane (1.0 mL, 6.3 mmol), and trifluoroacetic acid (0.5 mL, 6 mmol) in acetonitrile (10 mL) was stirred at 40 0C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate and brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with methanol in dichloromethane to provide the desired compound as a yellow solid (549, 0.1 1 g, 9%). MS (ESI) [M-H+J+= 451.10.

Step 2 - Preparation of[2-(4-fluoro-benzylamino)-thiazol-5-yl]-(lH~pyrrolo[2,3~b]pyridin~3-yl)-methanone (P-0177):
[0186] To a solution of (4-fluoro-benzyl)-[5-(lH-pyrrolo[2, 3-b]pyridine-3-carbonyI)-thiazol-2-yl]-carbamic acid tert-butyl ester (549, 0.1 Ig, 0.2 mmol) in dichloromethane (2 mL) was added hydrogen chloride (4 M in 1 ,4-dioxane, 2 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into cold sodium bicarbonate solution, extracted with ethyl acetate, washed with brine and dried over magnesium sulfate. After removal of solvents, the residue was washed with ethyl acetate lo provide the desired compound as a yellow solid (P-0177, 9 mg, 10%). MS (ESI) [M+H!j = 353.12.

Example 20: Synthesis of {2-[(4-chloro-benzyl)-methyl-amino]-thiazoI-5-yl}-(lH-pyrrolo[2,3- b]pyridin-3-yl)-methanone P-0178.

[0187] {2-[(4-Chloro-benzyl)-methyl-amino]-thiazol-5-yl}-(lH-pyrrolo[2,3-b]pyridin-3-yl)- methanone P-0178 was synthesized in 3 steps as shown in Scheme 174.


Step 1 - Preparation of4-chloro-2-[(4-chloro-benzyl)-methy l-aminoJ-thiazoleS-carbaldehydc (551):
[0188] To a solution of (4-chloro-benzyl)-methyl-amine (550, 2 g, 0.01 mol) and
N,N-diisopropylethylamine (4 mL, 0.03 mol) in tetrahydrofuran (50 mL) was added 2,4-dichloro-thiazole-5-carbaldehyde (93, 3 g, 0.01 mmmol) in tetrahydrofuran (20 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was collected by filtration and washed with hexanes to provide the desired compound as a light-yellow solid (551, 3.6 g, 90%).

Step 2 — Preparation of {4-chloro-2-[(4-chloro-henzyl)-methyl-amino] -thiazol-5-yl}-( 1-triisopropylsilanyl-l H-pyrrolo[2,3-b] pyridin-3-yl)-methanol (552):
|01891 To a solution of 3-iodo-l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, 0.82 g, 2.0 mmol) in tetrahydrofuran (5 mL) at -20 0C, isopropylmagnesium chloride (2 M in tetrahydrofuran. 1.1 mL, 2.2 mmoi) was added dropwise. The reaction mixture was allowed to warm to 0 CC in 10 minutes. The reaction mixture was then cooled to -40 0C. To the reaction mixture was added a solution of4-chloro-2-[(4-chloro-benzyl)-mcthyl-amino]-thiazole-5-carbaldehyde (551, 0.41 g, 1.4 mmol) in tetrahydrofuran (10 mL). The reaction mixture was allowed to waπn to -10 °C in 30 minutes. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to provide the desired compound as a yellow solid (552, 0.5 g, 60%). MS (ESI) [M+lT]+= 575.29.

Step 3 - Preparation of{2-[(4-chloro-ben∑yl)-methyl-aτnino]-thiazol-5-yl}-(lH-pyrrolo[2,3-hJpyridin-3-ylJ-methanone (P-Ol 78):
[01901 Λ mixture of {4-chloro-2-[(4-chloro-benzyl)-methyl-amino]-thiazol-5-yl}-(l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-methanol (552, 1 g, 2 mmol), triethylsilane (2 rnL, 12 mmol), and trifluoroacetic acid (1 mL, 13 mmol) in acetonitrile (10 mL) was stirred at 40 0C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate and brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with methanol in dichloromethane to provide the desired compound as a yellow solid (P-0178, 0.17 g, 30%). MS (ESI) [M+H+]+= 383.09.

Example 21 : Synthesis of aldehyde intermediates.

[0191] (3-Chloro-pyridin-4-ylmethyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester 558 was synthesized in 4 steps from 6-amino-nicotinic acid methyl ester 553 as shown in Scheme 175. Scheme 175


Step 1 - Synthesis of 6-[(3-chloropyridin-4-ylmethyl)-amino] -nicotinic acid methyl ester (555): [0192J To 6-amino-nicotinic acid methyl ester (553, 2.15 g, 0.014 mol) in acetonitrile (60.0 ml,) were added 3-chloro-pvridme-4-carbaldehyde (554, 2.00 g, 0.014 mol), triethylsilane (1 1.00 mL. 0.069 mol) and trifluoroacetic acid (5.00 mL, 0.065 mol). The reaction was stirred at 80 CC overnight. The reaction was concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% elhyl acetate in hexane to give the desired compound (555, 1 ,5 g, 38,2%). MS (ESI)
[M+ff]' = 278.9.

Step 2 - Synthesis of6-[(3-Chloro-pyridin-4-ylmethyl)~amino]-pyridin-3-yl-methcιnol (556j:
[0193] To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-nicotinic acid methyl ester (555, 1.00 g, 3.60 mmol) in tctrahydrofuran (120 mL) was added a solution of lithium tetrahydroaluminate (1.00 M in tetrahydrofuran, 5.00 mL) under an atmosphere of nitrogen at room temperature. The reaction was stirred at room temperature overnight, followed with addition of sodium sulfate dccahydrate. After 1 hour, the reaction mixture was filtered, concentrated, and purified with silica gel column chromatography eluting with 2% to 20% methanol in dichloromethane to give the desired compound as a white solid (556, 0.5 g, 56%). MS (ESI) [M Hr]+ = 250.1.

Step 3 - Synthesis of6-[(3-chloro-pyridin~4-ylmethyl)-amino]-pyridine-3-carbaldehyde (557);
[0194] To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-yl-methanol (556, 0.50 g, 2.00 mmol) in tetrahydrofuran (20.0 mL) was added Dess-Martin pcriodinane (1.02 g, 2.40 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (557, 0.45 g, 91 %) that was used in the next step without further purification.

Step 4 - Synthesis of(3-chloro-pyridin-4-ylmethyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (558):
[0195] To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridine-3-carbaldehyde (557, 0.45 g, 1.80 mmol) in dichloromethane (20.0 mL) were added di-tert-butyldicarbonatc (0.65 g, 3.00mmol), 4-dimethylaminopyridine (0.012 g, 0.010 mmol) and triethylamine (0.28 mL, 2.00 mmol). The reaction was stirred at room temperature overnight, then concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (558, 250 mg, 40.0%).

[0196] (2-Difluoromethoxy-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester 559



was prepared following the protocol of Scheme 175, substituting 3-chloro-pyridine-4-carbaldehyde 554 with 2-difluoromethoxy-benzaldehyde in Step 1.

[0197] [2,6-Difluoro-3-(propane-l -sulfonylamino)-benzyl]-(5-formyl-pyridin-2-yl)-carbamic acid tcrt-butyl ester 560



was prepared following the protocol of Scheme 175, substituting 3-chloro-pyridine-4-carbaldehyde 554 with propane- 1 -sulfonic acid (2,4-difluoro-3-formyl-phenyl)-amide in Step 1. MS (ESI)

[M+H']* = 470.3,

[0198] (6-Fluoro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 565 was synthesized in 4 steps from 2,6-Difluoro-nicotinic acid methyl ester 60 as shown in Scheme 176.
Scheme 176


5/ep / - Synthesis of 2-fluoro-6-[(6-trifluσromethyl-pyridin-3-ylmethyl)-amino] -nicotinic acid methyl ester (562):
[0199] To 2,6-difluoro-nicotinic acid methyl ester (60, 1.82 g, 0.0105 mol) in N,N-dimethylformamide (20.0 mL), under an atmosphere of nitrogen at -40 0C, C-(6-trifluoromethyl-pyridin-3-yl)-methylamine (561, 1.00 g, 5.68 mmol) was added. The reaction was stirred at -40 CC then allowed to warm to room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in liexane to give a white solid (562, 1.40 g, 74.9). MS (ESl) [M+H1] ' = 330.1.

Step 2 - Synthesis of2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-methanol (563): [0200] To 2-fluoro-6-[(6-trifluoroπiethyl-pyridin-3-ylmethyl)-amino]-nicotinic acid methyl ester (562, 1.40 g, 4,25 mmol) in tetrahydrofuran (100.0 mL) under an atmosphere of nitrogen at room temperature, a solution of lithium tetrahydroaluminate (1.00 M in tetrahydrofuran, 10.0 mL) was added slowly. The reaction was stirred at room temperature overnight, followed by addition of an appropriate amount of sodium sulfate decahydrate. After 1 hour, the reaction mixture was filtered and concentrated to give crude compound (563, 1.2 g, 93.7%) that was used in the next step without further purification.

Step 3 - Synthesis of2-flnoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-carbaldehyde (564):
[0201] To 2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-methanol (563, 1.20 g, 3.98 mmol) in dichloromethane (40.0 mL) was added Dess-Martin periodinane (1.86 g, 4.38 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous sodium thiosulfate and potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (564, 0.28 g, 23.5%).

Step 4 - Synthesis of(6-fluυro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (565);
[0202] To 2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-carbaldehyde (564, 0.28 g, 0.94 mmol) in tetrahydrofuran (10.0 mL) were added di-tert-butyldicarbonate (0.245 g, 1.12 mmol) and 4-dimethylaminopyridine (0.050 g, 0.41 mmol). The reaction was stirred at room temperature overnight, then concentrated and purified with silica gel column
chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (565, 0.22 g, 59%).

[0203] (6-Chloro-5-formyl-pyridin-2-yl)-(6-trifIuoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 570 was synthesized in 4 steps from 6-chloro-pyridin-2-ylamine 537 as shown in

Scheme 177.
Scheme 177

Step 1 - Synthesis of(6-chlow-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (567). [0204] To 6-chloro-pyridin-2-ylamine (537, 0.760 g, 5.91 mmol) in acetonitrile (30.0 niL), ό-trifluoromethyl-pyridine-θ-carbaldehyde (566, 1.06 g, 6.05 mmol), trifluoroacetic acid (3.00 mL, 0.0389 mol) and triethylsilanc (6.00 mL, 0.0376 mol) were added. The reaction was heated to reflux for 4 hours. The reaction was concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (567, 1.60 g, 94.1 %).

Step 2 - Synthesis υf(5~bromo-6-chlora-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (568):
[0205] To (6-chloro-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (567, 4.50 g, 0.0156 mol) in acetonitrile (120.0 mL) under an atmosphere of nitrogen, N-bromosuccinimide (3.03 g, 0.0170 mol) in acetonitrile (50 mL) was added slowly. The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and purified with silica gel column chromatography eluting with 25% to 100% ethyl acetate in hexane to give a white solid (568, 6,20 g, 8

Step 3 — Synthesis of2-chloro-6-[(6-triβuυromethyl-pyridin-3~ylmethyl)-amino]-pyridine~3-carhaldehyde (569):
J0206J To (5-bromo-6-chloro-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3->lmethyl)-amine (568, 4.60 g, 0.0125 mol) in tetrahydroftiran (60 0 mL) under an atmosphere of nitrogen at -78 0C.
isopropylmagnesium chloride (2.00 M in tetrahydrofiiran, 6.44 mL) was added over 10 minutes. The reaction was stirred at -78 13C for 20 minutes, and then allowed to warm to room temperature for 10 minutes. The reaction was cooled to -78 3C, followed by adding tert-butyllithmm (1.70 M m hexane. 15.3 mL) over 10 minutes. After 40 minutes, N,N-dimethylformamide (1.23 mL, 0.015S mol) was added and the reaction was stirred at -78 0C for 40 minutes, then allowed to warm to room temperature for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in hexane to give a light yellow solid (569, 2.84 g, 71.7%).

Step 4 - Synthesis of{6-chloro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (570)
[0207] To a solution of 2-chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-carbaldehyde (569, 0.545 g, 1.73 mmol) in tetrahydrofuran (10 mL), N,N-diisopropylethylamine (0.60 mL, 3.40 mmol), 4-dimethylaminopyridine (20 mg, 0.10 mmol), and a solution of di-tert-butyldicarbonate (0.41 g, 0.0019 mol) were added. The reaction mixture was stirred at room temperature overnight, then concentrated, poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (570, 0.60 g, 83.6%).

[0208] (5-Bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-aminc 571



was prepared following the protocol of Steps 1 and 2 of Scheme 177, substituting 6-chloro-pyridin-2-ylamine 537 and 6-trifluoromethyl-pyridine-3-carbaldehyde 566 with 6-fluoro-pyridin-2-ylamine and 2-chloro-benzaldehyde, respectively in Step 1.

[0209] (ό-Fluoro-S-formyl-pyridin^-ylXό-methoxy-pyridin-S-ylmethyO-carbamic acid tert-butyl ester 572



was prepared following the protocol of Scheme 177, substituting 6-chlorc-ρyridiH-2-}lainine 53"! and ό-trifluoromethyl-pyridine-S-carfcaidehyde 566 with 6-fluoro-pyridin-2-ylaminc and 6-methoxy-pyridine-3-carbaldehyde, respectively in Step 1 , Example 22: Synthesis of propane-1-sulfonic acid (2,4-difluoro-3-[5-(lH-pyrrolo[2,3- b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl-pheαyl)-amide P-0258

[0210] Propane- 1 -sulfonic acid (2,4-diiluoro-345-(lH-pyrrolo[2,3-b]pyridin-3-ylmefhyl> pyridin-2-ylamino]-methyl-phenyl)-amide P-0258 was synthesized in 2 steps from 3-Iodo-l - triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine 96 as shown in Scheme 178.

Scheme 178



Step 1 - Synthesis of[2, 6-difluoro-3-(propane-l~sulfonylamino)-benzyl]-5-[hydroxy-(l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyr idin-3-yl)-methyl]~pyridin-2-yl-carbamic acid tert-butyl ester (574):
[0211] To a solution of 3-Iodo-l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, 0.644 g, 1.61 mmol) in tetrahydrofuran (10.0 niL) at -40 °C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.80 mL) was added slowly. The reaction was allowed to warm to 15 0C over 100 minutes, then cooled to -40 0C, followed by adding [2,6-difluoro-3-(propane-l-sulfonylamino)-benzyl]-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (560, 0.100 g, 0.21 mmol, prepared as described in Example 21, Scheme 175) in tetrahydrofuran (2.0 mL). The reaction was allowed to warm to 5 °C over 2 hours, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a yellow solid (574, 75 mg, 47%). MS (ESI) [M+H"y=- 744.7.

Step 2 - Synthesis of Propane- 1 -sulfonic acid (2,4-difluoro-3-[S-(lH-pyrro1o[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl-phenyl)-amide (P-0258):
[0212J To [2,6-difluorυ-3-(propane-l -sulfonylamino)-benzyl]-5-[hydroxy-(l -triisoprυpyϊsilanyl-lH-pyrrolo[2,3-b]pyr idin-3-yl)-methyl]-pyridin-2-yl-carbamic acid tert-butyl ester (574, 75.0 mg, 0.10 mmol) in acetonitrile (10.0 mL) were added triethylsilane (0.40 mL, 2.5 mmol) and trifluoroacetic acid (0.20 mL, 2,6 mmol). The reaction was stirred at 80 0C for 4 hours. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in dichloromethane to give an off-white solid (P-0258, 29.3 mg, 61.6%). MS (ESI) [M+HT ~ 472.4.

[0213J Propane-1 -sulfonic acid (3-{[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-ylamino]-methyl}-2,4-difluoro-phenyl)-amide (P-0259), [6-Fluoro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-0378), and
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-0379),



respectively, were prepared following the protocol of Scheme 178. P-0259 was prepared by replacing 3-iodo-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine 96 with 5-chloro-3-iodo-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine in Step 1 (MS [M+H+]+ = 506.1). P-0378 was prepared by replacing [2,6-difluoro-3-(propane-l -sulfonylamino)-benzyl]-(5-formyl-pyridin-2~yl)--carbamic acid tert-butyl ester 560 with (6-Fluoro-5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 572 (prepared as described in Example 21, Scheme 177) in Step 1 (MS [M+ET]+ = 364.1). P-0379 was prepared by replacing both azaindole 96 with 5-chloro-3-iodo-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine and aldehyde 560 with aldehyde 572 in Step 1 (MS [M+H+]+ = 400.0).

Example 23: Synthesis of [6-fluoro-5-(5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-y]methy])-amine P-0187

[0214] [6-Fluoro-5-(5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0187 was synthesized in 3 steps from
l-bcnzcncsulfonyl-3-iodo-5-methoxy-lH-pyrrolo[2,3-b]pyridinc 575 as shown in Scheme 179.

Scheme 179


Step 1 - Synthesis of5-[(l-benzenesulfonyl-5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy- methyl] -6-fluoro-pyridin-2-yl-(6-trifluoromethyl-pyrιdin-3-ylmethyl)-carbamic acid tert-butyl ester (576):
[0215] To l-benzenesulfonyl-3-iodo-5-methoxy-lH-pyπOlo[2,3-b]pyridine (575, 0.326 g, 0,000788 mol) in tetrahydrofuran (3.00 mL) at -45 0C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.380 mL) was added slowly. The reaction was allowed to warm to -25 0C in 30 minutes, and then cooled to -45 0C followed by adding (6-fluoro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (565, 80.0 mg, 0.20 mmol, prepared as described in Example 21 , Scheme 176) in tetrahydrofuran (1.0 mL). The reaction was allowed to warm to room temperature over 2 hours. The reaction was poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (576, 0.080 g, 60%). MS (ESI) [M+H+]+ = 688.1.

Step 2 - Synthesis of [5-(l-Benzenesulfonyl-5-methoxy-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluorυ-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (577) :
[0216J To 5-[(l-benzenesulfonyl-5-methoxy-lH-pyrrolo[2,3-b]pyτidin-3-yl)-hydroxy-methyl]-6-fluoro-pyridiii-2-yl-(6-trifluoromethyl-pyridin-3-ylmethyl )-carbamic acid tert-butyl ester (576,

0.100 g, 0.15 mmol) in acctonitrile (12.6 mL) were added tricthylsilane (0.34 mL, 2.10 mmol) and trifluoroacetic acid (0.17 mL, 2.20 mmoϊ). The reaction was heated to 80 0C for 2 hours. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude compound (577, 90 mg, 100%) that was used in the next step without further purification Step 3 - Synthesis of [6-Fluoro-S-(5-methoxy-lH-pyrrolo[2,3-b]pyridirι-3-yhnethyl)-pyridin-2-ylj- (6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0187):
[0217] To [5-(l -benzenesulfonyl-5-methoxy-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (577, 0.08 g, 0.13 mmol) in tctrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.1 10 g, 0.35 mmol). The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give an off-white solid (P-0187, 8.1 mg, 10%). MS (ESI) [M+H+]+ = 431.9.

[0218] [6-Fluoro-5-(5-chloro-lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0186 and [6-Fruoro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0188,


respectively,
were prepared following the protocol of Scheme 179, substituting l-benzenesulfonyl-3-iodo-5-methoxy-lH-pyrrolo[2,3-b]pyridine 575 with l-benzcnesulfonyl-3-iodo-5-chloro-lH-pyrrolo[2,3~ b]pyridinc or l-Benzenesulfonyl-3-iodo-lH-pyrrolo[2,3-b]pyridine, respectively, in Step 1. MS (ESI) [M+H+]+ = 435.7 and 401.6, respectively.

Example 24: Synthesis of [6-(2-fluoro-benzylamino)-pyridin-3-yl]-(lH-pyrrolo[2,3-b]pyridiπ-3-yl)-methanoπe P-0403

[0219] Synthesis of [6-(2-fluoro-benzylamino)-pyridin-3-yl]-(lH-pyrrolo[2,3-bJpyridin-3-yl)-methanone P-0403 was synthesized in 2 steps from 3-Iodo-l -triisopropylsilanyl-l H-pyrroIo[2,3-bjpyridine 96 as shown in Scheme 180.

Scheme 180


Step 1 - f2-FIuaro-benzyl)-[5-ClH-pyrrolof2,3-bJpyridine-3-carbonylJ-pyridin-2-ylJ-carbamic acid tert-butyl ester (580)
[0220] To 3-iodo-l -tπisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, O 550 g, 1 37 ininol) in tetrahydrofuran (15 0 mL) at -40 0C under nitrogen, isopropylmagnesium chloride (2 0 M m tetrahydrofuran, 0 65 mL) was added slow Iy The reaction was allowed to warm to 5 CC o\ cr 70 minutes, then cooled to -40 0C1 followed by adding (2-fluoro-benzyl)-(5-formyl-pyπdm-2-yl)-carbamic acid tert-butyl ester (579, prepared according to the protocol of Example 1 , Scheme 19, Steps 1-3, replacing 4-chlorobenzaldehyde 40 with 2-fluoro-benzaldehyde m Step 1) in tetrahydrofuran (4 0 mL) The reaction was allowed to warm to room temperature over 1 hour, then poured into aqueous ammonium chloride, and extracted with ethyl acetate The organic layer was dπed over anhydrous sodium sulfate and filtered The filtrate was concentrated and purified by silica gel column chromatography elutmg with 20% to 100% ethyl acetate in hexane to gi\c the desired compound (580, 0 14 g, 26%) MS (ESI) [M+H+]+ = 447 0

Step 2 - Synthesis of [6-(2-Fluoro-benzylamino)-pyrιdιn-3-yl]-(lH-pyrrυlυ[2,3-b]pyrιdιn-3-yl)-melhanone (P-0403)
[0221] To (2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3 b]pyπdine-3 carbonyl)-pyπdm-2-yl]-carbamic acid tert-butyl ester (580, 0 080 g, 0 18 mmol) m dichloromeihane (3 0 mL) was added tπfluoroacetic acid (1 0 mL, 0 013 mol) The reaction was stirred at room temperature overnight, then concentrated, poured into water, and extracted with ethyl acetate The organic layer w as dried over anhydrous sodium sulfate and filtered The filtrate was concentrated and purified by silica gel column chromatography elutmg with 2% to 15 % methanol in dichloromethane to give the desired compound (P-0403, 15 0 mg, 23 0%) MS (ESI) [M+HT = 347 5

Example 25: Synthesis of (5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-[6-(2-fluoro-beπ7ylamiπo)-p> ridin-3-yl]-methanone P-0404

[0222] (5-Chloro-lH-pyrrolo[2)3-b]pyridin-3-yl)-[6-(2-fluoro-benzylammo)-pyridin-3-yl]-methanone P-0404 was synthesized in 4 steps from l -benzcncsulfonyl-S-chloro-S iodo IH pyrrolo[2,3-b]pyπdine 581 as shown in Scheme 181

Scheme 181


Step 1 Synthesis of 5- [(I -benzenesulfonyl-5-chloro-lH-pyrrolo[2, 3-b]pyridln-3-yl)-hydroxy~ methyl] -pyridin-2-yl-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (582)
[0223] To a solution of l-bcnzenesulfonyl-5-chloro-3-iodo-lH-pyrrolo[2,3-b]pyridine (581, 0.420 g, 1.00 mmol) in tetrahydrofuran (15.0 mL) at -40 0C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.49 mL) was added slowly. The reaction was allowed to warm to 5 0C over 70 minutes, then cooled to -40 0C, followed by adding (2-fluoro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester 579 in tetrahydrofuran (6.0 mL). The reaction was allowed to warm to room temperature over 1 hour, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography elutmg with 20% to 100% ethyl acetate in hexane to give the desired compound (582, 0.25 g, 41%). MS

Step 2 - Synthesis of [5-(l-Benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carbonyl)~ pyridin-2-yl]-(2-fluυro-benzyl)-carbamic acid tert-butyl ester (583):
[0224] To 5-[(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (582, 0.25 g, 0.40 mmol) in dichloromethane (5.0 mL) was added Dcss-Martin periodinane (0.20 g, 0.48 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered The filtrate was concentrated and purified by silica gel column chromatography elutiπg with 20% to 100% ethyl acetate in hexane to give the desired compound (583, 0.060 g , 24%)

Step 3 ~~ Synthesis of[5-(5-Chloro-lH-ρyrrolo[2,3-b]pyridine~-3-carhonyl)~pyridin-2-yl]~f2-fluorβ-benzyl)-carhamic acid tert-butyl ester (584):
S0225] To [5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carbonyl)-pyπdin-2-yi]- 7 083910
106

(2-fluoro-benzyl)-carbamic acid tcrt-butyl ester (583, 60.0 mg, 0.097 mmol) in tetrahydrofiiran (1.0 mL) was added aqueous potassium carbonate (1.0 M, 1.0 mL). The reaction was irradiated with microwave on 300 watts, 1000C for 10 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (584, 0.040 g, 64%) that was used in the next step without further purification.

Step 4 - Synthesis nf(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-[6-(2-βuoro-henzylamino)-pyridin-3-yl] -methanone (P-0404):
[0226] To [5-(5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carbonyl)-pyridin-2-yl]-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (584, 0.030 g, 0.062 mmol) in dichloromethane (1.0 mL) was added trifluoroacetic acid (1.0 mL, 0.013 mol). The reaction was stirred at room temperature overnight, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in dichloromethane to give the desired compound (P-0404, 2.8 mgs 12%). MS (ESI) [M+H+]+ = 381.0.

Example 26: Synthesis of (5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-6-[(6-mcthoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-methanone P-0405

[0227] (5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-6-[(6-methoxy-pyridin-3-ylmcthyl)-amino]-pyridin-3-yl-methanone P-0405 was synthesized in 3 steps from 5-Chloro-lH-pyrrolo[2,3-bjpyridine 532 as shown in Scheme 182.

Scheme 182


Step 1 - Synthesis nf5-[(5-chloro-lH-pyrrolo[2.3-b]pyridin-3-yl;-hydroxy-melhγll-pyrιdιn-2-j I-(6-methoxv-pyrιdιn-3-ylmethyI)-carbamic acid ten-butyl ester (586).
10228] To 5-chloro-lH-pyrrolo[2,3-b]pyndinc (532, 0.092 g, 0.60 mmol) in methanol (15.0 mL) were added (5-formyl-pyridin-2-yl)-(6-methoxy-pyrldin-3-ylmethyl)-carbamic acid tert-bul>l ester US2007/083910
107

(585, 0.240 g, 0.70 mmol, prepared according to the protocol of Example 1, Scheme 19, Steps 1-3, replacing 4-chIorobenzaldehyde 40 with ό-methoxy-pyridine-S-carbaldehydc in Step 1 ) and potassium hydroxide (1.2 g, 0.021 mol). The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (586, 0.110 g, 37%).

Step 2 - Synthesis of [5-(5-chloro-lH-pyrrolo[2,3-b] pyridine-3-carbonyl)-pyridin-2-yl] ~(6~ methoxy-pyridin~3-ylmethyl)~carbamic acid tert-butyl ester (587):
[0229] To 5-[(5-chloro-lH-pyrrolo[2,3-b]pyτidin-3-yl)-hydroxy-methyl]-pyridin-2-yl-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (586, 0.060 g, 0.12 mmol) in dichloromethane (10.0 mL) was added Dess-Martin periodinane (0.062 g, 0.15 mmol). The reaction was stirred at room temperature for 10 minutes. The reaction was concentrated and purified with a silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (587, 0.020 g, 33%).

Step 3 - Synthesis of(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-yl)-6-[(6-methoxy-pyridin-3-yimethyl)-amino] -pyridin-3-yl-methanone (P-0405):
[0230] To [5-(5-chloro-lH-pyrrolo[2,3-b]pyridme-3-carbonyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (587, 0.020 g, 0.040 mmol) in dichloromethane (2.0 mL) was added trifluoroacetic acid (0.30 mL, 0.0039 mol). The reaction was stirred at room temperature for 2 hours, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0405, 5.5 mg, 34%). MS (ESl) [M+ET]+ -394.3.

[0231] {6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-yl}-(lH-pyrrolo[2)3-b]pyridin-3-yl)-methanone P-0406



was prepared following the protocol of Scheme 182, substituting 5-chloro-lH-pyrrclo[2.3-bjpyπdine 532 with 5-methoxy-lH-pyrrolo[2,3-b]pyridinc in step 1. MS (ESI) [M+H~] r = 390.1.

Example 27: Synthesis of intermediate 5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3- b] pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 592

[02321 -(l-Benzenesulfonyl-S-chloro-lH-pyrroloP^-bJpyridin-S-ylmethy^^-chloro-thiazol- 2-ylamine 592 was synthesized in 4 steps from 2-amino-4-chloro-thiazole-5-carbaldehyde 588 as shown in Scheme 183.

Scheme 183


Step J - Synthesis of(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (589):
[0233] To 2-amino-4-chloro-thiazole-5-carbaldehyde (588, 5.00 g, 0.0308 mol) in
tetrahydrofuran (122 mL) were added di-tert-butyldicarbonate (7.38 g, 0.0338 mol) and
4-dimethylaminopyridine (0.35 g, 0.0029 mol). The reaction was stirred at 58 0C for 2 hours, then concentrated and purified with silica gel column chromatography eluting with 20% to 80% ethyl acetate in hcxane to give a yellow solid (589, 7.0 g, 87%).

Step 2 - Synthesis of5-[(l-ben∑enesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-4-chloro-thiazol-2-yl-carbamic acid tert-butyl ester (590):
[0234] To a solution of l-benzenesulfonyl-5-chloro-3-iodo-lH-pyrrolo[2,3-b]pyridine (581, 4.40 g, 10.5 mmol) in tetrahydrofuran (30.0 mL) at -45 °C under nitrogen, a solution of isopropylmagncsium chloride (2.0 M in tetrahydrofuran, 5.4 mL) was added slowly over 10 minutes. The reaction was allowed to warm to -25 0C over 30 minutes. The reaction was cooled to -65 0C5 followed by adding the cold deprotonated (4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester 589, which was prepared in situ by adding iscpropylmagnesium chloride (2.0 M in tetrahydrcfuran, 5.0 mL) to (4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (589, 2.51 g, 9.55 mmol) in tetrahydrofuran (23.0 mL) at -78 0C under an atmosphere of nitrogen, 'lhe reaction was allowed to warm to room temperature in 2 hours, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25%to 100% ethyl acetate in hexane to give the desired compound (590, 3.70 g, 60.3%). MS (ESI) [M+H1]+ = 554.2.

Step 3 - Synthesis of [5-(l-benzenesulfonyl-5~chlυro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thia∑ol~2-yl] -carbamic acid tert-hutyl ester (591):
[0235] To 5-[(l-ben/enesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-meth3'l]-4-chloro-thiazol-2-yl-carbamic acid tert-butyl ester (590, 0.200 g, 0.32 mmol) in dichloromethane (15.0 mL) were added triethylsilane (0.600 mL, 376 mmol) and trifluoroacetic acid (0.300 mL, 3.89 mmol), The reaction was stirred at room temperature for 3 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25%to 100% ethyl acetate in hexane to give the desired compound (591, 0.155 g, 88.7%). MS (ESI) [M+H~]+ = 538.9.

Step 4 - Synthesis of5-(l-Benzenesulfonyl-5-chlaro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4~ chloro-thiazol-2-ylamine (592):
[0236] To [5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-yl]-carbamic acid tert-butyl ester (591, 4.30 g, 7.97 mmol) in dichloromethane (70.0 ml.) was added a solution of hydrogen chloride (4.00 M in 1,4-dioxane, 42.0 mL). The reaction was stirred at room temperature for 2 days, then concentrated, and titrated with ethyl ether and ethyl acetate to give the desired compound (592, 2.60 g, 74.2%). MS (ESI) [M+H4]" = 439.0.

[0237] 5-(l-Benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine

593



was prepared following the protocol of Scheme 183, substituting l-benzenesulfonyl-5-chloro-3-iodo-lH-pyrrolo[2,3-b]ρyridine 581 with l-benzenesulfonyl-3-iodo-lH-pyrrolo[2.3-b]pyridine in

Step 2. MS (ESI) [M-HT = 404,4.

Example 28: Synthesis of [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)- thiazol-2-yl]-(5 -fluoro-pyridin-3-ylmethyl)-amine P-0231

[0238] [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro- pyridin-3-ylmcthyl)-amine P-0231 was synthesized in 2 steps from 5-(l-benzenesulfonyl-5-chloro- l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 592 as shown in Scheme 184.

Scheme 184


Step 1 - Synthesis of [5-(l-benzemsulfυnyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (595):
[0239] To 5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine (592, 50,0 mg, 0.11 mmol, prepared as described in Example 27, Scheme 183) in ethanol (1.60 mL) and acetic acid (0.08 niL) were added 5-fluoro-pyridine-3-carbaldehyde (594, 43 mg, 0.34 mmol) and silica supported cyanoborohydride (1,21 mmol/g, 0.180 g). The reaction was irradiated with microwave on 300 watts, 1000C for 7 minutes. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give the desired compound (595, 0.030 g. 48%).

Step 2 - Synthesis of[4-chloro-5-(5-chIoro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thia∑ol-2-ylj-(5-fluoro-pyridin-3-ylmethyl)-amine (P-0231):
[0240] To [5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (595, 0,030 g, 0.055 mmol) in tetrahydrofuran (6,0 mL} was added tetrabutylammomum fluoride, trihydrate (0,034 g, 0.11 mmoi) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 hours, then jjoured into waler and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0231, 1.5 mg.

6.7%). MS (ESI) [M+HT = 408.1.

Example 29: Synthesis of 5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridiπ-3- ylmethyl)-pyridiπ-2-ylamine 599

[0241] S-Cl-Bcnzenesulfonyl-S-chloro-lH-pyrroloP.B-bJpyridin-S-ylmethyO-pyTidin^-ylamine 599 was synthesized in 4 steps from 5-chloro-lH-pyrrolo[2,3-b]pyridine 532 as shown in Scheme 185.

Scheme 185


Step 1 - Synthesis of5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carhaldehyde (596):
[0242] To 5-chloro-lH-pyrrolo[2,3-b]pyridine (532, 10.0 g, 65.5 mmol) in acetic acid (28.3 mL) were added hexamethylenetctramine (11.9 g, 85.2 mmol) and water (56.7 mL). The reaction was refluxed overnight, followed by addition of 200 mL of water. After 30 minutes, the reaction was filtered to recover the solid, then dried under air to give the desired compound (596, 7.0 g. 59%).

Step 2 — Synthesis of l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (597):
[0243] To 5-chloro-lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (596, 3.60 g, 0.0199 mol) in dichloromelhane (100 mL) were added a solution of potassium hydroxide (9 M in water, 50 mL), tetrabutylammonium hydrogen sulfate (400 mg, 0.001 mol) and benzenesulfonyl chloride (2,9 mL, 0.023 mol). The reaction was stirred at room temperature for 3 hours, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered, i'he filtrate was concentrated and washed with ethyl acetate to give a white solid (597. 2.3 g, 36.0%).

Step 3 - Synthesis of(6-amino-ρyridiπ-3-yl)-(l-benzencsulfonyI-5-chloro-lH-py>rolol2,3-b]pyridin-3-yl)~methanol (598):
10244] To 2-amino-5-bromopyridine (15, 3.10 g, 17.9 mmol) in tetrahydrofuran (80.0 mL) under an atmosphere of nitrogen at -78 0C, a solution n-butyllithium (2.50 M in hexane, 7,10 mL) was added slowly. After 30 minutes. l,2-bis-(chloro-dimcthyl-silanyl)-ethane (3.90 g dissolved in tetrahydrofuran 20.0 mL, 18.1 mmol) was added to the reaction mixture slowly, and then allowed to warm to room temperature for 1 hour. The reaction was cooled to -78 0C followed by adding a solution of n-butyllithium (2.50 M in Hexane, 7.10 mL). The reaction mixture was stirred at -78 0C for 30 minutes, then allowed to warm to room temperature for 60 minutes. The reaction mixture was cooled to -78 0C, followed by adding a solution of n-butyllithium (2.50 M in Hexane, 7.50 mL) slowly. After 60 minutes, l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyτidine-3-carbaldehyde (597, 1.90 g in 30 mL tetrahydrofuran, 5.92 mmol) was added to the reaction mixture. The reaction mixture was stirred at -78 0C for 2 hours, then allowed to warm to room temperature for 1 hour. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 20% methanol in dichloromethane to give the desired compound (598, 1.25 g, 50.9%). MS (ESI) [M -KH T = 415.2.

Step 4 - Synthesis of5-(l-henzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine (599):
[0245] To (6-amino-pyridin-3-yl)-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-methanol (598, 1.00 g, 0.00241 mol) in dichloromethane (25.0 mL) were added triethylsilane (3.00 mL, 0.0188 mol) and trifluoroacetic acid (1.50 mL, 0.0195 mol). The reaction was stirred at room temperature overnight, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (599, 0.70 g, 73%).

[0246] 5-(l-Benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine 600



was prepared following the protocol of Scheme 185, substituting 5-chloro-!H-pyrroio|2,3~ b]pyπdine 532 with lH-pyrrolo[2,3-b]pyridine in Step 1. MS (ESI) [M+HT = 365.2.

Example 30: Synthesis of [S-CS-chloro-lH-pyrroIolI^-blpyridin-S-ylmethyO-pyridin-l-yll^S-fluoro-pyridln-3-ylmethyI)-amIne P-0324 [0247] [5 -(5 -Chloro-1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyridin-2-yl]-(5 -fluoro-pyridin-3 - ylmethyl)-amine P-0324 was synthesized in 2 steps from 5-(l -benzenesulfonyl-5 -chloro-1 H- pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine 599 as shown in Scheme 186.

Scheme 186


Step 1 - Synthesis of [5-(l-benzenesulfonyl-5-chlυro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]~-(5~fluoro-pyridin-3-ylmethyl)~amine (601):
[0248] To 5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyridin-2-ylamine (599, 80.0 mg, 0.20 mmol, prepared as described in Example 29, Scheme 185) in ethaπol (2.0 mL) and acetic acid (0.10 mL, 0.0018 mol) were added 5-fluoro-pyridine-3-carbaldehyde (594, 62.7 mg, 0.50 mmol) and sodium cyanoborohydride on silica gel (1.200 mmol/g loading; 0.251 g, 0.30 mmol). The reaction was irradiated with microwave on 300 watts, 100 0C for 10 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (601, 0.060 g, 59%).

Step 2 - Synthesis of[5-(5~chloro-lH~pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (P-0324):
[0249] To [5-(l -benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyridin-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (601, 0.060 g, 0.12 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutyl ammonium fluoride, trihydrate (0.11 g, 0.35 mmol). The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0324, 13.5mg, 31%). MS (ESI) [M+UT] ' = 368.0.

Example 31 : Synthesis of (3-Chloro-pjτidin-4-yImethyI)-[5-(lH-pyrrolo[2,3-b]pyridin-3-yImethyI)-pyridin-2-yI]-amine P-0183 |0250] (S-Chloro-pyridin^-ylmethy^-fS-ClH-pyrroloCZ.S-blpyridin-S-ylmethy^-pyridin^-yl]- amine P-0183 was synthesized in 2 steps from 5-(l -benzenesulfonyl-lH-pyiτolo[2,3-b]pyridin-3- ylmethyl)-pyridin-2-ylamine 600 as shown in Scheme 187.

Scheme 187


Step 1 - Synthesis of[S-(l-benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylj- (4-chloro-pyridin-3-ylmethyl)-amine (602) :
[0251] To 5-(l-benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine (600, 120.0 mg, 0.33 mmol, prepared as described in Example 29, Scheme 185) in acetonitrile (10.0 niL) were added 3-chloro-pyridine-4-carbaldehyde (554, 51.3 mg, 0.36 mmol), trifluoroacetic acid (0.30 niL, 0.0039 mol) and triethylsilane (0.60 niL, 0.0038 mol). The reaction was heated to reflux overnight, then poured into aqueous potassium carbonate and extracted with ethyl acetate, The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% to 100% ethyl acetate in hexane to give the desired compound (602, 80 rug, 49.6%). MS [M+H'f - 490.2.

Step 2 - Synthesis of(3-chloro-pyridin-4-ylmethyl)-[5-(lH-pyrrolo[2,3~b]pyridin-3-ylmethyl)-pyridin-2-yl] -amine (P-0183):
|0252] To [5 -( 1 -benzenesulfonyl- 1 H-pyrrolo [2,3 -b]pyri din-3 -ylmethyl)-pyridin-2-yl] -(4-chloro-pyridin-3-ylmethyl)-amine (602, 0.08 g, 0.16 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.240 g, 0.76 mmol). The reaction was stirred at room temperature overnight. The reaction was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a yellow solid (P-0183, 4.0 mg, 7%). MS (ESI) [M+Ff ]+ = 350.2.

Example 32; Synthesis of IS-CS-Chloro-lH-pyrroloflsS-blpyridln-S-ylmethyO-pyridin-Z-yll-[6-(2,2,2-tήfluoro-cthoxy)-ρyridin-3-ylmethyl]-amine P-0409

{0253] [5-(5-Chlϋro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine P-0409 was synthesized in 2 steps from 5-(l-benzenesulfonyl-5-chloro-lH-p>τrolo[2.3-b]p>τidin-3-ylmethyl)-pyridin-2-ylamine 599 as shown in Scheme 188.

Scheme 188


Step 1 - Synthesis of[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine (P-0409):
[0254] To 5-(l -benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine (599, 124.1 mg, 0.31 mmol, prepared as described in Example 29, Scheme 185) in ethanol (3.00 mL) and acetic acid (0.2 mL) were added 6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbaldehyde (603, 164.0 mg, 0.80 mmol) and silica supported cyanoborohydride (1.21 mmol/g, 0.700 g). The reaction was irradiated with microwave on 300 watts, 1000C for 150 minutes. To the reaction was added a solution of potassium hydroxide (9.0 M in water, 1.0 mL). The reaction was irradiated with microwave on 300 watts, 100 0C for 10 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0409, 10.6 mg, 7.6%). MS ESI) [M+H+]+ = 448.4.

Example 33: Synthesis of l-(3-fluoro-phenyl)-3-|5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-urea P-0412

[0255] 1 -(3 -Fluoro-phenyl)-3-[5 -( 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyridin-2-yl]-urea P-0412 was synthesized in 2 steps from 5-(l-benzenesulfonyl-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylaminc 600 as shown in Scheme 189.

Scheme 189


Step 1 Synthesis ofl-[5-(l-henzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl}-pyridin~2--yl]~

3-(3~fluoro-phenyl)-urea (60S): [0256] To 5-(l -benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine (600, 150,0 mg, 0.41 mmol, prepared as described in Example 29, Scheme 185) in acetonitrile (12.5 ml) were added 3-fluoro-isocyanato-benzene (604, 61.6 mg, 0.45 mmol), 4-dimethylaminopyridine (10.0 mg, 0.082 mmol) and triethylamine (0.25 mL, 0.0018 mol). The reaction mixture was heated at 70 CC overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (605, 0.100 g, 48.4%).

Step 2 — Synthesis of l-(3-Fluoro-phenyl)-3-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylj-urea (P-0412):
[0257] To l -[5-(l -benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p>τidin-2-yl]-3-(3-fluoro-phenyl)-urea (605, 0.100 g, 0.20 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.240 g, 0.76 mmol). The reaction was stirred at room temperature for 5 hours, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0412, 17.9 mg, 24.8%). MS (ESI) [M+H+]+ = 362.2.

Example 34: Synthesis of (2-chloro-benzyl)-[6-fluoro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-0335

[0258] (2-Chloro-benzyl)-[6-fluoro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-0335 was synthesized in 2 steps from (5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine 571 as shown in Scheme 190.

Scheme 190


Step 1 - Synthesis of '[ό-(2~ckloro-benzyiamiπoj-2-fluoro-pyridin~3-ylj '-(1-triisopropylsilanyl- IH-pvrrolo[2, 3-b] pyridin-3-ylj-methanol (606):
[0259] To (5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine (571, 0.635 g, 2.01 mmol, prepared as described m Example 21, Scheme 177) in tetrahydrofuran (25,0 mL) under an atmosphere of nitrogen at -78 0C, a solution of n-butyllithium (2,50 M in hexane, 0.80 rnL) was added slowly. After 20 minutes, tert-butyllithium (1.7 M in hexane, 2.40 mL) was added to the reaction and after 30 minutes, l-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (47, 0.575 g, 1.90 mmol) in tetrahydrofuran (8.0 mL) was added to the reaction. The reaction mixture was stirred at -78 0C for 60 minutes, then allowed to warm to room temperature for another 10 minutes. The reaction mixture was poured into aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (606, 0.180 g, 17.6%). MS (ESI) [IVMr]+= 539.2.

Step 2 ~ Synthesis of(2-chloro-benzyl)-[6-fluoro-5-(lH-pyrrolo[2,3-b]pyriάin-3-ylmethyl)-pvridin-2-yl] -amine (P-0335):
[0260] To [6-(2-chloro-benzylamino)-2-fluoro-pyridin-3-yl]-(l-triisopropylsilanyl-l H-pyrrolo[2,3-b]pyridin-3-yl)-methanol (606, 180.0 mg, 0.33 mmol) in acetonitrile (15.0 mL) were added triethylsilane (1.00 mL, 6.26 mmol) and trifluoroacetic acid (0.50 mL, 6.50 mmol). The reaction was heated to reflux for 2 hours, then poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0335, 24.9 mg, 19.4%). MS (ESI) [M+H'J1 = 367.0.

Example 35: Synthesis of l-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine 610

[0261] l-Benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine 610 was synthesized in 3 steps from l -benzenesulfonyl-5-chloro-3-iodo-lH-pyrrolo [2,3 -b]pyri dine 581 as shown in Scheme 191.
Scheme 191


Step 1 - Synthesis of(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-(2- methylsulfanyl-pyrimidin-5-yl)-methanol (608):
[0262J To a solution of l-Benzenesulfonyl-5-chloro-3-iodo-lH-pyrrolo[2,3-b]pyridinc (581. 4.36 g, 10,4 mmol) in tetrahydrofuran (100,0 mL) at -40 0C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran. 5.06 mL) was added slowly. The reaction was allowed to warm to 5 0C over 60 minutes, then cooled to -40 0C, followed by adding 2-methylsulfanyl-pyrimidine- 5-carbaldehyde (607, 1.30 g, 8.43 mmol, dissolved in tetrahydrofuran 15.0 mL). The reaction was allowed to warm to 10 0C over 2 hours. The reaction was poured into aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in dichloromethane to give the desired compound (608, 3.00 g, 79.6%). MS (ESI) [M-H+J+ = 447.2.

Step 2 - Synthesis ofl-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2, 3-b] pyridine (609):
[0263] To (l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-(2-methylsulfanyl-pyrimidin-5-yl)-methanol (608, 0.35 g, 0.78 mmol) in dichloromethane (15.0 mL) were added tricthylsilane (2.00 mL, 12.52 mmol) and trifluoroacetic acid (1.00 mL, 13.0 mmol). The reaction was stirred at 35 0C overnight, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (609, 0.25 g, 74%). MS (ESI) [M+H+]+ = 430.9.

Step 3 - Synthesis of 1 -benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-l 'H-pyrrolo[2, 3-b] pyridine (610) and l-benzenesulfonyl-5-chloro-3-(2-methanesulfinyl-pyrimidin-5-ylmethyl)-! H-pyrrolo[2, 3-b] pyridine (611):
[0264] To l-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine (609, 0,500 g, 1.16 mmol) in dichloromethane (15.0 mL) was added meta-chloroperoxybenzoic acid (max. 77%, 0.572 g, 2.55 mmol) at 0 0C. The reaction was stirred at 0 0C for 70 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate In hexane to give the desired compounds (610, 0,310 g, 57.7%), MS (ES!) [M+H1] = 463.1 ; and (611, 0.200 g, 38.60O). MS (EST) [Mi-HT = 447.2.

[0265] 1 -Benzenesulfonyl-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-l H-pyrrolo[2,3- b]pyridine 612



was prepared following the protocol of Scheme 191, substituting l-benzcnesulfonyl-5-chloro-3- iodo-lH-pyrrolo[2,3-b]pyridine 581 with l-benzenesulfonyl-3-iodo-lH-pyrrolo[2,3-b]pyridine in Step 1.

Example 36: Synthesis of (4-chloro-benzyl)-[5-(5-chloro-lH-pyrroloI2,3-b]pyridin-3- ylmethyl)-pyrimidin-2-yl]-amine P-0260

[0266] (4-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidm-2-yl]- amine P-0260 was synthesized in 2 steps from l-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine 610 as shown in Scheme 192.
Scheme 192


Step 1 - Synthesis of [5-(l-benzenesulfonyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)~ pyrimidin-2-yl]-(4-chloro^benzyl)-amine (613):
[0267] To l-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine (610, 0.060 g, 0.13 mmol, prepared as described in Example 35, Scheme 191) in N-methylpyrrolidinone (1.80 mL) was added p-chlorobenzylamine (61, 0.20 g, 1.4 mmol). The reaction was irradiated with microwave on 300 watts, 150 0C for 15 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (613, 0,05 g, 74%). MS (ESI) [M+H } '~ = 524.3.

Step 2 - Synthesis of(4-chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] -amine (P-0260j:
|0268J To [S-Cl-benzenesulfonyl-S-chloro-lH-pyrroloP^-blpyridin-S-ylmethyO-pyrimidin-Z- yl]-(4-chloro-benzyl)-amine (613, 0.050 g, 0.095 mmol) m tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.20 g, 0.63 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate in hexane to give an off-white solid (P-0260, 16.9 mg, 46%). MS (ESI) [M+tfJ ' = 385.9.

[0269] Additional compounds were prepared following the protocol of Scheme 192, substituting p-chlorobenzylamine 61 with a suitable amine in Step 1. The following compounds were prepared following this protocol:
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,6-difluoro-benzyl)-amine

(P-0261),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyrimidin-2-yl]-(2-tritluoromethyl-benzyl)-amine (P-0262),
(2-Chloro-benzyl)-[5 -(5 -chl oro-1 H-pyrrolo [2,3-b]pyridin-3 -ylmethyl)-pyrimidin-2-yl] -amine

(P-0263),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-benzyl)-amine

(P-0264),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,4-difluoro-benzyl)-amine

(P-0265),
[5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl)-amine (P-0266),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,5-difluoro-benzyl)-amine

(P-0267), and
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trifluoromethyl-benzyl)-amine (P-0268).
The following table indicates the amine (Column 2) used in Scheme 192 to provide the compounds

(Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.
MS (ESI)

Compound
Amine in Step 1 Compound [M+H ] number observed

H,N -N r-1 i
P-0261 384.1
>
N H


Example 37: Synthesis of (2-fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin- 3-ylmcthyl)-pyrimidin-2-yll-aminc P-0291

[0270] (2-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-p>τrolo[2,3-b]pyridin-3-ylmethyl)- pyrimidin-2-yl] -amine P-0291 was synthesized in 1 step from l -benzenesulfonyl-3-(2- methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine 612 as shown in Scheme 193.

Scheme 193


Step 1 - Synthesis of(2-fiuoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] -amine (P-0291):
[0271] To l -benzenesulfonyl-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3^ bjpyridine (612, 0.080 g, 0.19 mmol, prepared as described in Example 35, Scheme 191) in N- methylpyrrolidinone (1.00 mL) was added 2-fluoro-5-trifluoromethyl-benzylamine (614, 0.20 g, 1.0 mmol). The reaction was irradated with microwave on 300 watts, 1500C for 15 minutes. Potassium hydroxide in water (1.00 M, 2.00 mL) was added to the reaction. The reaction was irradiated with microwave on 300 watts, 900C for 10 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0291, 37.4 mg, 50%). MS (ESI) [M+Hy -402.6.

[0272] Additional compounds were prepared following the protocol of Scheme 193, substituting

2-fluoro-5-trifluoromethyl-benzylamine 614 with a suitable amine. The following compounds were prepared following this protocol:
(2,5-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylJ-amine (P-0292),

(2-Chloro-5-trifluoromethyl-benzyl)-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0293),
(3-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0294),
(3,5-Difluoro-benzyl)-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0295),

(2-Fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0300),

(2-Chloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0301),

[5-(lII-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl)-amine
(P-0302),
[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trilluoromethoxy-benzyl)-amine

(P-0303),
(5-Chloro-2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyτimidin-2-yl]-amine

(P-0304),
(2,4-Dichloro-bcnzyi)-[5-(lH-pyrroio[2,3-b]pyndin-3-ylmethyl)-pyrimidin-2-ylj-amine (P-0305 ),

(2,4-Difluoro-benzyl)-[5-(iH-p>τrolof2,3-b]pyriditi-3-ylmethyl)-pyrimidin-2-yl]-amiπc (P-0306),

(4-Chloro-bcnzyl)-[5-(lH-pyiτolo[2,3-b]ρyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0307),

[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifliK5romethyl-benzyl)-amine
(P-0308),
(2-Fluoro-3-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]- amine (P-0309),
(2)5-Dichloro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidiri-2-yl]-aininc (P-0310), (3 -Chloro-2-fluoro-benzyl)-[5-( 1 H-pyrrolo [2,3 -b]pyridin-3 -ylmethyl)-pyrimidin-2-yl] -amine (P-0311),
(2-Difluoromethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrirnidin-2-ylJ-aminc (P-0312),
(2,3-Dichloro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridiii-3-ylmcthyl)-pyrimidin-2-yl]-amine (P-0313).

(4-Chloro-2-fluϋro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylinethyl)-pyrimidin-2-yl]-amine

(P-0314),
(5-Fluoro-2-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-bJpyπdin-3-ylmethyl)-pyrimidiπ-2-yl]- amine (P-0315),
(2-Chloro-4-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0316),
(5-Chloro-2-methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amme

(P-0317),
(5-Fluoro-2-methyl-ben2yl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyrimidm-2-ylJ-aminc

(P-0318),
(2-Fluoro-4-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]p>Tidin-3-yhTiethy])-pyrimidin-2-yl]- amine (P-0319),
(4-Fluoro-2-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidm-2-yl]- amine (P-0320), and
(2-Chloro-5-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine

(P-0407).
The following table indicates the amine (Column 2) used in Scheme 193 to provide the compounds

(Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.





Example 38: Synthesis of [S-CS-Chlαro-lH-pyrrolo^^-blpyridin-S-ylmethyO-pyrimidiπ-l- yl]-(2-difluoromethoxy-benzyl)-amine P-0390

[0273] [5-(5-Chloro-lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-difluoromethoxy- benzyl)-amine P-0390 was synthesized in 1 step from l -benzenesulfonyl-5-chloro-3-(2- methanesulfonyl-pyrimidin-5-ylmethyl)-lH-pyrrolo[2,3-b]pyridine 610 as shown in Scheme 194. Scheme 194


Step 1 - Synthesis of [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-yImethyl)-pyrimidin-2-yl]-(2- difluoromethoxy-benzyl)-amine (P-0390)
[0274] To 1 -benzenesulfonyl-5 -chloro-3 -(2-methanesulfonyl-pyrimidin-5 -ylmethyl)- 1 H- pyrrolo[2,3-b]pyridine (610, 0.060 g, 0.13 mmol, prepared as described in Example 35, Scheme 191 ) in N-methylpyrrolidinone (1.40 mL) was added 2-difluoromethoxy-benzylamine (615, 0.200 g, 1.16 mmol). The reaction was irradiated with microwave on 300 watts, 150 °C for 15 minutes. Potassium hydroxide in water (1.00 M, 2.00 mL) was added to the reaction. The reaction was irradiated with microwave on 300 watts, 90 0C for 10 minutes, then poured into ethyl acetate and water. The organic layer was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0390, 10.9 mg, 20%).

[0275] Additional compounds were prepared following the protocol of Scheme 194, substituting 2-diΩuoromethGxy-benzylamine 615 with a suitable amine. The following compounds were prepared following this protocol:
[5-(5-Chioro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyi)-pyrimidin-2-yl]-(2-fluorc-5-trifiuoromethyi- benzyl)-aminc (P-0289),
[5-(5-Chloro-lH-ρyrrolo[2,3-b]pyridm-3-ylmeώyl)-pyrimidin-2-yl]-(5-fluoro-2-trifluoromethyl- benzyl)-amine (P-0391), (3-Chloro-2-fIuoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2^yl]- amine (P-0392),
[S-CS-Chloro-lH-pyrroloP^-blpyridin-S-ylmethy^-pyrimidin-Z-ylJ-CZ-fluoro-S-trifluoromethyl- ben7yl)-amine (P-0393),
[5-(5-Chloro-lH-pyrrolo[2>3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-4-trifluoromethyl- benzylj-amine (P-0394),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyrimidin-2-yl]-(2,3-difluoro-benzyl)-am;ne (P-0395),
(2-Chloro-4-fluoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylj- amine (P-0396),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethoxy-benzyl)- amine (P-0402), and
(2-Chloro-5-fluoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]]- amine (P-0408).
The following table indicates the amine (Column 2) used in Scheme 194 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.



Example 39: Synthesis of (2-chloro-6-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3- ylmethyl)-pyridin-2-yl]-amine P-0210

[0276] (2-Chloro-6-fluoro-benzyl)-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yll- amine P-0210 was synthesized in 2 steps from 5-(l-Benzenesulfonyl-lH-pyrrolo[2,3-b]pyridm-3- ylmethyl)-pyπdin-2-ylamine 600 as shown in Scheme 195.

Scheme 195


Step I - Preparation of[5-(l-benzenesulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethylj-pyridin-2- yl]-(2-chloro-6-fluoro-benzyl)-amιne (617):
[0277] 5-(l-Benzeπesulfonyl-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-ρyridin-2-ylamiπe (600, 30 mg, 0,083 mmol, prepared as described in Example 29, Scheme 185) was combined with 2-chlcro- 6-fluoro-bcnzaldehyde (616, 26.2 mg, 0,165 mmol) m a 2 mL microwave reaction vial. The mixture was dissolved in cthanol acetic acid (95:5, 0.6 mL). Silica supported cyanoborohydπde (1.0 mmol/g, 83 mg, 0.083 mmol) was added and the mixture was irradiated with microwave OH 300 watts for 5 minutes at 100 0C. The silica was separated by centrifugmg and the supernatant solution was decanted. The silica residue was rinsed with ethanol (0.500 mL) and centπfuged The solvents were combined and removed under reduced pressure to give compound 617, which w as used in the next step without further purification.

Step 2 - Preparation of(2-chloro-6-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] -amine (P-0210):
[0278] [S-Cl -Benzenesulfonyl-lH-pyrroloP.S-blpyridin-S-ylmethyO-pyridin-Z-ylJ-fZ-chloro-ό-fluoro-benzyl)-amine 617 was combined with methanol :potassium hydroxide (IM) (1 : 1 , 0.5 mL). The mixture was heated at 80 0C for 2 hours. Acetic acid (0.1 ml.) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in dimethylsulfoxide (0.4 mL) and purified by reverse phase HPLC on a Phenomenex column (50mm x 10mm ID) eluting with 0.1 % trifluoroacetic acid in water and 20-100 % acetonitrile with 0.1 % trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0210, MS (ESI) [M+HT = 367.1.

[0279] Additional compounds were prepared following the protocol of Scheme 195, replacing 2-chloro-6-fluoro-benzaldehyde 616 with an appropriate aldehyde in Step 1. The following compounds were made following this procedure:
Phenethyl-[5-(l H-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyridin-2-yl]-amine (P-0211),
(2,4-Difluoro-bcnzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0212), (2-Fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0213), (3-Bromo-pyridm-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-amine (P-0214),
(2-Methoxy-pyridin-3-ylmethyl)-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-aminc

(P-0215),
(2-Chloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0216), (2-Methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0217), (1 -Methyl- 1 H-benzoimidazol-2-ylmethyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0218),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-pyridin-2-yl]-aminc

(P-0219),
lJ H-Benzoirnidazol-2-ylmetIiyl)-[5-(lH-ρyrro!o[2,3-b]pyridin-3-ylmeth>l)-pyridin-2-yi]-amind

(P-0220),
(2-Chloro-4-fluoro-benz>1)-[5-(lH-ρyrrolo[2,3-b]pyτidin-3-ylmethyl)-pyridin-2-yl]-arniπe (P- 0221),
(5-Methoxy-pyridin-3-ylmethyl)-[5-(lII-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0222), (3-Fluoro-pyridin-4-ylmethyl)-[5-(lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyndin-2-yl]-amine (P- 0223),
(6-Methoxy-pyridin-2-ylmethyl)-[5-(lH-pyrrolo[2.3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amme (P-0224),
(4-Huoro-2-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyndin-3->lmethyl)-pyridin-2-yI]- amine (P-0225),
[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-tnfluoromethyl-benzyl)-amme
(P-0226),
(3,5-Dichloro-pyridin-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyndm-3-ylmethyl)-pyridin-2-yl]-amme

(P-0227),
(6-Morpholm-4-yl-pyridin-2-ylmethyl)-[5-(lH-p>τrolo[2,3-b]pyndm-3-ylmethyl)-pyπdm-2-yI]-amine (P-0228),
(3-Fluoro-pyridin-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2->l]-amine (P- 0229),
(5-Fluoro-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine

(P-0230),
(2,4-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-yl]-amine (P-0342),

(3-Fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme (P-0343),

(2-Fluoro-4-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-y]]-amine (P-0344),
(4-Chloro-2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0345),
(3-Fluoro-5-tπlluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0346),
(2-Morpholm-4-yl-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yI] amine (P-0347),
(4-Chloro-3-trifluoromethyl-benzyl)-[5-(lH-pyiτolo[2,3-b]pyπdin-3-ylmethyl)-pyndin-2-yI]-amine (P-0348),
(2-Chloro-5-tπfluoromethyl-benzyl)-[5-(lH-pyrrolo[2!3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0349),
(2-Fluorr-5-tπfluorometh>l-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmeth>l)-pyπdin-2->l]-amine (P-0350).
(,2)3-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylinethyl)-pyπdin-2-yl]-ammc (P-0351 ),

(2-Fluoro-3-methoxy-bcnz>l)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdin-2-yl]-amine (P- 0352),
Dimethyl-(5-{[5-(l H-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-ylammo]-mclhyl}-pyrimidin-2- yl)-amine (P-0353),
(3-Chloro-2-fluoro-benzyl)-r5-(lH-pyπOlo[2,3-b]pyπdm-3-ylmethyl)-pyridm-2-yl]-amme (P- 0354),
(5-Fluoro-pyπdm-2-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-amme (P- 0355),
(3,5-Difluoro-ben/yl)-[5-(lH-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-amme (P-0356), (2-Propoxy-benzyl)-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] -amine (P-0357), (2-Moφholin-4-yl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-pyridin-2-yl]-amine (P-0358),
(2-Chloro-3-methoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyτidin-3-ylmethyl)-pyridin-2-yl]-amine (P-0359).
(2-Fluoro-6-tπfluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyπdm-2-yl]-amine (P-0360),
[2-(2-Moφholm-4-yl-ethoxy)-benzyl]-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyπdm-2-yl]-amine (P-0361),
(2,3-Difluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyπdm-2-yl]-aminc (P-0362), (2-Chloro-3-tπfluoromethyl-benzyl)-[5-(lH-pyrrolo[2J3-b]pyπdin-3-ylmethyl)-pyπdm-2-yl]-amme (P-0363),
(2-Chloro-5-fLuoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-amme (P-0364),
(2-Fluoro-3-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0365),
(5-Fluoro-2-methoxy-ben2yl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amme (P-0366),
(2-Difluoromethoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridm-3-ylmethyl)-pyπdin-2-yl]-amine (P-0367),
(2-Fluoro-4-methyl-benzyl)-[5-(lH-pyπOlo[2,3-b]pyridin-3-ylmethyl)-pyridm-2-yl]-ammc (P-0368),
[2-(3-Dimethylamino-propoxy)-benzyl]-[5-(lH-pyτrolo[2,3-b]pyridin-3-ylmethyl)-pyπdin-2-yl]-amine (P-0369),
(2,6-Dimcthoxy-pyndm-3-ylmethyl)-[5-(] H-pyrrolof2,3-b]pyndm-3-yImethyl)-p>Tidm-2-yl]-amine (P-9370),
(2-Fluoro-5-methoxy-benzyl)-[5-(lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-amine (P-0371),
(4-Fluoro-2-methyl-benzyl)-[5-(lH-pyπOlo[2,3-b]pyπdin-3-ylmethyl)-pyridin-2-yl]-amme (P-0372), (3-Chloro-5-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0373),
(6-Cyclopcntyloxy-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]- amine (P-0374),
(S-Fluoro^-trifluoromethyl-benzy^-fS-ClH-pyrrolopj-bJpjTidin^-ylmethyO-pyridin^-yl]- amine (P-0375),
[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine (P-0376),
Propane- 1 -sulfonic acid (2-fluoro-3-{[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino] -methyl} -phenyl)-amide (P-0377),
(2,5-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0380),

Pyrimidin-5-ylmethyl-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylinethyl)-pyridin-2-yl]-amine (P-0381),

(5-Chloro-2-fluoro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0382),
(2-Ethyl-benzyl)-[5-(lII-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0383),

2,2-Dimethyl-N-(3- {[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyridin-2-yl)-propionamide (P-0384),
Methyl-(3-{[5-(lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl} -pyridin-2-yl)-amine (P-0385),
Methyl-(5-{[5-(lH-pyrτolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2-yl)-amine (P-0386),
(2-Chloro-4-methanesulfonyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0387),
(5-Fluoro-2-methyl-benzyl)-[5-(lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-pyridin-2-yl]-amine (P- 0397),
(2,2-Difluoro-benzo[l ,3]dioxol-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0398),
Dimethyl-(3 - { [5 -( 1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyridin-2-ylamino] -methyl } -pyridin-2-yl)-amine (P-0399),
(5-Chloro-pyridin-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-smine (P- 0400), and
(l-Methoxy-pyrimidin-S-ylnicthyO-tS-ClH-pyrroloP^-bjpyridin-S-yimethylj-pyTidiri^-ylj-aminc

(P-0401).
The following table indicates the aldehyde (Column 2) used in Step 1 of Scheme 195 to provide the compounds (Column 3), Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.








Example 40: Synthesis of ^-Chloro-S-^-chloro-lH-pyrrolo^-blpyridin^-ylniethyl)- thiazol-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amiπe P-0190

[0280] [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methoxy- pyridin-3-ylmethyl)-amine P-0190 was synthesized in 2 steps from 5-(l -benzenesulfonyl-5-chloro- l H-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 592 as shown in Scheme 196.

Scheme 196


Step I - Preparation of[5-(I-ben∑enesuljbnyl-5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethylj 4- chloro-thiazol-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (619):
|92811 S^l -Benzenesulfonyl-S-chloro-IH-pyrroloP^-bJpyridin-S-ylmethyO^-chloro-thiazoI- 2-ylamine (592, 30 mg, 0.083 πunol, prepared as described in Example 27, Scheme 183) was combined with δ-methoxy-pyridine-S-carbaldehyde (618, 26.2 mg, 0.165 nitxrøl) in a 2 mL microwave reaction vial. The mixture was dissolved in ethanoi; acetic acid (95:5, 0.6 mL). Sihca supported cyanoborohydride (1.0 mmol/g, 83 mg, O.0S3 mmol) was added and the mixture was irradiated with microwave on 300 watts for 5 minutes at 100 "C. The silica was separated by centrituging and the supernatant solution was decanted, The silica residue was rinsed with ethanoi (0.500 mL) and centrifuged. The solvents were combined and removed under reduced pressure to give the desired compound 619, which was used without further purification.

Step II ~ Preparation of [4-ChIOrO-S-(S-ChIOrO- lH-pyrrolo[2, 3-bJpyridin-3-y!methyl)-thiazol-2-yl]-(6-methoxy-pyridin-3-ybnethyl)-amine (P-0190):
[0282] [5-(l -Benzcncsulfonyl-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine 619 was combined with methanol: potassium hydroxide (I M) (1 : 1 , 0.5 mL). The mixture was heated at 80 0C for 2 hours. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in dimethylsulfoxide (0.4 mL) and purified by reverse phase HPLC on a Phenomenex column (50mm x 10mm ID) eluting with 0.1 % trifluoroacetic acid in water and 20-100 % acetonitrilc with 0.1% trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0190, MS (ESI) [M+H+]+= 419.9.

[0283] Additional compounds were prepared following the protocol of Scheme 196, replacing 6-methoxy-pyridine-3-carbaldehyde 618 with a suitable aldehyde in Step 1. The following compounds were made following this procedure:
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-thiazol-2-ylmethyl-amine (P-0189),
Benzyl-[4-chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-0192), [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-thiazol-2-yl]-(3-methoxy-benzy!)-amine (P-Ol 93),
(4-Chloro-benzyl)-[4-chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-Ol 94),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzy!)-amine (P-Ol 95),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2!4-dimethyl-thiazol-5-ylmethyO-aminc (P-0196),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyI-3H-imidazol-4-ylmethyl)-amine (P-0197),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-2H-pyrazol-3-ylmethyl)-amine (P-0198):
μ-Chloro-S-fS-chloro-lH-pyrrolotZ.S-bJpyridin-S-ylmethy^-thiazol^-ylJ^ό-mcthoxy-pyridin-l-ylmcthylj-amine (P-Ol 99).,
t4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-thiazol-2-yl]-(3-fluoro-pyridin-4-ylmethyl)-amine (P-0200), [4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methyl-thiazol-4- ylmethyl)-amine (P-0201),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-methyl-thiazol-5- ylmethyl)-amine (P-0202),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-chloro-p>'ridin-2- ylmethyl)-amine (P-0203),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine (P-0236),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl-amine (P-0237),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-chloro-pyridin-4-ylmethyl)-amine (P-0238),
[4-Chloro-5-(5-chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(l-ethyl-lH-pyrazol-4-ylmcthyl)-amine (P-0239),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2-ylmethyl)-amine (P-0240),
[4-Chloro-5 -(5 -chloro-1 H-pyrrolo[2,3 -b]pyridin-3 -ylmethyl)-thiazol-2-yl] -(5 -methoxy-pyridin-3 -ylmethyl)-amine (P-0241),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0242),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-6-fluoro-benzyl)-amine (P-0243),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-phenethyl-amine

(P-0244),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-difluoro-benzyl)-amine (P-0245),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-fluoro-bcnzyl)-amine (P-0246),
[4-ChIoro-5-(5-chloro-lH-pyrrolo[2,3-b]pyndin-3-ylmethyl)-thiazol-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-0247),
(2-Chloro-benzyI)-[4-chloro-5-(5-chloro-lH-pyiτolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-Θ248),
[4-Chlurϋ-5-(5-chloro-l H-ρyττolot2,3-b]ρyridin-3-ylmethyl)-thiazol-2-ylJ-(2-methyl-benzyl)-amine (P-0249),
[4-Chloro-5-(5-chloro-lH-p\τrolo[2,3-b]pyridin-3-ylmethyl)-thiazGl-2-yl]-(2-chloro-4-fluoro-benzvlVamine fP-02501 [4-Chloro-5-(5-chloro-lH-pyπ-olo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-fluoro-pyridin-2- ylmethyl)-amine (P-0251),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]p>τidin-3-ylmethyl)-thiazol-2-yl]-(6-moφholin-4-yl- pyridin-2-ylmethyl)-amine (P-0252),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3,5-dichloro-pyridin-4- ylmethyl)-amine (P-0253),
[4-Chloro-5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-trifluoromethyl- benzyl)-amine (P-0254), and
[4-ChIOrO-S-(S-ChIOrO-IH-PyTToIoP1S^]PyHcUn-S -ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2- ylmethyl)-amine (P-0255).
The following table indicates the aldehyde (Column 2) used in Step 1 of Scheme 196 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.


ı43


[0284] Additional compounds were prepared following the protocol of Scheme 196, replacing S-Cl -benzenesulfonyl-S-chloro-lH-pyrrolop^-bJpyridin-S-ylmethy^^-chloro-thiazol^-ylamine

592 with 5-(l-benzenesulfonyI-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine

593 (prepared as described in Example 27, Scheme 183) in addition to replacing 6-methoxy- pyridine-3-carbaldehyde 618 with a suitable aldehyde in Step 1. The following compounds were made following this procedure;
[4-Chloro-5-(lH-pyπ-olot2,3-b]pyridm-3-ylmethyl)-thiazol-2-yl]-(2,4-dimethyl-thiazol-5- ylmethyl)-amine (P-0204),
[4-Chloro-5-(lII-pyrrolo[2,3-b]pyridm-3-ylmcthyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H-imidazol- 4-ylmcthyl)-amine (P-0205),
[4-Chloro-5-(lH-pyrrolo[2)3-b]pyndin-3-ylmcthyl)-thiazol-2-yl]-(5-fluoro-pyπdin-2-ylmethyl)- amine (P-0206),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmt;thyl)-thiaz»l-2-yl]-(5-methoxy-p>τidm-3-ylmethyl)- amine (P-0207),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4,5-dimethyl-thiophen-2- ylmethyl)-amme (P-0208),
[4-Chloro-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmcth>l)-thiazol-2-yl]-(2,5-dimethyl-thiophen-3- ylmethyl) -amine (P-0209),
The following table indicates the aldehyde (Column 2) used in Step 1 of Scheme 196 to prox ide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result.


Example 41: Synthesis of 5-[l-(lH-pyrrolo[2,3-b]pyridiπ-3-yl)-ethyl]-pyridin-2-yl-(4- trifluoromethyl-benzyl)~aniine P-0388

[0285] 5-[l -(I H-Pyrrolot2,3-b]pyridin-3-yl)-ethyl]-pyτidin-2-yl-(4-trifluoromethyl-ben2yl)- araine P-0388 was synthesized from (5-bromo-pyridin-2-yl)-(4-trifSuoromethyUbenzyl)-amine 17 as shown in Scheme 197.

Scheme 197


Step 1 - Preparation of l-[6-(4-lrifluoromethyl-benzylamino)~pyridin-3-yl]-ethanone (620):
[0286] (5-Bromo-pyridin-2-yl)-(4-trifluoromethyl-benzyl)-amine (17, 3.00 g, 9,06 mmol) was dissolved in tetrahydrofuran (80 mL). The reaction was cooled at -78 0C under an atmosphere of argon, 2.5 M n-butyllithium in hexane (10.9 mL) was added. The reaction was stirred at -78 °C for 60 minutes. N-Methoxy-N-methylacetamide (1.93 mL, 18.1 mmol) was added to the reaction, which was allowed to warm to room temperature. The reaction was poured into IM ammonium chloride and brine and extracted with ethyl acetate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (ethyl acetate:hexanes) to provide the desired compound as an oil that crystallized to a white solid (620, 1.328 g, 50%), consistent with the compound structure by 1H-NVIR and MS(ESl); [M+IT]+=295.3.

Step 2 - Preparation qff5-acetyl-ρyridiπ-2-yl/-f4-trifluoromelhyl-benzy])-carbamic acid tert-butyi ester '621/:
|02871 To 1 -[6-(4-trifIuoromcthyl-ben2ylamino)-pyridin-3-yl]-ethanone (62Θ, 1 JO g, 4,42 mmol) in tetrahydrofuran (15,0 mL) were added di-tert-butyldicarbonate (1.10 g, 5,04 mmcl), 4-dimethylaminopyridine (0.0259 g, 0.21 mmoi) and N,N-diisoproρylethylamine (0.S8S mL, 5.10 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 days, The mixture was extracted with ethyl acetate and saturated sodium bicabonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (0-15% ethyl acetate:hexanes) to provide the desired compound as an oil that solidified to a white solid (621, 1.29g, 74%), consistent with the compound structure by 1H-NMR.

Step 3 - Preparation ofl-[6-(4-trifluoromethyl~benzyIamino)-pyridin-3-yl]~l~(l-triisυprυpyIsilanyI-lH-pyrroIo[2,3-b]pyridin-3~yl)~ethanol (622):
[0288] 3-Iodo-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, 485.9 mg, 1 .21 mmol) was dissolved in tetrahydrofuran (8 mL) at -20 0C under an atmosphere of nitrogen. 2.0 M
isopropylmagnesium chloride in tetrahydrofuran (0.655 mL) was added. The reaction was stirred at -20 0C for 1 hour. Into the reaction was added (5-acetyl-pyridin-2-yl)-(4-trifluoromethyl-benzyl)-carbamic acid tert-butyl ester (621, 300.0 mg, 0.76 mmol) in tetrahydrofuran (6 mL) The reaction was allowed to warm to room temperature overnight. The mixture was extracted with ethyl acetate and saturated sodium bicabonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography on the (ethyl acctate:hexanes), to provide the desired compound as an oil (622, 125 mg, 29%), consistent with the compound structure by 1H-NMR,

Step 4 - Preparation of5-[l-(lH-pyrrolo[2,3-b]pyridin-3-yl)-vinyl]-pyridin-2~yl-(4-trifluoromethyl-benzyl)-amine (623):
[0289] 1 -[6-(4-Trifluoromethyl-benzylamino)-pyridin-3 -yl] -1 -( 1 -triisopropylsilanyl- 1 H-pyrrolo[2,3-b]pyridin-3-yl)-ethanol (622, 125.0 mg, 0.22 mmol) was dissolved in acetonitrile (1 1 ,7 mL) and trifluoroacetic acid (0.175 mL, 2.3 mmol) and triethylsilane (0.292 mL, 1.8 mmol) were added. The reaction was heated to reflux overnight. The reaction was concentrated, then washed with ethyl acetate and saturated sodium bicarbonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (0-60% ethyl acetate:hexanes) to provide the desired compound (623, 43 mg, 50%), consistent with the compound structure by 1H-NMR.

Step 5 - Preparation of5-[l-(lH-pyrrolo[2,3-b]pyridin-3-yl)-ethyl]-pyridin-2-yl-(4-trifluorometkyl-benzyl)-amine (P-0388) :
[0290) 5-[l -(l H-P}τrolo[2,3-b]pyridin-3-yl)-vmyl]-ρyridiπ-2-yl-(4-trifluoromcthyJ-benzyl)-amine (623, 0.043 g, 0.00011 mol) was dissolved in tetrahydroftiraii (10 mL) and methanol (10 mL). The reaction was shaken under an atmosphere of hydrogen (30 psi) overnight. The reaction was filtered through Celite and the filtrate adsorbed onto silica and purified by silica gel column chromatography (ethyl εcetate:hexanes) to provide the desired compound as a white solid (P-0388, 2.1 mg, 5%), consistent with compound structure by 1H-NMR and MS(ESI): [M+IT]*=397.6.

Example 42: Synthesis of [5-(5-Chloro-lH-pyrroIo[2,3-blpyridiπ-3-ylmethyl)-thiazoI-2-yI]- (4-fluoro-beπzyl)-amiπe P-0290

[0291] t5-(5-Chloro-lH-pyrrolof2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyI)-aminc P-0290 was synthesized in four steps from (4-fluoro-benzyl)-(.4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester 624 as shown in Scheme 198.

Scheme 198


Step 1 - Preparation of(4-fluoro-benzyl)-(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (625):
[0292] To a solution of (4-fluoro-benzyl)-(4-chloro-5-foπnyl-thia2θl-2-yl)-carbamic acid tert-butyl ester (624, 1 g, 2.70 mmol, prepared as described in Example 5, Scheme 159, Step 2, where 4-(aminomethyl)pyridine 516 is replaced with p-fluorobenzylamine, i.e. intermediate in preparing compound P-0156) in methanol (100 mL) was added Pd/C (100 mg, 50% water wet) and sodium acetate (660 mg, 8.09 mmol) and the mixture was shaken under an atmosphere of hydrogen (50 psi) overnight observing —50% conversion by LC/MS. The mixture was filtered over a bed of Celite and the solvent was removed in vacuo and purified by silica gel chromatography (ethyl acetate ''heptane) to provide the desired compound as an off-white solid (450 mg, 50 %), consistent with compound structure by 'H-NMR.

Step 2 - Preparation of{5-[(5-chloro-l-triιsopropylsilanyl-lH-pyrro]o[2,3-h]pyridin-3-yl)-hydroxy-mcthylj-thιazol-2-ylj-(4-fluoro-benzyl)-carbamic acid tert-butyl ester (627/:
[0293] To a solution of 5-chloro-3-iodo-l-(triisopropylsilyl)-lH-pyrrolo[2,3-b]pyridine (626. 300 mg, 0,69 mmol) in tetraliydrcfuran (10 mL) at -20 0C was added dropwise iso-propyl- magnesium chloride (2M in tetrahydrofuran, 0.44 mL, 0.88 mmol). The reaction mixture was allowed to warm to 0 0C over 10 minutes and then cooled to -40 0C. To this reaction mixture was added a solution of (4-fluoro-benzyl)-(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (625, 211 mg, 0.63 mmol) in tetrahydrofuran (5 mL). The reaction mixture was allowed to warm to 0 °C over 30 minutes and then quenched with brine (50 mL). The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was dried over sodium sulfate and evaporated in vacuo to give the crude material which was purified by silica gel column chromatography (0-30% ethyl acetate/heptane) to provide the desired compound as a foam (120 mg, 30%), consistent with structure by 1H-NMR.

Step 3 - Preparation of[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fiuoro-benzylj-carbamic acid tert-butyl ester (628):
[0294] To a solution of {5-[(5-chloro-l -triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridin-3-yl)~ hydroxy-methyl]-thiazol-2-yl}-(4-fluoro-bcnzyl)-carbamic acid tert-butyl ester (627, 120 mg, 0.186 mmol) in acetonitrile (3 mL) was added trifluoroacetic acid (0.14 mL, 1.86 mmol) and triethylsilane (0.30 mL, 1.86 mmol). The resulting mixture was stirred for 2 hours at 40 0C. The solvent was then removed in vacuo and the residue was used directly in the next step.

Step 4: Preparation of [5-(5-chloro- 1 H-pyrrolo [2 ,3-b] pyridin-3~ylmethyl)-thiazol-2-yl] -(4-βιωro-benzyl) -amine (P-0290):
[0295] To the solution of crude [5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylJ-(4-fluoro-benzyl)-carbamic acid tert-butyl ester (628, 0.186 mmol theory) in dichloromethane (5 mL) at room temperature was added trifluoroacetic acid (1 mL) and the reaction was allowed to stir overnight. The solvent was removed in vacuo and the residue taken up in ethyl acetate and then washed with saturated aqueous potassium carbonate making sure basicity was reached. The layers were separated and the aqueous layer was back-extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and evaporated in vacuo to give the crude product which was purified by silica gel chromatography (0-10% methanol/ethyl acetate). The solvent was removed in vacuo and the material was triturated with dichloromethane to give the desired compound as an off-white solid (20 mg. 29 % over 2 steps) consistent with compound structure by 1H-NMR and MS(ESI): [M+HT=372.9 [0296] (4-Fluoro-ben2yl)-[5-(lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-thiazol-2-yl]-amine P-0389



was synthesized following the protocol of Scheme 198, replacing 5-chloro-3-iodo~l - (triisopropylsilyl)-lH-pyrτolo[2,3-b]pyridine 626 with 3-iodo-l -triisopropylsilanyl-l H-pyrrolo[2,3-b]pyridinc 96, to provide the desired compound, consistent with structure by IH-NMR and MS(ESI): [M+IT]+=339.0.

Example 43: Additional compounds

[0297] The following compounds of the invention were synthesized following the methods of the Examples above, or similar methods known to those of skill in the art:
(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethyl-5-(4-fluoro-benzylamino)-2H-ρyrazol-3-yl}-methanone (P-0184),
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyπdin-3-ylmethyl)-l -ethy]-lH-pyrazol-3-ylJ-(4-fluoro-benzyl)~ amine (P-0185),
(3-Chloro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l-methyl-lH-pyrazol-3-yl]-amine (P-0410), and
[5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l-methyl-lH-pyrazol-3-yl]-(2,5-difluoro-benzyl)-amine (P-0411).

Example 44: Enzyme activity assays

[0298] Assays for the activity of c-Kit or c-Fms are known in the art, for example as described in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference in its entirety. Similar assays may be used to assess the activity of TrkA, TrkB, and HGK,

{0299} Additional cell based assays can be correlated to the Fms activity of compounds of the invention. For example, the ability of osteoclast precursor cells (commercially available from Lonza) to differentiate into mature osteoclasts, due to stimulation by M-CSF and RΛNKL. in the presence of compounds, can he measured using a method analogous to that previously reported (Hudson et al.. Journal of Urology, 1947, 58:89-92), where the amount of acid phosphatase in rhe supernatant (i.e. TRAP5b excreted by mature osteoclasts) is proportional to the number of mature osteoclasts present. In another example, the ability of M-CSF-dependent murine macrophage cells (BAC1.2F5) to proliferate in the presence of compounds can be measured by culturing cells as previously described (Morgan et al., Journal of Cellular Physiology, 1987, 130:420-427) and determining cell viability by analysis of ATP levels in the cell culture (Crouch et al., Journal of Immunological Methods, 1993, 160:81-8).

[0300| Compounds P-0092, P-0093, P-0094, P-0095, P-0096, P-0097, P-009S,
P-0099, P-0100, P-0101 , P-0102, P-Ol 03, P-0104, P-0105, P-0107, P-0108, P-Ol 09, P-Ol 1 1, P-Ol 12, P-Ol 13, P-Ol 14, P-Ol 15, P-Ol 16, P-Ol 18, P-0120, P-0121 , P-0122, P-0123, P-0125, P-0126, P-0127, P-0128, P-0129, P-0131, P-0132, P-0138, P-0143, P-0144, P-0145, P-0148, P-0154, P-01 S6, P-0157, P-0159, P-0161 , P-0163, P-0170, P-0171, P-0173, P-0174, P-0176, P-0177, P-0179, P-Ol 80, P-0181 , P-0182, P-0186, P-0187, P-Ol 88, P-0190, P-0192, P-0193, P-Ol 94, P-Ol 95, P-Ol 97, P-Ol 99, P-0201 , P-0203, P-0205, P-0206, P-0208, P-0211 , P-0212, P-0213, P-0214, P-0215, P-0216, P-0217, P-0218, P-0219, P-0221, P-0222, P-0224, P-0225, P-0226, P-0228, P-0234, P-0237, P-0239, P-0240, P-0242, P-0243, P-0244, P-0245, P-0246, P-0252, P-0253, P-0255, P-0257, P-0258, P-0259, P-0260, P-0262, P-0263, P-0264, P-0265, P-0266, P-0267, P-0268, P-0269, P-0270, P-0271, P-0272, P-0273, P-0274, P-0275, P-0276, P-0277, P-0278, P-0279, P-0280, P-0281, P-0282, P-0283, P-0284, P-0285, P-0286, P-0287, P-0288, P-0289, P-0290, P-0291 , P-0294, P-0297, P-0298, P-0301, P-0302, P-0303, P-0305, P-0306, P-0307, P-O3O8, P-0309, P-0311, P-0312, P-0313, P-0314, P-0316, P-0319, P-0320, P-0321 , P-0322, P-0323, P-0324, P-0325, P-0326, P-0327, P-0328, P-0329, P-0330, P-0331 , P-0332, P-0334, P-0336, P-0337, P-0338, P-0339, P-0340, P-0341, P-0342, P-0343, P-0344, P-0345, P-0346, P-0347, P-0348, P-0350, P-0351, P-0352, P-0354, P-0355, P-0356, P-0357, P-0358, P-0359, P-0361 , P-0362, P-0363, P-0365, P-0366, P-0367, P-0368, P-0369, P-0370, P-0371, P-0372, P-0373, P-0375, P-0376, P-0377, P-0378, P-0379, P-0382, P-0383, P-0385, P-0387, P-0390, P-0392, P-0393, P-0394, P-0395, P-0396, P-0402, P-0404, P-0406, P-0407, P-0408, P-0409, and P-0412 demonstrated an IC50 of less than 1 μM in at least one of the c-kit assays described in US Patent Application Publication number US 2007/0032519.

[03011 Compounds P-0092, P-0093, P-0094, P-0095, P-0096, P-0097, P-0098,
P-0099, P-0100, P-0101 , P-0102. P-0103, P-0104, P-0105, P-0106, P-0107, P-0108, P-0109,

P-Ol 10, P-O! 11 , P-Ol 12, P-Ol 13, P-Ol 14, P-Ol 15, P-Ol 16, P-Ol 17, P-OI iS, P-OI 19, P-0120, P-0121 , P-0122. P-G123, P-0125, P-0126, P-G127, P-0128, P-0129, P-0130, P-OO l , P-0132, P-Cl 34. P-Ol 35, P-Ol 36. P-0137, P-0140, P-0141, P-0142, P-0143, P-0144, P-Ol 45, P-U 146. P-Ol 47, P-0148, P-0149, P-Ol 50, P-0151, P-Ol 52, P-0153, P-0154, P-0156, P-0157, P-0158, P-0159, P-Ol 60, P-0161 , P-0163, P-0164, P-0165, P-0167. P-0168, P-0169, P-0170, P-0171 , P-0172. P-0173, P-0174. P-0175, P-0176, P-0179, P-0180, P-0181 , P-Ol 82, P-Ol 83, P-Ol 85, P-Ol 86, P-Ol 87, P-Ol 88, P-0189, P-Ol 90, P-0191, P-Ol 92, P-Ol 93, P-0194, P-Ol 95, P-0196, P-0197, P-0198, P-0199, P-0200, P-0201, P-0202, P-0203, P-0204, P-0205, P-0206, P-0207, P-0208, P-0209, P-0210, P-021 1, P-0212, P -0213, P-0214, P-0215, P-0216, P-0217, P-0218, P-0219, P-0220, P-0221 , P-0222, P-0223, P-0224, P-0225, P-0226, P-0227, P-0228, P-0229, P-0230, P-0231 , P-0232, P-0233, P-0234, P-0235, P-0236, P-0237, P-0238, P-0239, P-0240, P-0241 , P-0242, P-0243, P-0244, P-0245, P-0246, P-0247, P-0248, P-0249, P-0250, P-0251, P-0252, P-0253, P-0254, P-0255, P-0256, P-0257, P-0258, P-0259, P-0260, P-0261 , P-0262, P-0263, P-0264, P-0265, P-0266, P-0267, P-0268, P-0269, P-0270, P-0271, P-0272, P-0273, P-0274, P-0275, P-0276, P-0277, P-0278, P-0279, P-0280, P-0281, P-0282, P-0283, P-0284, P-0285, P-0286, P-0287, P-0288, P-0289, P -0290, P -0291, P-0292, P-0293, P-0294, P-0295, P-0296, P-0297, P-0298, P-0299, P-0300, P-0301 , P-0302, P-0303, P-0304, P-0305, P-0306, P-0307, P-0308, P-0309, P-0310, P-0311 , P-0312, P-0313, P-0314, P-0315, P-0316, P-0317, P-0318, P-0319, P-0320, P-0321 , P-0322, P-0323, P-0324, P-0325, P-0326, P-0327, P-0328, P-0329, P-0330, P-0331 , P-0332, P-0333, P-0334, P-0335, P-0336, P-0337, P-0338, P-0339, P-0340, P-0341, P-0342, P-0343, P-0344, P-0345, P-0346, P-0347, P-0348, P-0349, P-0350, P-0351 , P-0352, P-0353, P-0354, P-0355, P-0356, P-0357, P-0358, P-0359, P-0360, P-0361 , P-0362, P-0363, P-0364, P-0365, P-0366, P-0367, P-0368, P-0369, P-0370, P-0371, P-0372, P-0373, P-0374, P-0375, P-0376, P-0377, P-0378, P-0379, P-0380, P-0381 , P-0382, P-0383, P_0384, P-0385, P-0386, P-0387, P-0390, P-0391 , P-0392, P-0393, P-0394, P-0395, P-0396, P-0402, P-0403, P-0404, P-0405, P-0406, P-0407, P-0408, P-0409, and P-0412 had IC50 of less than 1 μM in at least one of the Fms assays described in US Patent Application Publication number US 2007/0032519.

[0302] Compounds were similarly assayed to determine IC50 values with respect to inhibition of TrkA kinase activity, for which compounds P-Ol 57, P-0171, P-0179, P-0180, P-0303 and P-0412 had IC50 of less than 1 μM. in this TrkA assay. Compounds were similarly assayed to determine IC30 values with respect to inhibition of HGK kinase activity, for which compounds P-Ol 56, P -0177, P-0179, P-0195, P-0201, P-0203, P-0206, P-0207, P-0231, P-0240, P-0241, P-0255, P-0324, P-0341 , and P-0403 had IC50 of less than 1 μM.

[03031 Ail patents and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, fo the same extent as if each reference had been incorporated by reference in its entirety individually,

[0304J One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions descnbed herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention Changes therein and other uses will occur to those skilled m the art, which are encompassed within the spirit of tk, invention, are defined by the scope of the claims

[0305] It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spiπt of the invention For example, vaπations can be made to provide additional compounds of Formula I and/or various methods of administration can be used Thus, such additional embodiments are within the scope of the present invention and the following claims

[0306] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof but it is recognized that various modifications are possible within the scope of the invention claimed Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to b> those skilled in the art, and that such modifications and vanations are considered to be within the scope of this invention as defined by the appended claims

[0307] In addition, where features or aspects of the invention are descnbed in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described m terms of any individual member or subgroup of members of the Markush group or other group

[0308] Also, unless indicated to the contrary, where various numerical values are provided foi embodiments additional embodiments are described by taking any 2 different values as the endpomts of a range Such ranges are also within the scope of the descnbed invention

|Θ309] Thus, additional embodiments arc within the scope of the invention and w ilhin the following ciaims